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Summary 
The integrin αIIbβ3 is a heterodimeric protein that exists in an inactive, resting state 
within the membrane of quiescent platelets. In response to platelet activation 
within a pro-thrombotic environment, the integrin αIIbβ3 becomes active, serves 
as a receptor for a number of ligands including fibrinogen, and orientates platelet 
– platelet cohesion. The αIIb and β3 subunits maintain the integrin in a resting 
conformational state by forming a tight clasp at their cytoplasmic tails (CT’s). 
Disruption of this clasp by platelet activation initiates the transition of the integrin 
from an inactive conformation to an active ligand binding state. The highly 
conserved αIIb membrane proximal motif (
989KVGFFKR995) resides at the binding 
interface of the αIIb and β3 CT contacts and acts as a docking site for integrin 
binding proteins. These binding partners regulate the association of the integrin 
αIIb and β3 CT’s and hence, the activation state of the integrin. Therefore, since 
αIIb and β3 CT seperation is a fundamental feature of integrin activation, much 
research has emphasized on the dynamic relationship between the conserved 
motif of the αIIb CT and its binding partners. RNF181 was previously 
demonstrated to be a potential integrin binding protein as it had an affinity for the 
989KVGFFKR995 motif. Given the preliminary nature of this earlier work, this thesis 
focused on exploring a possible, functional relationship between RNF181 and 
αIIbβ3. Using a variety of experimental approaches, strong evidence for a 
functional co-association of integrin αIIbβ3 and RNF181 was revealed. Using 
confocal microscopy, co-localization between the two proteins in platelets and 
integrin αIIbβ3 expressing CHO cells was demonstrated. Using CO-IP’s, 
Thermophoresis and ITC, a direct affinity between RNF181 and αIIbβ3 was 
demonstrated. The interaction was observed to have a moderate and transient 
affinity. Using bioinformatics and peptide arrays, the precise binding sites that 
allowed RNF181 to interact with the integrin αIIb cytoplasmic tail was explored. In 
particular, short linear peptide sequences that mediate their binding capacity 
were identified. Using platelet function assays, it was demonstrated that 
palmitoylated RNF181 derived peptides potently and specifically inhibited platelet 
/ integrin αIIbβ3 activation. Finally, through a preliminary study using siRNA, a role 
for RNF181 as being a positive regulator of integrin αIIbβ3 activation was 
suggested.     
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1.1: Platelets in haemostasis 
Platelets are blood cells that travel in close proximity to the endothelial lined 
wall of the blood vessel. In normal healthy blood vessels, platelets circulate 
in an inactive, resting condition. This platelet inactivity is mediated through 
the anti-thrombotic environment within the vessels. Bio-molecules such as 
Nitric Oxide (NO) and prostaglandins are secreted from the endothelial lining 
into circulation to stimulate cell signalling pathways that suppress platelet 
activation (Riddell and Owen 1999) (Mustard, Kinlough-Rathbone, and 
Packham 1980). In addition, the expression of ecto-ADPase enzymes on the 
surface of endothelial cells (Marcus et al. 1997) and red blood cells (Luthje, 
Schomburg, and Ogilvie 1988) minimize the possibility of platelet activation 
in healthy circulation. In response to vascular damage, the local environment 
shifts towards pro-thrombotic conditions by the exposure of platelet adhesive 
substrates in the subendothelial matrix (such as collagen), the generation of 
coagulation factors (such as thrombin) and the reduced capacity of damaged 
endothelial lining to produce anti-thrombotic / vasodilator agents (such as 
NO). These thrombotic conditions (in addition to many others not described) 
coordinate platelet activation, blood coagulation and vasoconstriction at 
damaged sites to prevent blood loss (through clotting). In the context of 
platelets, haemostasis involves adhesion to substrates (including collagen 
and vWF) followed by activation and release of platelet agonists such as 
thromboxane A2 (Samuelsson 1976) and ADP (Haslam 1964) (Holmsen 
1965). Platelet release mechanisms activate and recruit additional platelets 
(Mills, Robb, and Roberts 1968) to the injured sites to ultimately lead to the 
local formation of a stable thrombus. A critical component of stable thrombus 
generation is the interaction between the plasma protein; fibrinogen and the 
integrin αIIbβ3 expressed on the surface of platelets. 
 
 
1.2: Integrins 
Integrins are a class of adhesion proteins found abundantly in biological 
systems. They are interesting proteins in that they play key roles in a vast 
array of healthy cellular functions including embryonic development 
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(Darribere et al. 2000), cell differentiation (Martin-Bermudo 2000), cell 
migration (Huttenlocher, Ginsberg, and Horwitz 1996)  (Vicente-Manzanares, 
Choi, and Horwitz 2009) and tissue repair (Liu et al. 2010). However, integrin 
expression contributes significantly to the progression of a variety of cancers 
(Desgrosellier and Cheresh. 2010) while genetic mutations in integrin genes 
can result in severe hereditary disease states. Examples include 
Glanzmann’s Thrombosthenia; a bleeding disorder associated with defective 
integrin αIIbβ3 expression or function (French and Coller 1997) or multi organ 
disorders associated with mutations of the integrin α3 gene (Has et al.) with 
many additional phenotypes reported in integrin knockout mice (Zent 2010). 
Structurally, integrins are comprised of single  and  subunits cross-linked 
as a heterodimer through noncovalent associations. Each subunit has an N-
terminal extracellular domain, a single pass transmembrane domain and a 
short C-terminal cytoplasmic tail (Hynes 2002). Extracellular domains of 
integrins are large structures that bind to protein ligands; collagen, laminin, 
or fibronectin found in the extracellular matrix to support cell adhesion and 
cell surface receptors such as vascular cell adhesion molecule – 1 (VCAM-1) 
(Jones et al. 1995) to support cellular interactions. The single spanning 
transmembrane domains of integrins embed the protein within the cell 
membrane providing the structural support for the shorter cytoplasmic tails to 
be anchored inside of the cell. The cytoplasmic domains are capable of 
binding to complex networks of intracellular proteins involved in many 
cellular functions including migration, proliferation, differentiation and 
apoptosis (Schwartz, Schaller, and Ginsberg 1995). In their ligand bound 
state, integrins form complex structures with extracellular matrix proteins and 
intracellular cytoskeletal proteins simultaneously to fabricate focal adhesions 
essential for stabilising integrin - ligand binding, cell adhesion and migration. 
(as depicted in Figure 1.1). In this context, they act as bidirectional signalling 
molecules that facilitate molecular communication between intracellular 
components and the extracellular framework. Although this is a simple 
envision of integrin function in general, an elaborate understanding of 
specific integrin structures and their regulation has been gathered through 
crystal structure studies, NMR analysis, computational modelling and genetic 
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mutations. Even though there are eighteen different α subunits and eight 
different β subunits identified to date that form a large family of twenty four 
different integrin heterodimers (Hynes 2002), a common structure for integrin 
proteins has been accepted. The generalisation of integrin structure and 
function stems from the fact that many features of a conserved nature lie 
within the family of glycoproteins (Brower et al. 1997) (Bergelson and Hemler 
1995), thus suggesting that they fold into predictable homologous structures. 
In addition, due to their conservation; knowledge of integrin conformations, 
domain structures, cytoplasmic tail binding proteins and signalling networks 
has been gathered.  
 
          
Figure 1.1: Integrin adhesion molecule 
Illustrations represent integrin protein in a resting, inactive state (A) and a 
ligand bound state connected to the cytoskeletal protein talin (B). Structures 
were generated by (Berman et al. 2000) using multiple PDB entries. In the 
resting conformation the extracellular domain was generated by (Xiong et al. 
2001) which is connected to the short transmembrane domains (Lau et al. 
2009) and cytoplasmic tails (Vinogradova et al. 2002). The open 
conformation was generated by the PDB entries predicting structures for 
extracellular domain (Zhu et al. 2008) when bound to fibrinogen peptide 
(Springer, Zhu, and Xiao 2008) bound to the transmembrane domain 
domains (Lau et al. 2009) and connected to the talin bound cytoplasmic tail 
(Wegener et al. 2007).  
 
B A 
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Figure 1.2: Electron micrographs of integrin αVβ3 conformational states 
Images were captured of the integrin molecule in a clasped (A) and 
unclasped ligand (RGD) bound state (B) (Takagi et al. 2002). 
 
 
 
 
1.2.1: Integrin Extracellular domains 
The extracellular domains of integrin subunits are large. The α subunits 
contain 7 homologous (FG-GAP) β-propeller repeats (Mould, Askari, and 
Humphries 2000) that constitute the ligand binding and metal ion binding 
regions, a thigh domain and two calf domains (Zhu et al. 2008). There is an 
I-domain embedded within the beta-propeller repeats in some α subunits (α - 
D,L,M,X,E,1,2,10,11) while other α subunits lack an I-domain (α - 
4,V,8,5,3,6,IIb) (Liddington and Ginsberg 2002). The extracellular β subunit 
contains an I-like domain, a PSI (plexrin/ semaphoring /integrin) domain, a 
hybrid domain, four EGF repeats and a membrane proximal β tail domain 
(Mould et al. 2005). Extracellular ligand binding is dependent on the 
structural activity relationship of integrins. Integrins transition from an 
inactive, low affinity conformation to an active high affinity conformation in 
response to cell-specific activation signals or ligand binding (Resting and 
active, RGD ligand bound conformations of the αVβ3 are represented in the 
electron micrographs in Figure 1.2). Throughout this transition, the 
extracellular domain of integrins can switch between multiple distinct 
conformational states (Chen et al. 2012) (Zhu, Zhu, and Springer 2013), 
generally represented by; a resting closed head piece in a bent conformation 
B A 
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with low affinity for its ligands;  intermediate extended closed head piece with 
low ligand affinity; and active extended open head piece conformation with 
high affinity for its ligands (Cox, Brennan, and Moran 2010). The change in 
conformation is coordinated by Ca2+ and Mg2+ occupation of the metal ion-
dependent adhesion sites (MIDAS), adjacent metal ion-dependent adhesion 
sites (AdMIDAS) and the synergistic metal ion binding site (SyMBS) (Zhu et 
al. 2008) within the β-propeller and I domains with ligand binding occurring at 
the interface between the α and β subunit’s β-propeller domain and I-like 
domains (Xiao et al. 2004). The conformational change of the extracellular 
domain from a resting to an active structure is largely influenced and 
preceded by the separation and unclasping of the α and β subunits of the 
transmembrane and cytoplasmic domains (Luo, Springer, and Takagi 2004) 
and (Muller et al. 2014). This physical change is caused by inside-out 
signalling (Wang, Zhu, et al. 2011).  
 
1.2.2: The integrin transmembrane domains 
The hydrophobic transmembrane (TM) domains of integrins are highly 
conserved (Figure 1.3, A) and are essential for integrin regulation and 
signalling (Lau et al. 2009). The α and β subunits form a heterodimeric 
interface in resting integrins (Luo, Springer, and Takagi 2004) but in 
response to inside-out signalling and cytoplasmic tail separation the interface 
between the α and β TM domains is lost, leading to integrin activation 
(Wang, Zhu, et al. 2011). The affinity that the transmembrane subunits have 
for their counterpart is relatively weak (Yin et al. 2006) but also appropriate; 
given the necessity of integrins to undergo subunit separation during 
activation. Previous evidence suggested that the capacity for integrin 
subunits to separate, become active and form clusters involved a stronger 
affinity that the α subunits had for each other and a stronger affinity the β 
subunits had for each other to form homodimers (Yin et al. 2006). However 
alternative data revealed that integrins do not homodimerize during 
activation, inside-out or outside-in signalling (Wang, Zhu, et al. 2011). But 
this does not state that the affinity the homo subunits have for each has no 
effect on integrin subunit separation or clustering. Homodimerization may be 
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a forceful factor in the activation process but is just not a product of integrin 
activation.  
 
1.2.3: The integrin cytoplasmic domains 
The cytoplasmic tail (CT) domains of integrin subunits show evolutionary 
conserved motifs (Figure 1.3, B) in the membrane proximal region (Hynes 
1992),  which are expressed across all species (Hynes 1992) (Sastry and 
Horwitz 1993). In α cytoplasmic tails, the conserved region takes the form of 
the KxGFFKR motif and is contained in the membrane proximal region of the 
proteins tail. However there is much variation within the membrane distal 
region. Nevertheless, the observations of a conserved motif have pointed 
towards important functional roles for the α cytoplasmic tails; through binding 
to a number of integrin regulatory proteins (Larkin et al. 2004) (Daxecker et 
al. 2008). Interestingly, diverse integrin α tails meditate a variety of 
responses (Weber, Klickstein, and Weber 1999)   (Keely et al. 1999) (Sastry 
et al. 1999) (Liu, Calderwood, and Ginsberg 2000). For example, the αL and 
αM cytoplasmic tail domains differentially regulate the kinetics of the 
activation state of the integrin extracellular domain through distinct signalling 
pathways, in that αM signalling leads to a sustained activation state of the 
integrin extracellular domain, whereas αL triggers a transient response 
(Weber, Klickstein, and Weber 1999). Distinct signalling pathways have also 
been demonstrated between the α cytoplasmic tail domains of the integrins 
α2 and α5; where it was observed that R-Ras enhanced α2 cytoplasmic tail 
signalling but diminished α5 signalling (Keely et al. 1999). A final example of 
differences in integrin α subunit signalling has been observed by work which 
demonstrated that certain integrin dimers (α1β1, α5β1, and αvβ3) actively 
recruited Shc and activated MAPK during signalling, while other integrins 
(α2β1, α3β1, and α6β1) were unable to do so (Wary et al. 1996). These 
unique functions among integrin α tails could be due to either the lack of 
homology between the remaining membrane distal peptide sequences of the 
α cytoplasmic tails or that the α tails directly regulate β tail signalling (Liu et 
al. 1999) (Li et al. 2014).  
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The β cytoplasmic tails show much conservation within their structures (Liu, 
Calderwood, and Ginsberg 2000) even though there is much diversity 
associated with the number of β beta tail cytoplasmic binding proteins 
(Calderwood et al. 2003). Within the β tails there are three recognized 
motifs, (HDR(R/K)E, NPxY – membrane proximal and NxxY – membrane 
distal phosphotyrosine domains) that act as binding sites for an array of 
interaction partners. The HDRR/KE motif is involved in the clasp formed with 
the conserved motif of the α cytoplasmic tail (Hughes et al. 1996) 
(Vinogradova et al. 2002). The NPxY and NxxY sequences represent a 
Tyrosine (Y) residue that is susceptible to phosphorylation by cytoplasmic 
kinases. Once phosphorylated, these motifs serve as binding sites for 
phosphotyrosine binding (PTB) domain containing proteins which function as 
adaptors or scaffolds to organise the signalling complexes involved in wide-
ranging physiological processes including neural development, immunity, 
tissue homeostasis and cell growth (Calderwood et al. 2003). 
Phosphorylation of the β-NxxY domains may serve to negatively regulate 
(Anthis, Haling, et al. 2009) or positively regulate integrin functions 
(Deshmukh, Gorbatyuk, and Vinogradova 2010) (Nieves et al. 2010) (Law et 
al. 1999) (Blystone et al. 1997) (Sakai et al. 1998). Since integrin CTs lack 
an actin binding domain and generally do not contain enzymatic activity, they 
must interact with signaling or adaptor proteins that connect to the 
cytoskeleton in order to affect or respond to changes in cellular activity. 
However, due to the complexity of integrin cytoplasmic tail hubs and also the 
transient nature of integrin conformations during activation, the particular role 
of many integrin binding proteins remains unknown. What it is clear though, 
is that α and β tail separation is a critical point in integrin activation, ligand 
binding and signal transduction.   
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Figure 1.3: Sequence alignment of human α-integrin domains 
Sequence alignment of a selection of α-integrin transmembrane domains (A) 
and cytoplasmic tails domains (B) were compiled using clustal sequence 
alignment. Highly conserved motifs are highlighted by yellow columns, while 
less similar regions are highlighted by less bright colours. 
 
 
 
1.3: Integrin αIIbβ3 in platelet function 
The integrin αIIbβ3 is an abundant membrane protein in platelets that acts as 
a receptor for the highly abundant plasma protein; fibrinogen. Integrin αIIbβ3 
binding to fibrinogen is a critical step in the process of haemostasis and is 
essential for thrombus formation. The activation of integrin αIIbβ3 is tightly 
regulated by platelet signalling whereby in resting platelets, αIIbβ3 exists in an 
inactive conformation that is unable to bind to soluble fibrinogen. However, in 
response to platelet activation and signal transduction, the integrin 
transitions to an active state capable of high-affinity binding to fibrinogen 
(Hawiger 1991). Platelet activation propagates inside-out signalling 
mechanisms which causes recruitment of proteins to the cytoplasmic region 
of the integrin tails to induce integrin activation (Kahner et al. 2012). 
 
B 
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1.4: Structure and function of the integrin αIIb transmembrane and 
cytoplasmic tail domains  
The transmembrane and cytoplasmic tail domains of the integrin αIIbβ3 are 
crucial points of contact that regulate integrin activation (Lau et al. 2009) 
(Luo, Springer, and Takagi 2004). In resting platelets, the integrin αIIb TM 
domain interacts with the β3 transmembrane domain over a range of 12 
residues (Metcalf et al. 2010) (Luo, Springer, and Takagi 2004) while the CT 
domains of integrin αIIb and β3 subunits are maintained in a tight clasp 
through a salt bridge formed between the arginine residue R995 and the 
aspartic acid residue D723 at the membrane proximal regions of the α and β 
subunits respectively (Hughes et al. 1996) (Vinogradova et al. 2002). This 
structure stabilizes the integrin in an inactive, resting conformation (Hughes 
et al. 1996) (Muller et al. 2014).  
 
The protein structure of the integrin αIIb CT domain is increasingly disordered 
(Metcalf et al. 2010) (Lau, Dua, and Ulmer 2008), especially distal to the 
Proline residues (P997P999) (Vinogradova et al. 2000), as shown in Figure 
1.4. This disordered region within the integrin αIIb CT is characteristic of 
intrinsically unstructured proteins (IUP). Intrinsically unstructured proteins 
are proteins that lack a fixed, three-dimensional fold. The unstructured 
region of an IUP can be the entire protein sequence or it can be just 
segments of the amino acid chain. IUP regions play critical roles that enable 
the function of many proteins (Chouard 2011), by acting as hubs for protein 
interaction networks or proteins involved in multiple signalling events 
(Uversky and Dunker 2008). They have been identified within many integrin 
cytoplasmic tails (Contois, Akalu, and Brooks 2009) (Liu, Calderwood, and 
Ginsberg 2000). Because IUP’s do not display strict tertiary conformations, 
they are able to undergo dynamic changeable conformations which allow 
them to take on many different shapes according to their diverse proteins 
targets (Yoon et al. 2009). This structural diversity elaborates on how the 
integrin αIIb CT has multiple, potential integrin regulatory proteins (Raab, 
Daxecker, et al. 2010). Current knowledge of the existence of many different 
integrin binding proteins suggests that the integrin’s IUP region can adopt 
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various structures to enable binding to specific proteins under precise 
physiological conditions and may explain how the cytoplasmic tails facilitate 
the switch between resting and active conformations.  
 
Often contained within IUPs are short linear interaction motifs (SLiMs); short 
stretches of protein sequences that play key roles in protein interactions and 
many biological functions (Diella et al. 2008). Indeed, the conserved region 
of the integrin membrane proximal motif (989KxGFFKR995) is considered a 
SLiM. Interestingly, SLiMs found in IUP regions are considered to mediate 
functional interactions independent from the rest of the protein (Meszaros, 
Dosztanyi, and Simon 2012) whereby one particular motif can undergo a 
variety of interactions with various consequences (Wright and Dyson 2015). 
This observation is comparable to the integrin signalling, whereby the CT 
binds with cytoskeletal proteins to induce conformational changes in the 
integrin extracellular domain (during inside-out integrin activation) that 
enable ligand binding and cell adhesion  (Das et al. 2014) while separately 
forms protein interactions with cytoplasmic proteins involved in cell signalling 
(during outside-in signal transduction).  
 
The importance of IUPs in αIIb regulation is also highlighted by the role of the 
CT, distal from the membrane motif. At this point, it is not the specific peptide 
sequence but only the structural support of amino acids that are important 
for integrin regulation (Li et al. 2014). Truncation of the CT distal to the 
989KVGFFKR995 abolished agonist induced inside-out activation; while by 
attaching non-homologous amino acids distal to the 989KVGFFKR995 restored 
the signalling activity (Li et al. 2014). Relative to this topic, are the integrin 
α4, α5 and α2 cytoplasmic tails which have dissimilar, non-conserved 
sequences distal to the conserved KxGFFKR motif (see Figure 1.3, B). 
Nevertheless, the adhesive properties of integrin α4 that are lost following 
removal of its CT tail distal to the conserved motif are functionally restored 
by the attachment of the non-conserved α5 and α2 cytoplasmic tail (Yauch et 
al. 1997) (Kassner and Hemler 1993). Thus integrin function is largely 
dependent on the SLiM and intrinsically unstructured properties of the 
integrin α cytoplasmic tails.    
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Figure 1.4: Prediction of disordered and SLiM regions within integrin 
αIIb subunits 
The alpha integrin transmembrane and cytoplasmic tail domains of human 
integrin ITGA2B, and integrins from other species were aligned and colour-
coded using a protein prediction tool (SLiMPred) (Mooney et al. 2012) to 
indicate disordered regions (highlighted in blue) and SLiM region (highlighted 
in green).  
 
 
 
1.5: Proteins binding to the integrin αIIb cytoplasmic tails  
In platelets, a group of proteins known as integrin binding proteins (IBP) 
have been reported, that regulate the activation status of integrin αIIbβ3 by 
dynamically binding to their cytoplasmic tail (CT) domains (Liu, Calderwood, 
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and Ginsberg 2000). Some of these IBPs (such as PP2A) have been 
regarded are negative regulators of integrin activation by binding to the αIIb 
CT (Gushiken et al. 2008) while others (such as talin) have been regarded 
as positive regulators of activation by binding to the β3 CT (Kahner et al. 
2012). The conserved 989KVGFFKR995 region of integrin αIIb CT has been 
implicated in the regulation of integrin activation (Peter and Bode 1996). 
Deletion of the 9889KVGFFKR995 region in integrin αIIbβ3 results in the 
expression of a constitutively activated integrin (Lu and Springer 1997) . 
Similarly, mutating residues within this motif, especially F992 and F993 as well 
as R995 results in integrin activation (Aylward et al. 2006) (Ahrens et al. 2006) 
(Hughes et al. 1996). As a result, this conserved motif is referred to as the 
integrin αIIb regulatory region. The search for integrin binding proteins that 
regulate inside-out and outside-in signalling of integrin αIIbβ3 has therefore 
focused on the binding capacity of the αIIb motif. Platelet proteins that have 
been identified to directly interact with this regulatory motif of the integrin αIIb 
cytoplasmic tail and affect integrin function include; RNF181 (Brophy et al. 
2008) CIB1 (Naik and Naik 2003), ICln (Larkin et al. 2004), PP1C (Vijayan et 
al. 2004), PP2AC (Gushiken et al. 2008), AUP1 (Kato et al. 2002), TIM (Liu 
et al. 2006).  
 
1.5.1: RNF181 
RNF181 is an 18 kDa protein that was initially identified by a high-density 
protein expression array to specifically interact with the integrin IIb 
989KVGFFKR995 motif (Larkin et al. 2004). Subsequently, the presence of 
RNF181 in human platelets and its potential to bind to the integrin IIb-CT 
was described (Brophy et al. 2008). RNF181 contains a RING-H2 finger 
domain and has been described as a member of the ubiquitin E3 ligase 
family of proteins. RING finger domains are zinc binding regions involved 
ubiquitination of target proteins (Hershko and Ciechanover 1998). The post-
translational modification of target proteins by ubiquitin can take place in the 
form of mono-ubiquitination or polyubiquitination. Mono-ubiquitination is the 
attachment of a single ubiquitin molecule to a single lysine of a target 
protein. This process regulates protein trafficking and function of target 
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proteins (Bonnet, Devys, and Tora 2014) (Ramanathan and Ye 2012). 
Alternatively polyubiquitination takes place when the lysine residue of a 
single ubiquitin molecule attached to a target protein can repeatedly accept 
additional ubiquitins to form a polyubiquitinated chain. Polyubiquitination 
directs the protein for 26S proteasomal degradation (Chitra, Nalini, and 
Rajasekhar 2012). RNF181 has the capacity to autoubiquitinate (Brophy et 
al. 2008), a feature that may inhibit E3 ligases from carrying out their 
ubiquitinating capacity (Hoeller et al. 2006). However, RNF181 
autoubiquitination is reduced following S-nitrosylation post-translational 
modification of RNF181 (Lee et al. 2014). Moreover, the ubiquitin 
proteasomal system has recently been implicated in the clearance of S-
nitrosylated proteins to maintain organelle function (Benischke et al. 2014). 
Since S-nitrosylation also has significant effects on integrin proteins (Thom 
et al. 2008) (Isaac et al. 2012), these findings implicate RNF181 in cellular 
activities previously unreported to its function.  
 
Although the platelet substrates for RNF181 are unknown, many proteins are 
ubiquitinated in response to platelet activation (Brophy et al. 2008). In 
addition, it was recently demonstrated that platelets contain an active 
ubiquitin / proteasome system that marks cytoskeletal proteins for proteolytic 
modification to promote platelet-platelet and platelet-wall interactions (Gupta 
et al. 2014). Moreover, many proteins, already identified in the integrin 
regulation pathways, such as Integrin linked kinase (ILK) (Morgner and 
Wickstrom 2013), paxillin (Didier et al. 2003) and ancient ubiquitous protein-
1 (AUP-1) (Jo, Hartman, and DeBose-Boyd 2013) are recognized to be 
involved with the ubiquitination process and integrin signalling pathways.     
 
From a different perspective, RNF181 has been demonstrated to 
significantly affect proliferation of human hepatocellular carcinoma (HCC) 
cells by regulating ERK/MAPK signalling pathways (Wang, Huang, et al. 
2011). Manipulation of RNF181 expression levels in HCC cells revealed that 
upregulation of RNF181 caused a significant decrease in tumour cell 
proliferation, whilst down regulation of RNF181 had the opposite effect, 
enhancing tumour cell growth (Wang, Huang, et al. 2011). Proteomic 
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analysis revealed that there were 33 cytoplasmic proteins differentially 
regulated by RNF181 expression and that 11 of these 33 proteins were 
associated with the ERK/MAPK signalling pathways. Interestingly, 16 of the 
33 HCC proteins that are regulated by RNF181 are also present in an “in-
house”, RCSI constructed proteome database derived from platelet proteins 
(Achim Treuman; Personal Communication). From these 16 RNF181 
regulated HCC proteins, 2 have been demonstrated in platelets to have an 
affinity for the integrin regulatory motif, which include Protein Phosphatase 
type 1Ac (PP1Ac) (Daxecker et al. 2008) and Triosephosphateisomerise 
(TIM) (Liu et al. 2006). Because RNF181 has also been identified to have an 
affinity with the integrin regulatory motif (Daxecker et al. 2008) a role for 
RNF181 may exist in platelets whereby it modulates ERK/MAPK dependent 
pathways following integrin activation or engagement. 
 
1.5.2: Calcium and integrin binding protein 1 (CIB1) 
CIB1 is a 22 kDa protein that was first identified to specifically interact with 
the integrin IIb-CT by yeast two-hybrid screening of a fetal liver cDNA library 
(Naik, Patel, and Parise 1997). It is involved in many cellular functions 
including migration, division, survival and DNA damage (Huang et al. 2011) 
(Kostyak, Naik, and Naik 2012) (Kostyak and Naik 2011). Moreover, it has 
been linked to the pathogenesis of diseases such as arterial fibrillation (Zhao 
et al. 2012) and various cancers. CIB1 is the most investigated of all integrin 
αIIb binding proteins. The integrin’s binding site for CIB1 is localized to the IIb 
transmembrane and adjacent membrane-proximal 983LAMWKVGFFKR995 
sequence with L983, W988, F992 and F993 being critical for the interaction. The 
integrin IIb and CIB1 primarily bind through hydrophobic contacts (Barry et 
al. 2002). CIB1 protein contains a metal ion binding EF-hand domain. EF-
hand domains are the most common domains found in proteins and are 
strongly implicated in CIB1’s ability to interact with αIIb (Huang et al. 2011). In 
the absence of metal ions (Ca2+and Mg2+), the structure of CIB1 is unstable 
(Huang and Vogel 2012). However, the binding of divalent metal ions; 
Ca2+and Mg2+ to EF-hand domains induces changes in CIB1’s structure with 
the protein acquiring a well folded conformation and upon binding to αIIb, the 
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C-terminal helix of Ca2+ bound CIB1 is displaced (Yamniuk, Ishida, and 
Vogel 2006) (Huang et al. 2011). Recently reported is the relationship 
between three other proteins from the calcium and integrin binding protein 
family; namely CIB2, CIB3 and CIB4, whose secondary structures are also 
altered by the binding of Ca2+ and Mg2+ ions and are capable of interacting 
with the integrin αIIb cytoplasmic domain (Huang, Bogstie, and Vogel 2012). 
CIB1 has been linked to the ERK1/2, AKT phosphorylation pathways in 
megakaryocytes stimulated with thrombopoietin. Interestingly, knockdown of 
CIB1 protein by RNA interference suppressed cell growth in hepatocellular 
carcinoma cells (Junrong et al. 2011); the same cell type affected by 
RNF181 expression levels (Wang, Huang, et al. 2011). These findings reveal 
that CIB1 promotes HCC proliferation whilst RNF181 has the capacity to 
reverse HCC proliferation. Moreover, HCC progression is an integrin 
dependent event (Bogorad et al. 2014). Whether RNF181 / CIB is a 
regulatory partnership and if it exists in platelet / integrin function remains to 
be seen.  
 
With regard to CIB1 in platelet function, conflicting data has emerged. One 
early study suggests that CIB1 binds preferentially to the activated 
conformation of IIb3, implicating a role of CIB1 in outside-in signalling 
(Vallar et al. 1999). These findings are confirmed by data showing that CIB1 
interacts with IIb3 after platelet adhesion to immobilized fibrinogen. 
Inhibition of complex formation by introducing either an antibody against 
CIB1 or an IIb-CT peptide into platelets prevents IIb-CIB1 interaction and 
consequently blocks spreading (Naik and Naik 2003). In contrast, by 
studying CIB1 over-expression and knock-down in a primary murine 
megakaryocyte model, others have suggested that CIB1 negatively 
regulates agonist-induced activation of IIb3 (Yuan et al. 2006). In a recent 
study, platelets from CIB -/-knockout mice showed no significant differences 
in aggregation, fibrinogen binding or P-selectin expression in response to 
platelet activation compared to CIB1 +/+. These treatments represent the 
inside-out activation pathways of integrin αIIbβ3. However, the ability of CIB 
-/- 
washed platelets to adhere and spread on fibrinogen was significantly 
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reduced, with the addition of ADP able to restore spreading capacity (Naik et 
al. 2009). In contrast, it was revealed that CIB -/- washed platelets adhered to 
and spread on fibrinogen in a manner similar to CIB1 +/+ washed platelets 
(Denofrio et al. 2008). This latter group suggested that the CIB1 deficiency is 
compensated by the up regulation of another CIB family member, CIB2. The 
rational came from the fact that the megakaryocytes of the CIB1 -/- mice had 
increased protein expression levels of CIB2. What can be concluded though, 
is that CIB1 functions as a key regulator of integrin IIb3.  
 
1.5.3: Chloride channel regulatory protein (ICln) 
ICln, a 26 kDa protein, is an important protein that regulates cell volume, 
cellular morphology, angiogenesis and RNA splicing (Furst et al. 2006). 
High-density protein expression array identified ICln as a binding partner for 
the integrin αIIb 
989KVGFFKR995 motif (Larkin et al. 2004). In platelets, ICln 
translocates from the cytosol to the membrane subcellular fractions following 
activation, allowing a transient interaction with the αIIb-CT (Larkin et al. 
2009). However, after prolonged platelet activation, the capacity of ICln to 
bind with the αIIb-CT is lost suggesting that ICln only binds to an intermediate 
activation state of integrin αIIbβ3 (Larkin et al. 2009). In addition, studies 
using an integrin-derived inhibitory (IDI) peptide (pal-KVGAAKR) describe a 
model for its anti-thrombotic action through a high affinity interaction with 
ICln, thereby suggesting that ICln has a pivotal role in platelet activation 
(Raab, Parthasarathi, et al. 2010). 
 
1.5.4: Protein phosphatase type 1 (PP1) and protein phosphatase type 
2A (PP2A) 
The role of protein phosphorylation in receptor signalling is widely studied. 
Regulation of platelet and integrin activation has been associated with src, 
syk, MAPK and ERK protein kinase signalling pathways. Even though de-
phosphorylation plays an equal role in signal transduction, the mechanism of 
protein phosphatase activity is lesser investigated. The protein 
phosphatases; PP1 and PP2A are enzymes that dephosphorylate their 
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substrates at serine/threonine residues. Inhibiting protein phosphatase 
activity abolishes thrombin induced rise in intracellular calcium, platelet 
activation and aggregation (Higashihara et al. 1992). In resting platelets, 
PP1C binds directly to the conserved integrin αIIb region
989KVGF992of the 
cytoplasmic tail. Integrin associated PP1c remains inactive (Vijayan et al. 
2004). Thrombin stimulation of platelets or αIIbβ3 engagement with 
immobilized fibrinogen leads to the dissociation of PP1C from integrin αIIb 
cytoplasmic tail and activation of the enzyme (Vijayan et al. 2004).  
 
In resting platelets a pool of PP2AC also associates with the 
989KVGFFKR995 
motif of integrin αIIb (Gushiken et al. 2008). Platelet adherence to 
immobilized fibrinogen does not disturb this interaction, but the activity of 
αIIb-associated PP2AC is reduced and phosphorylation on S
157 of the PP2A 
substrate VASP is increased. In addition, PP2A modulates the activity of 
kinases such as PKA, PKC and ERK/MAPK (Janssens and Goris 2001). It is 
suggested that PP2AC may suppress αIIbβ3 adhesiveness by 
dephosphorylating and inactivating ERK1/2, hence, negatively regulating 
αIIbβ3 signalling (Gushiken et al. 2008).  
 
1.5.5: Ancient ubiquitous protein 1 (AUP1) 
AUP1 is a 40 kDa cytoplasmic protein that was identified as being an integrin 
αIIb binding protein by a cDNA library of a megakaryocyte-derived cell line 
using yeast two-hybrid methodology. GST pull-down assays indicate a 
specific interaction with the membrane-proximal sequence 989KVGFFKR995 
(Kato et al. 2002). The protein is considered to function as an adaptor 
protein via its CUE domain, recruiting signalling molecules such as ubiquitin-
conjugating enzymes (E2) or ubiquitin itself to the integrin CT and exerting 
phosphate acyltransferase activity through its PlsC domain (Kato et al. 
2002). AUP1, αIIbβ3, src and syk are complexed together in resting platelets 
and that AUP1 dissociates from syk following phosphorylation of syk in 
activated platelets (Kato and Oshimi 2009). Since syk is rapidly ubiquitinated 
in a GPVI activation dependent manner in platelets (Dangelmaier et al. 
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2005), it may be likely that AUP1 functions as a ubiquitin transfer protein to 
syk in GPVI dependent manner.   
 
1.5.6: Triosephosphate isomerase (TIM) 
Triosephosphate isomerase (TIM) is a ubiquitously expressed enzyme that 
catalyzes the conversion of dihydroxyacetone phosphate (DHAP) to 
glyceraldehyde 3-phosphate (G3P) during glycolysis. It has been identified 
as a specific binder to the αIIb-CT by a yeast two-hybrid system. Site-directed 
mutagenesis indicates that the sequence 991GFFKRNRPPLEE1002 of the αIIb-
CT is being crucial for the interaction. Although the presence of TIM in 
platelets has been demonstrated at mRNA and protein levels, its role in 
integrin αIIbβ3regulation has not yet been pursued (Liu et al. 2006).  
 
 
 
1.6: Platelets in cardiovascular disease 
Cardiovascular disease encompasses a number of pathologies including 
stroke, myocardial infarctions and peripheral vascular disease. These are 
serious and often fatal conditions with the underlying pathology of 
atherosclerosis; a disease of large arteries (Lusis 2000). Atherosclerosis is 
characterized by the progressive accumulation of connective tissue, calcium 
deposits, inflammatory cells and lipids that form the complex structure of an 
atherosclerotic plaque. Although atherosclerosis can develop into advanced 
lesions that affect blood flow, the most significant clinical outcome is the 
acute occlusion that can form due to the formation of a platelet rich thrombus 
that leads to myocardial infarction or stroke. This complication is associated 
with plaque rupture which promotes thrombosis in the intact blood vessel 
(Verstraete 1990). The molecular activation mechanism of platelets in 
conditions of a pathological nature (such as thrombosis) in the 
cardiovascular environment is similar to their action in response to healthy 
haemostasis. Since platelet thrombus formation plays a significant role in 
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cardiovascular diseases as a result of atherosclerotic rupture, the increased 
knowledge of platelet activation in normal haemostasis has been important 
in order to assist with the design of therapeutic agents that modulate 
thrombotic development.  
 
1.6.1: Anti – platelet drugs 
The role of platelets in thrombotic disorders, including coronary artery 
disease (Willerson 1995), myocardial infarction (Davies and Thomas 1985) 
and stroke (Smith, Pathansali, and Bath 1999) has been recognized for 
many years. Thus the primary treatments for these disorders are drugs that 
modulate platelet activity. The first effective anti-platelet drug that inhibited 
platelet aggregation in thrombosis was aspirin (O'Brien 1968). Aspirin 
irreversibly inhibits prostaglandin synthesis from Arachidonic acid through 
the Cyclooxygenase (COX) pathway in the cell system. Since the COX 
metabolic pathway paves way for the generation of the pro-thrombotic 
molecule; thromboxane A2 in platelets, aspirin effectively inhibits TxA2 
synthesis and therefore TxA2 induced platelet activation (Patrono et al. 
1985).  
 
The anti-platelet drug, Clopidogrel acts as an irreversible antagonist to the 
receptor, P2Y12 thereby denying the receptor occupation by the pro-
thrombotic agent; ADP (Mills et al. 1992). Consequently the thrombotic 
effects of ADP on platelet activity (Gaarder et al. 1961) (Boullin, Green, and 
Price 1972) are diminished. Long term administration of Clopidogrel is an 
effective treatment for atherosclerotic vascular disease (Committee 1996). 
Currently, the most common anti-platelet drugs prescribed to cardiovascular 
disease patients are aspirin and clopidogrel which are given in combination 
or individually, depending on patient responsiveness to the treatment.  
 
Other common anti-platelet drugs available include dipyridamole. This drug 
inhibits phosphodiesterase (PDE) enzyme action (Gresele et al. 1986) thus 
preventing the degradation of cGMP (Aktas et al. 2003) thereby promoting 
the maintenance of platelets in an inactive state. Dipyridamole has additional 
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vasodilator properties that improve the outcome of patients with 
cardiovascular disease (Beller, Holzgrefe, and Watson 1983). Nevertheless, 
the search for a more potent and specific anti-platelet drug remains (Jackson 
and Schoenwaelder 2003). Previously, this led to the development of a 
subclass of anti-platelet agents that targeted the platelet integrin αIIbβ3.  
 
1.6.2: Antagonists of the platelet integrin     
In the 1980’s, David Phillips and his colleagues discovered that the 
membrane protein; integrin αIIbβ3 mediated the platelet - platelet interactions 
that followed thrombin stimulation (Phillips, Jennings, and Edwards 1980) 
(Phillips and Baughan 1983) (Phillips et al. 1987). Into the next decade, and 
with more than eight hundred scientific and medical publications in its field, 
the integrin IIb3 (also known as GPIIb/IIIa) was put forward as an ideal 
target for the development of new anti-thrombotic strategies for patients with 
cardiovascular disease (Ruggeri 1990). The then available anti-platelet 
agents were mainly aspirin or dipyridamole which had an effect upstream to 
integrin – fibrinogen binding. The platelet integrin was observed to mediate 
the final step in platelet activation, namely the binding of symmetrical plasma 
fibrinogen. Platelet cross-linking, aggregation and irreversible thrombus 
formation that follows fibrinogen binding highlighted the possibility that the 
fibrinogen – integrin αIIbβ3 interaction could successfully be targeted to 
develop an anti-platelet drug. Therefore, a group of anti-platelet agents, 
known as GPIIb/IIIa antagonists were developed that competitively inhibited 
fibrinogen binding  (Coller et al. 1983) (Plow et al. 1985) (Kloczewiak et al. 
1984) (Hartman et al. 1992). These antagonists were developed by various 
pharmacological strategies and included antibodies, peptides and 
nonpeptide inhibitors. The monoclonal antibody Fab fragment Abciximab) 
targeted the αIIbβ3 complex thus blocking fibrinogen binding (Coller et al. 
1983). Cyclic-RGD peptide inhibitors (Eptifibatide) imitated fibrinogen’s α-
chain binding site for the integrin αIIbβ3 thus potently inhibiting fibrinogen 
binding that follows platelet activation (Shebuski et al. 1989) (Shebuski et al. 
1990). Nonpeptide inhibitor based compounds (Tirofiban) mimicked the RGD 
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peptide sequence to potently inhibit fibrinogen binding and platelet 
aggregation (Hartman et al. 1992).  
 
During the drug development phase, fibrinogen binding to the integrin αIIbβ3 
was regarded as the final step permitting thrombus formation. By not 
realizing it was actually the first step in integrin mediated platelet signalling 
events (termed outside-in signalling) meant that the outcome for these drugs 
was not anticipated. Increased risk of bleeding was associated with these 
drugs when compared to any other anti-platelet agent, with 
thrombocytopenia being the second most serious side effect (Tcheng 2000). 
A lack of knowledge regarding the role of integrin signalling following 
receptor occupation (by ligand or inhibitor) was a drawback for GPIIb/IIIa 
antagonists, in particular the oral inhibitors (Chew et al. 2001). This led to a 
surge in effort to try and fully comprehend the unknowns of integrin function, 
specifically IIb3 (see Figure 1.5 demonstrating the trend in integrin 
research).  However, in spite of their failure to be top market anti-platelet 
drugs, since their development, GPIIb/IIIa antagonists have been widely 
used where all others fail. The use of Abciximab, Eptifibatide and Tirofiban 
are essential for percutaneous coronary intervention (PCI); the most 
common revascularisation technique for the treatment of coronary artery 
disease (Bledzka, Smyth, and Plow 2013). In addition, trials are ongoing to 
reduce side effects and improve administration of these drugs (Bledzka, 
Smyth, and Plow 2013). Furthermore, antagonists targeting the integrin IIb3 
have become imperative to platelet function studies in many platelet 
research labs. In recent years, a greater appreciation has been given to the 
role of integrin, specifically IIb3, in platelet function and thrombosis. 
Because thrombotic disease remains a major cause for mortality in the 
western world, therapeutic agents targeting the platelet specific integrin IIb3 
signalling pathways have the potential to offer advantages over the current 
anti-platelet drugs, in terms of specificity, efficacy and safety and could hold 
the key for the future development of anti-platelet agents. 
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Figure 1.5: Trend in integrin research 
A PubMed feature demonstrating research articles for the integrin IIb3; 
since its identification, interest as an anti-platelet target and subsequent 
decline in research activity 
 
 
 
1.7: Potential for new anti-platelet drugs  
1.7.1: Extracellular domain inhibitors 
Given the significant role of integrin IIb3 in thrombus formation, it remains 
an attractive therapeutic target for thrombotic diseases. Small molecule 
inhibitors (RUC-1 and RUC-2) that target the extracellular IIb domain of the 
platelet integrin have been identified. In contrast to the oral IIb3 antagonists 
that induce conformational changes in the integrin IIb3 (Cox 2004) or 
render the receptor in a ligand binding state upon dissociation (Du et al. 
1991), these recent inhibitors do not have such an effect (Zhu et al. 2010). 
The more potent RUC-2 is undergoing pre-clinical studies to determine its 
suitability in treating patients with ST elevation myocardial infarction (STEMI) 
(Coller 2012). The search for alternative inhibitors targeting integrin 
activation has identified a protein; Disabled-2 (Dab-2) that negatively 
regulates platelet aggregation by directly binding to integrin IIb3 (Huang et 
al. 2006). A Dab-2 derived peptide containing its sulfatide binding motifs 
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(Dab-2 SBM) exhibits anti-thrombotic activity similar to RGDS, by competing 
with fibrinogen for the IIb3 receptor (Xiao et al. 2012).  
 
From another angle, a peptide derived from the extracellular αIIb amino acid 
region 313Y - L320 has demonstrated anti-platelet potential. In contrast to the 
current antagonists of the integrin IIb3 receptor, this αIIb peptide mimetic 
instead binds to plasma fibrinogen, saturating its integrin binding capacity 
and thereby blocking its ability to cross link platelets during aggregation 
(Mitsios et al. 2006).  Moreover, in a rabbit model of arterial thrombosis, this 
peptide demonstrated further potential, whereby it specifically inhibited 
thrombus formation and carotid artery occlusion, without causing 
hemorrhagic complications (Papamichael et al. 2009). Thus research is 
ongoing in the search for integrin antagonists superior to the RGD class of 
compounds 
 
1.7.2: Intracellular inhibitors 
Extensive research investigating the molecular mechanisms underlying 
integrin IIb3 activation has revealed the potential for developing 
therapeutics that target mechanisms of integrin activation from an 
intracellular perspective. Understanding cytoplasmic proteins that negatively 
or positively regulate integrin activation could provide pathways for more 
advanced therapeutics that target integrin during transitional phases of 
activation, thereby minimizing adverse effects such as those seen with 
previous integrin antagonists. Even though the high volume of research on 
integrin regulating proteins is not reflected by an equal clinical output, 
studies have provided strategies that could successfully target cytoplasmic 
domains of integrins in thrombotic disease.  
 
The precedent for the intracellular approach came from studies revealing 
that certain peptide residues of the integrin cytoplasmic tails are critical in the 
regulation of integrin activation (Lu, Takagi, and Springer 2001). Moreover, 
peptides derived from IIb (Bernard et al. 2009) and 3 (Liu et al. 1996) 
inhibited integrin activation. A palmitoylated peptide derived from the 
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membrane proximal region of the integrin IIb cytoplasmic tail; 
989KVGFFKR995 demonstrated pro-thrombotic activity in platelets. However, 
when the peptide was modified with F992A, F993A substitutions, it 
demonstrated anti-thrombotic activity (Bernard et al. 2009) through a specific 
interaction with the integrin binding protein, ICln (Raab, Parthasarathi, et al. 
2010). In contrast to Pal-KVGFFKR, a palmitoylated peptide corresponding 
to the membrane distal region of the IIb cytoplasmic tail demonstrated anti-
thrombotic activity (Koloka et al. 2008) most likely by interfering with the 
interaction between talin and the membrane distal region of the IIb 
cytoplasmic tail, a protein interaction mechanism essential for talin-mediated 
inside-out integrin activation (Li et al. 2014).  
 
Peptides derived from the 3 cytoplasmic tail have also been recently 
demonstrated to possess potent and specific anti-thrombotic activity by 
interfering with an important integrin - G protein interaction (Shen et al. 
2013). The guanine nucleotide binding protein (G protein), Gα13 is a G 
protein that couples to the TxA2 receptor in unstimulated platelets, 
dissociates upon activation (Djellas et al. 1999) and activates RhoA thus 
facilitating platelet shape change (Moers et al. 2003). In addition, Gα13 
distinctly binds to the integrin IIb3 at the 3 K
729 - T741 region following 
agonist induced inside-out signalling to mediate outside-in signalling in a 
ligand dependent manner (Gong et al. 2010). Consequently, a 3 derived 
peptide 730FEEERA735 was generated with a myristoylation modification that 
specifically inhibited the early phase of outside-in signalling without affecting 
inside-out or late phase, outside-in talin binding. In contrast to Eptifibatide, 
this peptide had minimal adverse effects on blood loss (Shen et al. 2013). 
Two other 3 peptides, derived from the cytoplasmic region, containing the 
two membrane distal NxxY motifs; specifically 743NNPLYKEA750 and 
755TNITYRGT762 were examined for the effects on platelet function (Dimitriou 
et al. 2009) and demonstrated platelet inhibitory activity in a dose dependent 
manner. The exact mechanism of action of these anti-thrombotic peptides is 
incompletely understood. If they truly function by distinctly imitating the 
integrin cytoplasmic tails domains and specifically interacting with integrin 
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regulatory proteins, thus preventing the proteins carrying out their biological 
function, then this action would be similar to the binding mechanism of small 
interfering RNA (siRNA) during RNA interference, a powerful technique 
highly applicable to the treatment of many diseases (Dykxhoorn, Palliser, 
and Lieberman 2006). With a greater understanding of integrin regulatory 
proteins, these peptides could be tailored to target specific stages of integrin 
activation. Nevertheless, a greater understanding is required to achieve such 
standards. 
 
The transmembrane Integrin αIIbβ3 plays a significant role in mediating 
biological functions in platelets. During thrombosis, αIIbβ3 becomes activated, 
and enables binding of plasma fibrinogen and cross linking of platelets. 
Integrin αIIbβ3 is therefore a target for the development of anti-thrombotic 
drugs. However, early attempts to develop inhibitors of integrin adhesion 
largely failed to produce useful drugs. Since it is established that the integrin 
α and β cytoplasmic tails form a tight clasp to maintain the integrin αIIbβ3 
complex in a resting conformation and since the novel E3 ligase, RNF181, 
has been shown to have potential to interact with the integrin αIIb cytoplasmic 
tail, it was hypothesized that RNF181 regulates the activation state of the 
platelet integrin. If true, then a novel avenue for the development of anti-
thrombotic drugs will have been identified. In particular, agents that could 
interfere with the intracellular binding of RNF181 to integrin cytoplasmic tails 
may modulate integrin activation in thrombosis. 
 
To test this hypothesis, 3 different aspects of integrin regulation have been 
addressed in this thesis. Firstly, evidence for a direct interaction between the 
integrin αIIbβ3 and RNF181 was assessed under a variety of experimental 
conditions including platelet integrin activation and adhesion to fibrinogen, 
platelet aggregation and purified protein assays. Secondly, the precise 
binding sites that mediated binding between RNF181 and the integrin αIIb 
cytoplasmic tail was explored. In addition, the effect of manipulating the 
binding sites with platelet function was explored. Finally, a direct functional 
role for RNF181 integrin activation was assessed.   
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Chapter 2 
Materials and Methods 
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2.1: Materials  
All general materials were purchased from Sigma Aldrich, Ireland unless 
otherwise stated. Specific materials and reagents are detailed below and 
listed in alphabetical order. 
 
ADP was purchased from Bio-data Corporation, USA. 
Aggregation tubes were purchased from Bio-data Corporation, USA. 
Alexa-flour 488 goat anti-rabbit was purchased from Bio-sciences, Ireland. 
Alexa-flour 546 goat anti-mouse was purchased from Bio-sciences, Ireland. 
Amicon Ultra centrifugal filter units were purchased from Millipore Ireland. 
Ampicillin was purchased from Sigma Aldrich, Ireland 
Bespoke, peptide microarrays were purchased from JPT peptide 
technologies, Germany. 
Bradford protein assay kit was purchased from BioRad Laboratories Ltd, UK. 
CHO cell transfection reagent was purchased from Altogen Biosystems, Las 
Vegas, USA.  
Control siRNA molecules were purchased from Santa Cruz Biotechnology, 
Santa Cruz, California, USA. 
Custom made peptides were synthesised and purchased from JPT 
Technologies, Germany or Peptide 2.0, USA where indicated.  
Custom made siRNA molecules were generated and purchased from Sigma 
Aldrich, Ireland.  
DAKO fluorescent mounting media was purchased from DAKO, USA. 
Deoxyribonuclease I, from bovine pancreas was purchased from Sigma 
Aldrich, Ireland.  
DMEM F12 with L-glutamine & with 15mM Hepes was purchased from 
Biosera. 
Dulbeco’s Phosphate Buffered Saline (PBS) was purchased from Biosera. 
Falcon tubes (15ml and 50ml) were purchased from Becton-Dickinson, UK. 
Fetal bovine serum was purchased from Biosera, UK. 
FITC labelled CD41a was purchased from BD Biosciences, UK 
G418 was purchase from Sigma Aldrich  
Goat serum was purchased from Sigma Aldrich, Ireland. 
HIC-5; rabbit antibody was purchased from Santacruz Biotechnology 
(SCBT). Santa Cruz, California, USA 
Horseradish peroxidase (HRP) - conjugated goat anti-mouse antibody was 
purchased from Millipore Ireland. 
HRP-conjugated goat anti-rabbit antibody was purchased from Millipore 
Ireland. 
Human fibrinogen was purchased from Calbiochem, Germany. 
Human integrin αIIbβ3 was purchased from Enzyme Research Laboratories, 
UK. 
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Lightning link Cy3 conjugation kit was purchased from Innova biosciences, 
UK. 
Lysozyme was purchased from Sigma Aldrich, Ireland.  
Microscope slides were purchased from Thermo Fischer Scientific, Ireland.  
Non-enzymatic cell dissociation solution was purchased from Sigma Aldrich, 
Ireland. 
Normal mouse IgG was purchased from Santacruz Biotechnology (SCBT). 
Santa Cruz, California, USA 
Octyl-α/β-glucoside 10 mM solution was purchased from Sigma Aldrich, 
Ireland. 
Opti-MEM reduced serum transfection medium was purchased from Bio-
Science, Ireland. 
Penicillin / streptomycin was purchased from Sigma Aldrich, Ireland. 
Peptide cellulose membrane arrays were purchased from JPT peptide 
technologies, Germany.  
Poly-L-Lysine coated microscope slides were purchased from Thermo 
Fischer Scientific, Ireland 
Protease inhibitor cocktail solution (100X) was purchased from Thermo 
Fischer Scientific, Ireland.  
Protein G agarose beads were purchased from GE Healthcare, UK. 
Rabbit anti-ubiquitin antibody was purchased from Abcam, UK. 
Ribonuclease A, from bovine pancreas was purchased from Sigma Aldrich, 
Ireland. 
RNF181 antibody was generated by Theresa Brophy; RCSI.  
SDS PAGE Gradient gels (4% – 20%) were purchased from Thermo Fischer 
Scientific, Ireland. 
Slide-A-lyzer dialysis cassettes were purchased from Thermo Fischer 
Scientific, Ireland.  
Streptavidin-agarose beads were purchased from Thermo Fischer Scientific, 
Ireland 
Supersignal West Pico Chemiluminescent was purchased from Thermo 
Fischer  Scientific, Ireland 
SZ22; mouse anti-CD41 was purchased from Beckman Coulter Diagnostics, 
Co. Clare, Ireland 
TRAP was purchased from Tocris biosciences, UK. 
Tryptone was purchased from Sigma Aldrich, Ireland. 
Yeast extract was purchased from Sigma Aldrich, Ireland. 
Zeba deslating spin columns were purchased from Thermo Fischer 
Scientific, Ireland.  
Zeocin was purchased from Invivogen, France. 
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2.2: Methods 
2.2.1: Preparation of washed platelets 
Venous whole blood was drawn from healthy volunteers who were free from 
aspirin (and other drugs which could affect platelet function) for 10 days, as 
previously described (Stephens et al. 1998). Blood was taken, using a 19 
gauge butterfly needle, into 15% (v/v) acid citrate dextrose (ACD – 124mM 
dextrose, 38mM citric acid, 75mM sodium citrate) anti-coagulant. The 
Syringe was gently inverted to ensure total mixing with the anticoagulant. 
Following this the blood was aliquoted into 15ml tubes in 6 ml fractions and 
spun in a centrifuge at a force of 150g for 10 minutes at room temperature. 
Using a 3ml pasteur pipette, the top platelet-rich plasma (PRP) layer was 
removed without disturbing the buffy coat (a fractional layer of blood that 
contains mostly white blood cells and separates the plasma from the 
erythrocyte cell layer) and transferred to a fresh tube. ACD was added to 
acidify the plasma to pH 6.4. PGE1 was added to a final concentration of 
1µM to prevent platelet activation in the subsequent steps. Platelets were 
immediately placed in a centrifuge and spun for 10 minutes at 720g. The 
supernatant was removed without disturbing the platelet pellet. The pellet 
was then gently resuspended in JNL buffer (130mM NaCl, 10mM tri-sodium 
citrate, 9mM NaHCO3, 6mM dextrose, 0.9mM MgCl2, 0.81mM KH2PO4, 3mM 
KCL, 10mM Tris base, pH 7.4) or (10% v/v buffer A; 10% v/v buffer B; 10% 
v/v buffer D; 1% v/v buffer E -). Platelet concentrations were adjusted using a 
Sysmex blood cell counter and left to rest for 1 hour. Prior to use, CaCl2 was 
added to the washed platelets at a final concentration of 1.8mM.  
 
 
2.2.2: Platelet aggregation 
Light transmission platelet aggregometry is a simple technique used to 
determine the extent of platelet aggregate formation in either PRP or washed 
platelet preparations (Aylward et al. 2006). Washed platelets were prepared 
as described in section 2.2.1. In aggregation tubes (BioData) washed 
platelets (800μl) were incubated at 37°C in a BioData Platelet Aggregometer 
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(PAP-4 or PAP-8).  Each aggregometer channel was initially blanked (set at 
100%) using water. Magnetic stir bars were added and samples were stirred 
at a speed of 1100rpm, simulating vascular cell movement. When required, 
platelet inhibitors were added 5 minutes prior to the addition of agonists. 
Platelet agonists were added to the indicated samples at the described 
concentration. Control samples had no agonists or inhibitors. All samples 
were brought to equal volumes using JNL buffer. Aggregations were 
recorded for 3 minutes. 
 
 
2.2.3: Cell adhesion assay for confocal microscopy 
Platelets adhere to fibrinogen in vivo in response to normal thrombogenic 
stimuli. Using in vitro experiments, we attempt to mimic this response by 
allowing platelets to adhere to immobilized fibrinogen coated onto glass 
slides. Platelet behaviour can be assessed on this substrate in comparison 
to behaviour on an irrelevant protein substrate, such as BSA. Fluorescent 
confocal microscopy allows the substructures of platelets to be examined 
during the process of platelet spreading and adhesion. With this technique, 
the transmembrane protein; integrin αIIbβ3 was examined for its capacity to 
interact individually with the cytoplasmic proteins; RNF181 and HIC-5 in both 
platelets and CHO cells adhered to a thrombotic (fibrinogen) and non-
thrombotic (BSA) substrate coated surface. To describe this method in detail; 
poly-L-lysine coated glass slides (from Thermo Fischer Scientific) were 
marked with a hydrophobic pen creating four chambers per slide. The slides 
were coated with human fibrinogen (25μg/ml) overnight at 4°C to the 
described chambers. Slides were washed x 3 with PBS for CHO cells or JNL 
for washed platelet preparations. Because BSA is a protein that fails to bind 
to integrin, it was added to the slides at 1% w/v for 2 hours at 37°C to cover 
any surface area not coated with fibrinogen (as poly-L-sine can activate 
platelets). In addition, it was used in the designated control chambers. Slides 
were washed again x 3 with buffer and 200µl of washed platelets or CHO 
cells (at a concentration of 30 x 106/ml) were added for indicated times 
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(between 5, 15, 30, 45 and 90 minutes). Slides were gently washed with 
buffer. Paraformaldehyde (3.8% w/v) was added to each chamber to mark 
the end of the incubation period. It was allowed to act for 10 minutes to fix 
the samples. Slides were extensively washed with buffer. Triton 100X (0.1% 
v/v) was added to the slides for 10 minutes to permeabilise the cells. Slides 
were washed vigorously to ensure all triton is removed and blocked with 
1.5% (v/v) goat serum for 30 minutes at room temperature. Serum solution 
was removed by blotting the slides with tissue-paper (slides were not 
washed at this step). Primary antibodies (at indicated concentrations) were 
added to the described chambers and incubated overnight at 4°C or for 2 
hours at 37°C. Slides were then washed x 3 with buffer. After washing, goat 
anti-rabbit or goat anti-mouse labelled secondary antibodies (FITC- alexa 
flour 488 or Phalloidin-alexa flour 546), made up in 1.5% goat serum, were 
added to the slides for 45 minute at room temperature in the dark. Slides 
were subsequently washed and had all solution carefully removed by using a 
tissue-paper. A cover slip was mounted on top with DAKO fluorescent 
mounting media and left in the dark at room temperature for 1 hour. Slides 
were stored at 4°C until imaging with a Zeiss LSM501 microscope.  
 
 
2.2.4: Platelet lysate generation 
Washed platelets were prepared as described in section 2.2.1. Most 
analyses compared resting and activated platelets and were therefore 
subject to aggregation. Platelets were lysed using a 10x lysis buffer (10% v/v 
Triton 100X, 25mM TRIS pH7.4, 100μM EDTA, 2mM PMSF, 0.1% SDS w/v, 
250μM N-octyl glucoside, 0.1% v/v protease inhibitor cocktail, 33% JNL v/v) 
at 10% v/v and kept on ice. For 1 hour, the lysed samples were vortexed 
every 10 minutes. Lysates were then centrifuged at 10,000g for 5 minutes to 
precipitate unsoluble components. The supernatant was collected and the 
pellet discarded. Lysates were used immediately or else stored at -80°C.  
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2.2.5: Tissue culture of CHO cells 
Three alternative lines of Chinese Hamster Ovarian (CHO) cells were used 
throughout this thesis (prepared as described previously (Aylward et al. 
2006)). One batch (CHO-FF) was stably transfected with the wild type gene 
for integrin αIIbβ3 while an alternative batch (CHO-AA) was stably transfected 
with a mutated integrin αIIbβ3 gene. In addition, a CHO MOCK batch was 
transfected with an empty vector. To culture CHO cells, the cells were grown 
in T75 tissue culture flasks in the presence of 45% nutrient mixture F-12 
(HAM) with L-Glutamine, 45% Dulbeco’s Modified Eagle Medium ((DMEM), 
sodium pyruvate, 4500mg/ml pyridoxine HCL), 8% Foetal calf Serum (FCS), 
1% Penicillin/Streptomycin (Penstrep), 375μg/ml of G418 Geneticin® and 
375μg/ml of Zeocin. Cells were incubated at 37°C in a 5% CO2 incubator. 
When approximately 80% confluent, CHO cells were split at a 1:10 dilution. 
To do this, the media was removed and cells were washed with 5mls of 
sterile PBS. 2mls of a non-enzymatic cell dissociation solution was added to 
the flask and placed in the incubator for 5 minutes to detach cell from the 
flask. 8mls of culture medium was then added. Suspended cells were 
transferred to a 15ml tube and centrifuged at 1000g for 3 minutes. The 
supernatant was discarded and cells were resuspended in 10mls of DMEM. 
A 1ml volume of cells were then added to a fresh flask containing 10mls of 
fresh culture medium. 
 
 
2.2.6: Generation of CHO cell lysate 
CHO cells were lysed in a 10% (v/v) of a 10X lysis buffer (10% v/v Triton X 
100, 25mM TRIS pH 7.4, 100μM EDTA, 2mM PMSF, 0.1% SDS w/v, 250μM 
N-octyl glucoside, 0.1% v/v protease inhibitor cocktail, 33% dH2O v/v). 
Firstly, cells were detached from the tissue culture flask with cell dissociation 
solution. Following detachment the cells were placed into a 15ml tube, 
centrifuged at 1000g x 3 minutes. Supernatant was discarded and cells were 
resuspended in PBS to a concentration of 3 x 106/ml. In a 2ml eppendorf, 
1ml of cells were lysed on ice. Samples were vortexed vigorously every 10 
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minutes for up to 1 hour and then centrifuged at 10,000g for 5 minutes to 
pellet insoluble components. The supernatant was kept as the sample, which 
was either used immediately or stored at -80°C.  
 
 
2.2.7: Determining the expression levels of αIIbβ3 in CHO cells 
The CHO cells were harvested as described in section 2.2.2. 100μls of CHO 
cells were incubated with 10μl of a FITC labelled αIIbβ3 specific antibody 
(CD41a) for 10 minutes at 37°C in FACS tubes. 900μl PBS was then added 
to the tubes. Protein expression levels for αIIbβ3 were determined using the 
FACS-Calibur Flow Cytometer. CHO cells transfected with an empty vector 
(CHO MOCK) were also incubated with CD41a. Parallel samples for all cell 
types were incubated with a FITC labelled IgG control to detect background 
levels. Comparison of the αIIbβ3 transfected and the MOCK transfected CHO 
cells revealed the difference between αIIbβ3 expression levels. CHO cells 
were routinely assessed by this method because they lost the ability to 
express transfected protein over time. To overcome this, CHO cells were 
enriched with high integrin αIIbβ3 expressing cells by being subjecting cell 
populations to cell sorting. This process was routinely carried out on a FACS 
Aria cell sorter with the aid of a lab colleague.  
 
 
2.2.8: Bradford assay 
Protein concentrations were estimated using the BioRad DC Protein Assay 
Kit assay according to the manufacturer’s instructions. Using a Wallac Victor 
1420 Multilabel Counter (Perkin Elmer) absorbance values with a range of 
known protein concentrations were used to create a standard curve to 
estimate the concentration of an unknown protein concentration. Using 
bovine serum albumin (BSA) as the known protein, a linear range within the 
concentrations of 1mg/ml, 500μg/ml, 250μg/ml, 125μg/ml, 62.25μg/ml 
30μg/ml, 15μg/ml 7.5μg/ml 5μg/ml and 0μg/ml were prepared by serial 
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dilutions. Absorbance values were plotted on an excel spread sheet to create 
a standard curve for BSA. From this, the protein concentrations of the 
unknown samples were estimated.  
 
 
2.2.9: Gel electrophoresis 
 
2.2.9.1: SDS-PAGE  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is 
a technique used to separate a solution of different proteins by denaturing 
them to their primary structure (Laemmli 1970). Proteins are separated in 
response to an electric current that forces the proteins to migrate towards a 
cathode, according to their size. Subsequently, SDS-PAGE allows protein 
visualization, detection or analysis either by coomassie staining or by 
western blot. Protein migration depends on the percentage cross linking of 
the acrylamide polymer in SDS-PAGE gel components. Generally gels can 
be made with 5%, 7.5% 10% or 12% crosslinking. Lower %’age cross linking 
allows high resolution of high-molecular weight proteins. In contrast, high 
percentage gels will permit greater resolution of low molecular weight 
proteins. Gradient gels are useful tools to allow resolution of all proteins 
ranging in molecular weight from 10kDa to 200 kDa and are often purchased 
from suppliers, precast. This has the benefit that there tends to be less 
variability in results of samples resolved on commercially-produced gels. 
Even with good laboratory protocols, there will inevitability be day-to-day 
variance in the quality of individual gels prepared by individuals. 10% and 
gradient gels were used throughout this project. In a 10% gel preparation, 
resolving gel solution was prepared (375mM TRIS-Base, 3.5mM SDS, 10% 
acrylamide v/v, 7% dH2O, 0.06% w/v % ammonium persulphate (APS), 
0.055% v/v N,N,N’,N’-tetramethylethylenediamine (TEMED)) and pipetted 
into bottom sealed 1.0mm glass plates according to laboratory protocols. A 
stacking solution was prepared (23.5% v/v stacking Buffer [0.5M TRIS-Base, 
14mM SDS, and dH2O], 4.3% v/v acrylamide, 56% v/v dH2O, 0.07% APS, 
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0.09% TEMED) and laid on top of resolving gel. 10 or 15 well combs were 
placed into the glass plates. The solution polymerized after 1 hour.  
 
2.2.9.2: Sample preparation for SDS-PAGE 
Cell lysates were mixed 1:1 with 2X sample buffer (125mM TRIS pH 6.8, 4% 
SDS w/v, 0.1% Bromophenol blue w/v, 20% Glycerol v/v). Samples were 
denatured by heating to 95°C for 3 minutes in the presence of SDS, a 
denaturing detergent. 100mM dithiothreitol (DTT) was added to break 
disulfide bonds between multimeric proteins, thus further denaturing the 
protein structures. Samples were loaded into the wells using gel loading tips 
and separated under a standard electric current in a standardized SDS-
PAGE  running buffer pH 7.4 (2.5mM TRIS Base, 19.2mM glycine, 0.01% 
w/v SDS). A molecular weight marker was added (5μl) to allow comparison 
of the molecular weights of the proteins under analysis. Lanes that had no 
samples in them had a volume of sample buffer added to keep the lanes 
straight during electrophoresis. Proteins were separated by applying a 
current of 75 volts for 15 minutes then 100 volts for approximately 1 hour or 
until the bromophenol blue dye front reached the bottom of the gel.  
 
 
2.2.10: Western blot 
Following SDS-PAGE, separated proteins can be transferred onto an 
electrically charged polyvinyl difluoride (PVDF) membrane and probed with 
targeting antibodies (Burnette 1981). Electrical current is used in a similar 
fashion to gel electrophoresis to transfer the proteins onto the PVDF 
membrane. Following SDS-PAGE, the polyacrylamide gel was removed from 
the rig and placed into a cassette which sandwiches together the PVDF 
membrane and the gel to be transferred. The cassette was placed into a wet 
transfer rig in a 1X transfer buffer (2.5mMTRIS-Base, 19.2mM glycine and 
0.02% SDS) and a 100 volts current passed through for 1 hour while being 
kept cooled or else 30 volts applied overnight at 4°C. Following transfer, the 
membrane was placed into a blocking buffer (3% BSA in 1X TBS-T (20mM 
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TRIS, 150mM NaCl, 0.1% Tween, pH 7.4)) for 1 hour to block any protein-
binding sites on the PVDF membrane not occupied by the SDS-PAGE 
banded proteins. Membranes were washed 3 times in TBS-T for 5 minutes 
per wash. Membranes were then incubated in primary (1°) antibody made up 
in 1X TBS-T with 3% BSA, at the indicated concentrations; overnight at 4°C. 
Membranes were then washed x 3 in TBS-T for 5 minutes per wash. HRP 
conjugated specific  secondary (2°) antibodies were prepared (1:25,000 
dilution in 1X TBS-T in 3% BSA) and incubated with the membranes for 1 
hour at room temperature. Membranes were then washed 3 times for 5 
minutes and once for 15 minutes in TBS-T and then washed 3 times for 5 
minutes and once for 15 minutes in dH2O. Supersignal West Pico 
Chemiluminescent reagent (prepared according to manufactures 
instructions) was then added to each membrane for 1 minute. HRP - 
conjugated antibodies were detected with a BioSpectrum Imaging System 
(UVP Ltd; UK).  
 
 
2.2.11: Coomassie blue staining 
After gel electrophoresis, total cellular proteins from each sample were 
visualized by fixing and staining the gel with a coomassie blue stain (7% v/v 
acetic acid, 40% v/v Methanol, 53% v/v dH2O, 0.5% w/v coomassie brilliant 
blue). To do this the gel was carefully removed from the glass plate and the 
stacking lanes removed. It was then incubated with 50mls of coomassie stain 
in a covered container for 1 hour while gently rocking. Stain was removed 
and kept for use again. Gel was destained for up to 2 days with destain 
buffer (7% v/v acetic acid, 40% v/v Methanol, 53% v/v dH2O) with buffer 
replaced twice a day.  
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2.2.12: Immunoprecipitation (IP) 
Immunoprecipitation is a technique for extracting a target molecule (protein) 
out of solution using protein A or protein G conjugated agarose beads that 
are bound by target specific antibodies. In combination with western blot, 
protein-protein interactions can be determined by this method.  
 
2.2.12.1: Co-immunoprecipitation of RNF181 with integrin αIIbβ3 
Aliquots (25μl) of protein G sepharose beads were added to 1.5ml 
eppendorfs containing  1ml of JNL buffer (for platelet IP’s) or 1ml PBS (for 
CHO cell IP’s). Beads were washed by; i) centrifuging for 5 seconds, to a 
pellet; ii) removing supernatant; and ii) adding fresh buffer. This wash step 
was repeated two more times to remove the ethanol medium in which the 
beads are stored. After the final wash, blocking buffer (1ml of JNL buffer or 
PBS containing 3% BSA) was added to the beads and rotated end-over-end 
overnight at 4°C. Lysates of washed platelet or CHO cells were prepared as 
described in sections 2.2.4 and 2.2.6. One ml of cell lysates was added to 
the beads along with 1μg/ml of mouse - anti CD41 (SZ22) antibody. For 
negative control, to show that the immunoprecipitation is due to target 
recognition by the specific antibodies, 1μg/ml of non-specific mouse IgG 
antibody (for anti- αIIbβ3 IP) was added to a separate mixture of cell lysates / 
beads. Samples were rotated end-over-end at 4°C overnight. Samples were 
then placed on ice and washed x 3 in a low salt wash buffer (25mM TRIS, 
120mM NaCl, pH 7.4) and x 3 in a high salt wash buffer (250mM TRIS, 1M 
NaCl, pH 7.4). After washing, all solution was removed from the eppendorfs 
using crimped gel loading tips. Reducing sample buffer (2X) was 
immediately placed into the beads. The samples were heated at 95°C for 3 
minutes and loaded onto a polyacrylamide gel to be analysed by western 
blot.  
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2.2.13: RNA interference 
From a biochemical perspective, the technique of RNA interference is a 
method that introduces small interfering RNA (siRNA) molecules into a 
cultured cell whereby they bind to the targeted portions of mRNA strands 
and block gene expression. The result is down regulation of a targeted 
protein’s expression levels. In CHO cells, the expression of RNF181 was 
targeted by siRNA. Given that cells such as CHO rapidly divide, (with a 
doubling time of 1 day) the effect is transient. Therefore experiments must be 
systematically optimised for the most favourable conditions based on; i) 
siRNA concentration - too much can be highly toxic and cause cell death; ii) 
transfection efficiency – the ratio of cells with siRNA: cells without siRNA at 
the final stage of functional examination; iii) peak time point - when the knock 
down will be most effective. 
 
2.2.13.1: siRNA design 
To design siRNAs, the DNA sequence that encodes for the protein RNF181 
was obtained the genomic database at ncbi.nlm.nih.gov. There are various 
online tools that can help design siRNA molecules that will efficiently target a 
govern sequence. Small interfering RNA’s that fit a set of criteria were 
selected. These are described in the results section of chapter 5 in this 
thesis. Overall, three siRNA molecules were chosen that targeted the 
prescribing mRNA for RNF181 and generated by Sigma Aldrich, Ireland. The 
sequences were as follows;  
 
siRNA #1 
Sense             5’ GGCAGCAGAUCACUCUUUA dTdT   3’  
Antisense       5’ UAAAGAGUGAUCUGCUGCC dTdT   3’   
siRNA #2  
Sense             5’ AUGAAGAGCACAAGAAAGA dTdT   3’ 
Antisense       5’ UCUUUCUUGUGCUCUUCAU dTdT  3’ 
siRNA #3 
Sense       5’ GGAUGGACUUUGAGGACUU dTdT 3’ 
Antisense      5’ AAGUCCUCAAAGUCCAUCC dTdT 3’ 
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The selected siRNA were cross checked with regions of alternative mRNA 
molecules in the CHO cell line to rule out potential nonspecific interactions 
by carrying out a basic local alignment search (BLAST) (at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi).   
 
2.2.13.2: siRNA delivery 
To determine the optimal conditions for RNA interference, initial experiments 
delivered one control siRNA and three individual targeting siRNA into 
separate populations of CHO cells at two different concentrations (10nmoles 
and 25nmoles) over a range of incubation times (72 - 120 hours). At the 
same time, a CHO cell population treated under normal conditions and a 
population treated with transfection reagent only were subjected to the same 
incubations times and assay analysis as the siRNA samples. To carry out 
these experiments; 10μM stock concentrations of siRNA were prepared by 
solubilising each vial of siRNA in RNase free water. The solutions were 
gently resuspended and aliquoted in smaller volumes for storage at -20°C to 
avoid freeze thaw cycles. To carry out transfection, the siRNA was added (to 
the indicated final concentration) to an eppendorf containing 100μl of 
transfection medium (OptiMem) and mixed gently with a pipette to make 
solution A. Three microlitres of CHO cell transfection reagent (Altogen 
Biosystems, Las Vegas, USA) was added to another eppendorf containing 
100μl of transfection medium to make solution B. This step was repeated for 
all siRNA molecules to be tested. Eppendorfs were systematically labelled to 
describe their designated wells in the plate. Solution A was added to solution 
B with a pipette and gently mixed to make solution C. This mixture of 
transfection medium, transfection reagent and siRNA was left to sit at room 
temperature for 15 – 45 minutes. Cells that had been seeded the night 
before (at a concentration of 3x103/ml) in cell culture medium free from fetal 
calf serum and antibiotics at were washed with 2mls of transfection medium. 
800μl of transfection medium was added to each solution C, mixed and then 
immediately added to each prescribed well. Cells were incubated for 7 hours 
at 37°C in a CO2 incubator. The transfection reagent / siRNA mixture was 
removed and replaced with DMEM containing 2X antibiotic and 2X FCS. This 
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promoted cell replenishment after the toxic effects of the transfection. Cells 
were incubated for a further 24 hours. Media was again removed and 
replaced with normal DMEM (1X antibiotics, 1X FBS) and incubated for 
further 48 - 96 hours. Cells were then removed from the incubator after each 
time point and assayed. To assay the cells by western blot, media was first 
removed. 300μls of 2x reducing sample buffer was added. Cells were 
vigorously scrapped with a cell scraper and pipetted into a 1.5ml eppendorf 
and stored at -80°C until further analysis. For adhesion assays, following 
siRNA transfection protocol, the cells were removed using cell dissociation 
solution and carried through with the methods described in section 2.2.3. 
 
 
2.2.14: Recombinant poly His-tagged RNF181 protein expression in 
E.coli 
Poly-His tagged recombinant RNF181 was generated using an e-coli 
bacterial strain transfected with a DNA construct encoding for the RNF181 
human gene as described (Brophy et al. 2008). To express the recombinant 
protein, a 250ml volume of LB broth (1% tryptone, 0.5%yeast extract, 1% 
NaCl) was first prepared and autoclaved at 121°C for 30 minutes. 60μl of the 
E.coli stock was then added to 20ml’s of the LB broth containing 0.1mg/ml of 
ampicillin in a 500ml autoclaved conical flask. The top of the flask was 
plugged with cotton wool (to filter the air needed for E.Coli growth) and 
placed overnight in an incubator at 37°C, shaking at 200rpm. The next 
morning the remaining LB broth (230ml) was added to the overnight culture 
and incubated for 3 hours at 37°C while shaking at 200rpm. Isopropyl β-D-
thiogalacto pyranoside (IPTG) was then added to a final concentration of 
1mM and incubated at 37°C while shaking at 200rpm for 4 - 5 hours. The 
E.Coli containing LB broth was then poured into 50ml tubes and placed on 
ice. The tubes were then spun in a centrifuge at 4000g for 10 minutes at 4°C 
to pellet the E.Coli cells. The LB broth was removed and discarded. While 
being kept on ice, the E.Coli pellet was resuspended in 2mls of phosphate 
buffer saline (PBS), transferred to 2ml sized eppendorfs and spun again at 
4000g for 10 minutes at 4°C. The supernatant was removed leaving a pellet 
 59 
of E.Coli cells in the eppendorfs. Pellets were given a shock freeze by 
placing the eppendorfs into a container of liquid nitrogen. When the pellets 
turned a white colour the eppendorfs were removed from the nitrogen and 
left on ice to thaw for 20 minutes. This helped lyse the bacterial cells. Pellets 
were resuspended in 1ml of bacterial lysis buffer (50mM TRIS pH 8, 300mM 
NaCl, 10mM Imidazole, 1mM phenyl methane sulfonyl fluoride – PMSF*, 
0.06% w/v RNase, 0.06% w/v DNase, 0.06% w/v lysozyme, 62.5% v/v dH2O, 
10μl per sample of protease inhibitor cocktail), vortexed vigorously for 30 
seconds and placed at 4°C overnight.  
 
2.2.14.1: Purification of poly His-tagged RNF181 protein 
RNF181 protein was purified from the lysis solution by first centrifuging the 
samples for 10 minutes at 10,000g at 4°C and collecting the supernatant into 
new 2ml sized cold eppendorfs. 100μl of Ni-NTA agarose resin (a charged 
nickel agarose resin capable of binding strongly to proteins that contain a 
polyhistidine sequence in their structure) was then added to the supernatant 
and rotated end over end for 1 hour at 4°C to allow protein – resin binding. 
Samples were then collectively placed into one 5ml propylene column (from 
Qiagen LTD, UK) and left alone to allow the beads to pack into the column. 
The column tip was removed and the sample was allowed to drip through by 
adding pressure with the column lid. A sample fraction was collected (with 
additional fractions being collected where indicated, at every other stage of 
the purification process) to run on a 10% SDS-PAGE gel to test the 
purification of the protein from start to finish. A low Imidazole concentration 
(150ml) wash buffer (50mM TRIS-pH8, 300mM NaCl, 20mM Imidazole, 1mM 
PMSF*, 60.6% v/v dH20) was added to the column and allowed to pass 
through to remove any proteins non-specifically bound to the Ni-NTA 
agarose resin. Additional sample fractions were collected every 50ml to run 
on a gel to test the purification of the protein from start to finish. Following 
the wash procedure, polyhistidine tagged RNF181 was eluted from the Ni-
NTA agarose resin using 1ml x 5 of a high Imidazole concentration elution 
buffer (50mM TRIS-pH8, 300mM NaCl, 250mM Imidazole, 1mM PMSF* in 
dH20) and placed immediately on ice. The excess Imidazole displaces the 
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His-tag from the Nickel bound resin thus releasing the recombinant protein. 
50μl fractions per 1ml of elution were collected to run on a gel to test for 
purification. Samples were prepared for freeze drying by buffer exchange 
into 20mM NH4HCO3 buffer using 2ml size Zeba desalting spin columns (a 
rapid technique for buffer exchange) according to manufacturer’s 
instructions. Samples were placed in aliquots (1.5ml) in pre-weighed, 2ml 
eppendorf tubes and frozen at -20°C for 3 – 4 hours before being transferred 
to -80°C overnight. Right before freeze drying the samples were placed in 
liquid nitrogen. This stepwise freezing protocol helps to preserve the tertiary 
structure of the recombinant protein. The pre-weighed eppendorfs had the 
cap removed and replaced with a plastic film with punctured holes. Samples 
were then placed in a Maxy-Dry-Lyo freeze dryer overnight until samples 
were lyophilized. Pre-weighed eppendorfs were then re-weighed to 
determine the quantity of protein per eppendorf.  Protein was then stored at -
20°C until required.  
(*PMSF – added to the lysis buffer just before use) 
 
 
 
2.2.15: Integrin αIIbβ3 preparation 
Human integrin αIIbβ3 was purchased (from Enzyme Research Laboratories) 
in a buffer containing 50% v/v glycerol. This protein was purified from 
outdated activated human platelets obtained from the Blood transfusion 
laboratories. To use this protein in in vitro assays, it was crucial to eliminate 
the glycerol. Dialysis was used for this step by preparing 5 litres of desired 
assay buffer in a larger container. A slide-A-lyzer dialysis cassette (Thermo 
Fischer Scientific) was placed into the buffer for 30 seconds for hydration 
purposes prior to use. Using a 21 gauge needle, up to 2ml of sample was 
injected into the cassette through an injection port. The cassette was placed 
into the 5 litres of buffer with a buoyancy device attached and put in the 
fridge on a magnetic stirrer at a low stir speed. After 4 – 5 hours the total 
buffer was replaced with fresh buffer and left dialyzing overnight. Next day, 
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the sample was carefully removed with a syringe and the protein 
concentration estimated using the Bradford assay. Samples were then 
concentrated (if needed) by using amicon ultra centrifuge tubes (from 
Millipore) according to the manufacturer’s instructions.   
 
 
2.2.16: PepSpot peptide arrays on cellulose  
Cellulose membranes carrying peptides originating from the native sequence 
of RNF181 protein (PepSpot membrane I and II) were generated by JPT 
Peptide Technologies, Germany. PepSpot membrane I contained 49 
overlapping linear peptides (nine residues in length, overlap of six residues, 
protein N-terminus as starting point) derived from the entire RNF181 protein 
sequence (153 residues). Peptide C-termini were anchored onto the 
cellulose membrane via a 6-aminohexanoic acid (Ahx) spacer. The top and 
middle rows on PepSpot membrane II carried 37 overlapping linear peptides 
(ten residues in length, overlap of six residues) also derived from the native 
protein sequence, whereas the bottom row presented additional ten peptides 
also contained on PepSpot membrane I. The peptides plotted onto PepSpot 
membrane II were C-terminally attached to the cellulose membrane via an -
alanine spacer. The sequences of all peptides spotted onto PepSpot 
membrane I and II are given in table 2.2.1, B. 
Three identical copies of PepSpot membrane I and II, respectively, were 
used as follows: Membranes were blocked overnight at 4°C with 5% BSA in 
T-TBS (50 mM Tris, 137 mM NaCl, 2.7 mM KCl and 0.05% Tween-20). 
Membranes were then incubated for three hours at room temperature with 
0.5 mol biotin-Ahx-LAMWKVGFFKR-NH2 or a control peptide, biotin-Ahx-
MRDKAPGQ-NH2 (JPT Peptide Technologies), in 3% BSA/T-TBS. 
Thereafter, membranes were washed three times with T-TBS for five 
minutes, respectively, and incubated with avidin-horseradish peroxidase 
(1:100000 in 3% BSA/T-TBS) for one hour at room temperature. 
Subsequently, the membranes were washed five times with T-TBS for five 
minutes and then twice with TBS for 5 minutes, respectively. Avidin detection 
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was analyzed with SuperSignal WestPico. PepSpot membranes were 
regenerated with regeneration buffer IIA (8 M urea, 1% SDS, 0.1% 2-
mercaptoethanol) and regeneration buffer IIB (40% H2O, 50% ethanol, 10% 
acetic acid) according to the manufacturer’s instructions. 
 
 
 
Table 2.2.1: Amino acid sequence of RNF181 and the peptide fragments 
arrayed on the PepSpot membranes 1 and 2.  
The full length sequence of RNF181 (Q9P0P0 (RN181_HUMAN) derived from 
UniProtKB/Swiss-Prot is displayed (A). Starting at the N-terminus and ending at the 
C-terminus, the full length sequence of RNF181was diced into short linear 
overlapping peptides and arrayed onto nitrocellulose membranes (PepSpot arrays). 
The PepSpot arrays were generated by JPT technologies, Germany. The position 
and sequence for each peptide is displayed (B). The PepSpot membrane 1 has 49 
peptides; nine amino acids long, overlapping by six residues. PepSpot membrane 2 
has 37 peptides derived from RNF181 that are ten amino acids in length and 
overlap by six. Ten additional peptides are arrayed on PepSpot 2 at position 38 – 46 
that were positive for peptide binding from PepSpot membrane 1.  
 
 
RNF181 protein sequence 
MASYFDEHDCEPSDPEQETRTNMLLELARSLFNRMDFEDLGLVVDWDHHLPPPAAKTVVENLPRTVIRG
SQAELKCPVCLLEFEEEETAIEMPCHHLFHSSCILPWLSKTNSCPLCRYELPTDDDTYEEHRRDKARKQQ
QQHRLENLHGA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PepSpot membrane 1 
01 MASYFDEHD 11 LFNRMDFED 21 NLPRTVIRG 31 EMPSHHLFH 41 PTDDDTYEE 
02 YFDEHDSEP 12 RMDFEDLGL 22 RTVIRGSQA 32 SHHLFHSSS 42 DDTYEEHRR 
03 EHDSEPSDP 13 FEDLGLVVD 23 IRGSQAELK 33 LFHSSSILP 43 YEEHRRDKA 
04 SEPSDPEQE 14 LGLVVDWDH 24 SQAELKSPV 34 SSSILPWLS 44 HRRDKARKQ 
05 SDPEQETRT 15 VVDWDHHLP 25 ELKSPVSLL 35 ILPWLSKTN 45 DKARKQQQQ 
06 EQETRTNML 16 WDHHLPPPA 26 SPVSLLEFE 36 WLSKTNSSP 46 RKQQQQHRL 
07 TRTNMLLEL 17 HLPPPAAKT 27 SLLEFEEEE 37 KTNSSPLSR 47 QQQHRLENL 
08 NMLLELARS 18 PPAAKTVVE 28 EFEEEETAI 38 SSPLSRYEL 48 HRLENLHGA 
09 LELARSLFN 19 AKTVVENLP 29 EEETAIEMP 39 LSRYELPTD 49 ENLHGAMYT 
10 ARSLFNRMD 20 VVENLPRTV 30 TAIEMPSHH 40 YELPTDDDT   
 
PepSpot membrane 2 
01 MASYFDEHDC 11 GLVVDWDHHL 21 LEFEEEETAI 31 PTDDDTYEEH 38 ARSLFNRMD 
02 FDEHDCEPSD 12 DWDHHLPPPA 22 EEETAIEMPC 32 DTYEEHRRDK 39 NLPRTVIRG 
03 DCEPSDPEQE 13 HLPPPAAKTV 23 AIEMPCHHLF 33 EHRRDKARKQ 40 HRRDKARKQ 
04 SDPEQETRTN 14 PAAKTVVENL 24 PCHHLFHSSC 34 DKARKQQQQH 41 MASYFDEHD 
05 QETRTNMLLE 15 TVVENLPRTV 25 LFHSSCILPW 35 KQQQQHRLEN 42 RTVIRGSQA 
06 TNMLLELARS 16 NLPRTVIRGS 26 SCILPWLSKT 36 QHRLENLHGA 43 KTNSSPLSR 
07 LELARSLFNR 17 TVIRGSQAEL 27 PWLSKTNSCP 37 LENLHGAMYT 44 DKARKQQQQ 
08 RSLFNRMDFE 18 GSQAELKCPV 28 KTNSCPLCRY   45 ELKSPVSLL 
09 NRMDFEDLGL 19 ELKCPVCLLE 29 CPLCRYELPT   46 RKQQQQHRL 
10 FEDLGLVVDW 20 PVCLLEFEEE 30 RYELPTDDDT   47 DKAAAAQQQ 
B 
 
B 
A 
 
 
RNF181 protein sequence 
MASYFD CEPSDPEQETRTNMLLELARSLFNRMDFEDLGLVVDWD HLPPPAAKTVVENLPRTVIRGSQAELKCPVCLLEFEEEETAIEMPCHHLFHSSCILPWLSKTNSCPLCRYELPTDDDTYEEHRRDKARKQQQQHRLENLHGA 
 A 
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2.2.17: Pull down of native and purified integrin IIb3 with RNF181 
derived peptides  
Three biotinylated, peptides were purchased from JPT Peptide Technologies: 
two wild-type RNF181 peptides (Biotin-130HRRDKARKQ138, and a control, 
Biotin-1MASYFDEHD9) with the third being a modified test peptide containing 
three alanine substitutions, Biotin-130HRRDKAAAA138. 50 g/ml of the 
respective peptides were incubated with purified integrin IIb3 (Enzyme 
research laboratories, UK) in binding buffer A (25 mM HEPES, 150 mM NaCl, 
20 mM MgCl2, 5 mM CaCl2, 0.01% Tween-20, pH 7.4) for two hours at 4°C. 
Protein was precipitated with 30 l/ml streptavidin-agarose beads overnight at 
4°C. Beads were washed four times with binding buffer A and then boiled in 
SDS-sample buffer for three minutes. Thereafter, samples were loaded into 4-
20% gradient gels (from Thermo Fischer Scientific), separated by SDS-PAGE, 
transferred onto nitrocellulose membranes and probed with anti-IIb SEW-8 
(kind gift of Prof. Newman, Blood Research Institute, Milwaukee, WI, USA). 
Antibody detection was analyzed via SuperSignal WestPico. 
 
Peptide: protein (IIb3) interaction experiments in platelet lysates were 
performed using washed platelets prepared as described in section 2.2.1. 
Aliquots (800l) from 1x108 platelets/ml were lysed under sonification (twice 
for five seconds on ice) in 200l binding buffer B comprising 125 mM HEPES, 
150 mM NaCl, 100 mM MgCl2, 25 mM CaCl2, 0.075% Tween-20, pH 7.4, 
protease inhibitor cocktail and 1 mM PMS. Platelet lysates were incubated 
with the respective peptides as described above in the case of purified integrin 
and analysed by SDS-PAGE followed by western blotting. 
 
 
2.2.18: Isothermal titration calorimetry (ITC) 
ITC is a method that carries out real time, thermodynamic measurements of 
molecular interactions between a ligand and a target in solution. Measuring 
the total energy change of a reaction can determine the equilibrium binding 
constant (Ka), free energy change (ΔG), the enthalpy change (ΔH), the 
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entropy change (ΔS) and the stoichiometry (n) of the event. ITC analyses 
were carried out with the ITC200 (GE Healthcare Life Sciences, UK). The 
selected proteins for analyses included recombinant RNF181 and purified 
integrin αIIbβ3. The selected peptides for ITC analyses were based on 
previously identified binding regions between RNF181 and integrin αIIbβ3 and 
(Chapter 4) and from RNF181, these included 130HRRDKARKQ138 and 
133DKARKQQQ140 as test peptides and 1MASYFDEHD9 as a control peptide. 
Whereas the integrin αIIbβ3 derived peptides included one test peptide; 
985LAMWKVGFFKRNRPPLE1001 and one control peptide; 
RMALEVGAAEENEPPLR. The control peptide sequence was selected from a 
list of hypothetical controls peptides generated at 
bioware.ucd.ie/~compass/biowareweb/. The peptide was based on the 
original 985LAMWKVGFFKRNRPPLE1001 sequence but which had its positive 
amino acids replaced with negative residues and had hydrophobic regions 
replaced with random alternative hydrophobic regions. Proteins were 
prepared for ITC analyses by extensively dialysing (as described previously; 
section 2.2.15) in an ITC buffer-A (25mM TRIS, 100mM NaCl, 1mM CaCl2, 
0.1% (v/v) Triton 100X, pH 7.4) while peptides were prepared by solubilising 
with an ITC buffer-B (25mM TRIS, 100mM NaCl, pH 7.4). ITC runs were 
carried out by loading samples into the ITC syringe and cell according to the 
manufacturer’s instructions. The ITC command software was set up with; 
reference power (DP) set at 6; temperature set 25ºC; injections volume of 1 - 
2µl per injection; 180 seconds between each injection; 1000 oscillations/min 
stir speed. Data was acquired and analysed according to the manufacturer’s 
instructions using proprietary software (Origin) for the analysis of the reaction 
parameters. 
 
 
2.2.19: Microscale Thermophoresis (MST) 
Microscale thermophoresis is a method used to measure biomolecular 
interactions in vitro and is based on the movement of molecules in a 
temperature gradient environment (Jerabek-Willemsen et al. 2011). To 
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determine the interaction capacity between purified integrin αIIbβ3 and human 
fibrinogen or recombinant human RNF181 protein, thermophoresis was 
applied on separate occasions for each interaction. The integrin αIIbβ3 was 
labelled with NT-647 dye using NanoTemper’s Protein labelling Kit RED 
(NanoTemper Technologies) according to the manufacturer’s instructions. The 
concentration of the labelled integrin was kept constant at ~20nM 
concentration. For the unlabelled partners (RNF181 and Fibrinogen) 8 (1:2) 
serial dilutions were prepared using MST buffer (50 mM Tris (pH 7.6), 150 mM 
NaCl, 1 mM CaCl2, 0,05 % tween-20) starting at a highest concentration of 
25µM for fibrinogen and 100µM for RNF181. 10µl of the diluted unlabeled 
molecule was mixed with 10 µl of the diluted fluorescently labeled molecule. 
The samples were then loaded into standard treated MST-grade glass 
capillaries and after a short incubation period a MST-Analysis was performed 
using the Monolith NT.115. This machine was on demonstration (from 
NanoTemper Technologies, Germany) for a limited time and only one analysis 
for each reaction was carried out.  
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Chapter 3 
Confocal Microscopy;  
Protein co-localization studies 
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3.1: Introduction 
It is well known that platelet adhesions to thrombotic surfaces are important 
events for haemostasis and thrombosis. There are a number of thrombotic 
substrates that affect platelet adhesion which includes the integrin αIIbβ3 
ligand; fibrinogen. As a soluble plasma protein, fibrinogen is present in 
circulation at high concentrations with elevated levels being implicated in 
thrombosis and atherosclerosis development (van der Bom et al. 1998). 
Nevertheless, soluble fibrinogen can only bind to the integrin that is in an 
active conformation. However, when it adopts an immobilized structure, such 
as on the surfaces of damaged vascular endothelium and atherosclerotic 
plaques (Ruggeri 2002), fibrinogen acts as a high affinity ligand to integrin 
αIIbβ3 that is in a resting conformation where it gives rise to a potent and 
irreversible adhesion response (Savage, Saldivar, and Ruggeri 1996). The 
interaction between immobilized fibrinogen and integrin αIIbβ3 on the surface 
of platelets induces outside-in signalling events causing disruption of 
cytoskeletal actin and secretion of platelet agonists (Flaumenhaft et al. 2005) 
which ultimately lead to platelet spreading. Intracellular proteins involved in 
platelet adhesion and spreading include the direct and indirect integrin 
binding proteins; talin (Shattil, Kim, and Ginsberg 2010) and actin (Legate et 
al. 2006). Talin recruitment to the cytoplasmic region of integrin αIIbβ3 is a 
direct consequence of agonist induced platelet activation and promotes 
inside-out integrin activation by disrupting the salt bridge between the 
cytoplasmic tails of the α and Β subunits (Anthis, Wegener, et al. 2009). In 
addition, talin acts as an adaptor protein, linking filamentous actin with 
integrin thereby facilitating a connection between the extracellular matrix and 
the actin cytoskeleton (Critchley 2005) during which actin undergoes 
structural reorganization to promote a complete response to platelet and 
integrin activation. It is unclear whether talin is recruited to activate integrins 
following adhesion of resting platelets to immobilized fibrinogen prior to 
inside-out signalling. Since the integrin cytoplasmic domains are key 
recognition sites for the binding of multiple proteins likely to play key roles in 
integrin regulation and given that there is such high expression levels of 
integrin αIIbβ3 on the surfaces of platelets, there is no doubt that vast arrays 
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of other proteins present in platelet proteome directly regulate the activity of 
integrin activation.  
 
In recent years, the proteins HIC-5 and in particular RNF181 have been 
implicated in integrin-related functions in platelets (Daxecker et al. 2008) with 
the latter showing potential to bind to the conserved region (989KVGFFKR995) 
of the integrin αIIb cytoplasmic tail (Brophy et al. 2008). However, data 
published to date remains provisional and the nature of integrin activation in 
which RNF181 associates is uncertain. On the other hand HIC-5 has been 
implicated as regulator of thrombin induced integrin αIIbβ3 activation and 
platelet aggregation in murine platelets (Kim-Kaneyama et al. 2012). 
However, its association with integrin in an activation dependant manner is 
also undecided.   
 
The general aims of this chapter are therefore; to establish robust 
microscopy conditions to examine protein co-localization in platelets and 
CHO cells during the process of cell spreading on fibrinogen. Using talin and 
actin as indicators of known co-associates and HIC-5 as an unknown, a 
particular emphasis will be on determining if there is an activation dependent 
relationship between RNF181 and integrin αIIbβ3 during cell spreading on 
fibrinogen.  
 
 
3.2: The concept of confocal microscopy 
Fluorescent microscopy can provide evidence for protein interactions based 
on co-localization.  Image acquisition by confocal microscopy works different 
to standard widefield microscopy (Figure 3.1) where the latter acquires 
images by flooding the entire field of view with light and capturing the entire 
3D planes to generate a 2D image. In contrast, confocal microscopy 
captures specific planes of view through point illumination. The significance 
of this is to generate a 2D image from any 2D x, y plane within a 3D 
structure. What is more, stacking collective 2D images of x, y planes can 
generate a 3D image of the sample under investigation. Since many protein 
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structures are distributed into various subcellular regions, confocal 
microscopy is a very reliable method for representing the true nature of a 
protein’s location.  
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Figure 3.1: The method of how confocal microscopy captures images 
by point illumination in comparison to standard widefield microscopy 
The illustration provides a simple description of how cells can be 
differentially imaged using widefield microscopy (A) and confocal microscopy 
(B). A; Bright field microscopy fills a cell with light to capture an image. Focal 
planes in and out of focus are captured collectively to give a weak resolution 
in comparison to other microscopic methods. B; A confocal microscope 
builds an image by point illumination with a laser in combination with a 
scanning device that scans across the region of interest in a raster pattern 
from 128x128 to 1024x1024 sequential lines on the plane. Focal planes 
which are illuminated, but that are out of focus are excluded by the pinhole.  
 
 
 
All images in this chapter were acquired using a Zeiss laser scanning 
confocal microscope (LSM510). The fluorophores; alexa-fluor488 and alexa-
fluor546 were used as complimentary labels to targeting antibodies. 
Multitrack acquisition (which is a method that acquires images sequentially, 
rather than simultaneously) was employed to give a more precise 
measurement of co-localization because the absorption and emission 
A B 
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spectra between the fluorophores overlapped (as depicted in figure 3.2) 
which can give rise to cross talk. In addition, emission filters for the 488 
excitation probe had a band width of between 509-542nm and 560-615nm 
for the 546 probe. The objective magnification used was 63x with a 1.4 
numerical aperture oil immersion.  
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Figure 3.2: The spectral excitation and emission wavelength ranges for 
alexa-Fluor488 and alexa-Fluor546 
Detailed in the figure above are the excitation and emission wavelengths of 
the fluorophores used throughout this chapter. Grid A depicts alexa-fluor488 
excitation and emission capacities while grid B describes alexa-fluor546 
excitation and emission capacities.  
 
 
 
 
 
 
Results 
3.3: Establishing robust methods for confocal imaging in platelets 
Levels of excitation and detection of the fluorophores are important factors 
that are to be controlled for when examining protein co-localization by 
confocal microscopy. Following excitation, photons are emitted and captured 
by a photodetector that transfers the light signal into an image. Due to 
photodetector sensitivity, very small quantities of photon emissions are 
converted and amplified into large signals.  High detector gain can create 
A B 
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images with fluorescence that is far above a quantifiable range. This can 
give a misrepresentation of the quantity and locality of a particular labelled 
protein or lead to a signal where it appears that proteins of interest are 
localized together even though they might not be. 
On the other hand, if the detector gain is set significantly low, this can 
misrepresent the labelled proteins, therefore underreporting the level of an 
entity within an image. For this reason an LSM software tool (range 
indicator) can depict how much signal lies within range of the photodetector. 
By utilizing the range indicator, Figures 3.3 and 3.4 illustrate how maximizing 
or minimizing the detection range can lead to images of various natures with 
regard to protein distribution within the cell, especially in relation to protein 
co-localization. Focusing on the cell indicated by the single arrow in Figure 
3.3, excessively high detection from labelled integrin αIIbβ3 (image A) and 
RNF181 (image B) that represent fluorescence from integrin αIIbβ3 and 
RNF181 (in images C and D) indicate a platelet which appears to have very 
strong co-localization between the labelled proteins (Figure 3.3, image E).  
However, this fluorescence is far above range and therefore, selecting this 
particular cell for positive co-localization would be inaccurate. Optimal levels 
of detection for determining a more accurate nature of protein co-localization 
is represented by double arrows in Figure 3.3. In contrast, reducing detector 
gain to levels below range can also give rise to images of a different 
description. Focusing on the cell that was described as having co-localized 
integrin and RNF181 (Figure 3.3, E, double arrows); and then reducing 
fluorescent detection to levels below optimal range; (indicated by single 
arrows in Figure 3.4 A and B), the two proteins do not appear to be co-
localized (single arrow in Figure 3.4, E).  All images examined for co-
localization were acquired by consistently using the strictest methods for 
detecting protein fluorescence, as demonstrated above.  
. 
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Range indicator  Range indicator 
  
αIIbβ3 fluorescence  RNF181 fluorescence 
  
Merged        DIC 
  
Figure 3.3: Capturing fluorescence from labelled proteins using high 
detection settings 
Washed platelets were adhered for 15 minutes to a fibrinogen (25µg/ml) 
coated microscope slide. Cells were fixed with 3.8% paraformaldehyde and 
permeabilised with 0.1% Triton-100X. The proteins RNF181 and integrin 
αIIbβ3 were labelled with anti-rabbit and anti-mouse targeting antibodies, 
respectively. Secondary, goat anti-mouse and goat anti-rabbit antibodies (at 
a 1:500 dilution) conjugated with alexa-fluor 546 and alexa-fluor488 
respectively were added. The slide was then covered and images were 
acquired using a zeiss laser scanning microscope; LSM510. Using the range 
indicator on the LSM510 acquisition software, images were acquired with the 
detector gain set high. Panels A and B illustrate the range indicator used to 
capture fluorescent intensity from integrin αIIbβ3 (A) and RNF181 (B). Single 
arrows (in red) indicate over exposure of fluorescence. Double arrows (in 
green) indicate the optimal range to be set for detection of co-localization. 
Panels C and D illustrate normal fluorescence for integrin αIIbβ3 and RNF181. 
Image E is a merger of C and D. Image F is the Differential interference 
contrast (DIC) of the selected frame. Scale bars represent 5μm. 
A B 
C D 
E F 
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Range indicator  Range indicator 
  
 
αIIbβ3 fluorescence  RNF181 fluorescence 
  
 
Merged   DIC 
  
Figure 3.4: No co-localization is observed when capturing fluorescently 
labelled proteins using low detection settings 
The platelet images above are identical to the images in figure 3.3 except 
that during image acquisition, the range indicator was used to keep 
fluorescent detection at a minimum. Panels A and B are the range indicators 
for αIIbβ3 and RNF181 fluorescence respectively. C and D display normal 
fluorescence for αIIbβ3 and RNF18 respectively. Image E represents a 
merger of RNF181 and integrin αIIbβ3 fluorescence, while image F is the 
differential interference contrast (DIC) of the selected frame. Arrows indicate 
the platelet from Figure 3.3 that appeared positive for co-localization. Scale 
bars represent 5μm. 
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3.4: Controls 
To highlight the specificity of antibodies for their targets, control assays using 
only goat anti-mouse and goat anti-rabbit fluorescently conjugated antibodies 
were carried out and behaved as expected in platelets. (Figure 3.5, panels A 
and B). Non-permeabilised cells probed with rabbit anti-RNF181 and anti-
rabbit fluorescently conjugated antibodies revealed no fluorescent detection, 
demonstrating the cytoplasmic constraints of RNF181 and the specificity of 
anti-RNF181 antibody (Figure 3.5, panels C and D). The non-integrin αIIbβ3 
expressing CHO-MOCK cells show the presence of RNF181 (Panel E). The 
same frame as in panel E, but fluorescently probed for integrin αIIbβ3 
demonstrated no fluorescence as expected (panel F).  
 
  
  
  
Figure 3.5: Washed platelets and CHO cells labelled with non-specific, fluorescent 
antibodies 
Washed platelets were adhered to a 25µg/ml fibrinogen coated surface for 45 minutes. In 
panels A and B, platelets were incubated goat anti-mouse and goat anti-rabbit, alexa-
fluor488 and 546 conjugated antibodies. No primary antibodies were previously added. 
Images were acquired by DIC (A) and for fluorescence (B). Panels C and D, platelets were 
fixed but not permeabilised before being incubated with rabbit anti-RNF181 and goat anti-
rabbit. DIC (C) and fluorescence imaging (D) was performed.  Panels E and F, CHO MOCK 
cells were adhered to BSA for 45 minutes and fluorescently labelled for RNF181 (E) and 
integrin αIIbβ3 (F) as described in figure 3.3. Scale bars represent 10μm.  
10µm 
10µm 10µm 10µm 
A B 
C D 
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3.5: Timing of adhesion for image acquisition 
Platelet adhesion to exposed subendothelial components of damaged 
vasculature is a crucial step in haemostasis. This adhesive property to 
fibrinogen also plays a significant role to thrombosis. Using RNF181 protein 
immunostaining, the dynamic shape changes that a platelet undergoes when 
adhering to and covering a ligand surfaces is represented in Figure 3.6. 
Washed platelets were added to a BSA coated surfaces for 45 minutes or 
fibrinogen substrate for 5, 15 and 30 minutes. Platelets adhered to BSA 
(panels A) demonstrate that the cells were in a resting condition following 
their preparation. The differences in platelet morphology as they spread on 
immobilized fibrinogen are evident in panels B, C and D. Platelets develop 
extended filopodia after 5 minutes adhesion to fibrinogen (panel B).These 
extensions are followed by the enhancement of protruding features into a 
more spread lamellapodia structure after 15 minutes adhesion to fibrinogen 
(images C) followed by an increase in surface area into a fully spread 
platelet after extended adhesion times (Image D). Overall, these structural 
changes are important to note when trying to determine what stages of 
platelet shape change do proteins co-localize.  
 
    
Figure 3.6: Washed platelets undergoing time dependent changes in 
their morphologies following adhesion to fibrinogen 
Washed platelets were adhered to poly-L-lysine microscope slides that were 
pre-coated with 1.5% (w/v) BSA (panel A) or 25µg/ml of fibrinogen (panels B, 
C and D) for the times indicated below. Fluorescent staining for RNF181 
protein (in red) was carried as described in fig legend 3.3. Platelets are 
adhered to BSA for 45 minutes (A). Representative images of platelets 
spreading for 5, 15 or 30 minutes on a fibrinogen coated substrate are shown 
in panels B, C and D, respectively. Scale bars represent 10µm. Images are 
representative of four individual experiments.  
A B C D 
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3.6: Examining dual staining with αIIbβ3 and integrin binding and non-
integrin binding proteins 
From studying confocal microscopy, it has become apparent that making 
judgments on images to determine co-localization by a visual perspective 
alone can be questionable. To strengthen a verdict regarding protein: protein 
interactions by microscopy, including and discriminating with known integrin 
binding and non-binding proteins can improve analysis. Talin has been 
extensively studied and identified to play a specific role in integrin activation. 
This protein has been regarded as a key regulator of integrin activation 
through direct binding (Shattil, Kim, and Ginsberg 2010). To examine co-
localization, platelets adhered to fibrinogen were labelled with antibodies for 
both integrin αIIbβ3 and talin simultaneously. Fluorescent labelling gave a 
visual description of where a protein that interacts with and causes activation 
of integrin is most likely to be present in a spreading platelet (Figure 3.7, A). 
Co-localization between talin and integrin is most prominent at the periphery 
of the spreading platelets. In addition, examining a non-integrin binding 
protein was carried out by co-immunostaining for actin and integrin αIIbβ3 
(Figure 3.7, B). By comparing actin to talin and integrin co-staining (Figure 
3.7, A3), the merged image in Figure 3.7, panel B3 illustrates that actin and 
integrin αIIbβ3 do not have a direct interaction in platelets when spreading on 
immobilized fibrinogen. Overall, these images demonstrate the cellular 
location of a protein that directly activates the integrin αIIbβ3.  
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Talin   Integrin αIIbβ3   Merged 
   
 
Actin    Integrin αIIbβ3   Merged 
   
Figure 3.7: Fluorescent staining of proteins that directly influence (talin) 
and indirectly influence (actin) the activation status of integrin αIIbβ3 
To determine the manner of co-localization between a well established 
integrin regulating protein, talin and αIIbβ3, both proteins were examined by 
immunostaining washed platelets adhered to a fibrinogen coated surface (A1 
and A2). In addition, dual staining was carried out between integrin αIIbβ3 and 
actin (B1 and B2). Platelets were adhered for 45 minutes to a slide that had 
been pre-coated with 25gµ/ml of fibrinogen. Following adhesion, fixing and 
permeabilisation the cells were labelled with mouse anti-integrin αIIbβ3and 
rabbit anti-talin a dilutions of 1:1000 and 1:500 respectively. Cells were 
washed and incubated with alexa-fluor546 conjugated goat anti-mouse and 
alexa-fluor488 goat anti-rabbit (at a 1:500 dilution) for 1 hour. For actin 
staining, FITC conjugated phalloidin was incubated with platelets (at a 1:250 
dilution) following the labelling step with mouse anti-integrin αIIbβ3. Slides 
were covered and images acquired with a LSM510 confocal microscope. 
Talin (green) and integrin (red) staining is shown in panels A1 – A3. A3 is a 
merger of the two proteins. Actin and integrin staining is displayed in panels 
B1 – B3. Actin staining is green and integrin staining is red. B3 is a merger of 
B1 and B2. Scale bars represent 10µm. Talin images are representative of 
two separate experiments while actin staining are representative of four 
separate experiments. 
 
 
 
A1 A2 A3 
B1 B2 B3 
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3.7: Examining integrin αIIbβ3 and RNF181 co-localization by fluorescent 
staining in platelets 
One of the primary objectives of this thesis was to determine the nature of a 
RNF181 and integrin αIIbβ3 interaction. Confocal microscopy with dual 
protein immunostaining was carried out to examine if there was any 
particular time or particular location during platelet spreading on fibrinogen in 
which the two proteins co-localized. However, due to the limitations of the 
LSM510, the techniques of staining and  Over the following 3 pages directly 
below Figure 3.8 displays images representing platelets that were adhered 
to immobilized fibrinogen for the specific times of 5, 15, 30 45 and 90 
minutes and fluorescently labelled for RNF181 and integrin αIIbβ3 (panels A - 
I). Visual assessment identifies that RNF181 and integrin αIIbβ3 co-localize, 
particularly at the cell periphery of spreading platelets. Co-localization is 
apparent as early as 5 min (panel A) and persists for later measurements, 
except after 90 minutes of adhesion. However, no particular time point was 
recognized as the most prominent, to claim that an interaction between 
RNF181 and integrin αIIbβ3 occurs. Therefore statistical methods were 
employed to investigate RNF181 – integrin co-localization in platelets 
adhering to fibrinogen over time. These methods are elaborately explained in 
Section 3.8 with RNF181 and integrin αIIbβ3 co-localization analyses 
illustrated in Figures 3.10 and 3.11. 
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RNF181          Integrin αIIbβ3       Merged 
   
Figure 3.8: Co-localization between integrin αIIbβ3 and RNF181 in 
platelets spreading on immobilized fibrinogen. 
Panels A – I display representative images of washed platelets allowed to 
adhere to 25µg/ml of an immobilized fibrinogen surface for the times 
indicated below. Platelets were fluorescently labelled for integrin αIIbβ3 (red) 
and RNF181 (green) as described in figure 3.3. Two sets of images are 
shown for each time point to illustrate the extent and diversity of protein 
localization. Platelet adhesion and spreading times are as follows; A and B – 
5 minutes adhesion; C and D – 15 minutes adhesion; E and F – 30 minutes 
adhesion; G and H – 45 minutes adhesion; I – 90 minutes adhesion. Scale 
bars represent 10µm. Images are representative of four separate 
experiments... 
 
 
 
 
 
3.8: A statistical approach to measuring co-localization 
To examine co-localization in more depth, platelets co-immunostained for 
RNF181 and integrin αIIbβ3 were analyzed by a statistical approach using the 
colour intensity profile from the pixels of each image (Costes et al. 2004). 
The tools to measure co-localization were provided by the ImageJ plugin; 
“Just Another Colocalization Plugin” (JACoP), with Costes’ automatic 
threshold and randomization being checked from the analyses section 
before measuring with Pearson Coefficient. These tools have been 
established as competent methods for removing the bias of visual 
interpretation (Dunn, Kamocka, and McDonald 2011). The concept of 
Costes’ methods originates from the standard histogram profile that 
I1 I2 I3 
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determines the similarity of colour intensities from populations of two 
coloured pixels. To understand the approach taken by Coste, it is 
fundamental understand perception of image pixilation, which is described.  
 
Generally the colour of a pixel is formed by a combination of red, green and 
blue colour intensities and varies to any possible colour represented in 
Figure 3.9, A. However, imaging for this thesis was carried out with only two 
colours; red and green, so therefore, after removing blue from the picture, 
the possible colour for each pixel becomes simplified, as depicted in Figure 
3.9, B. Moreover, Figure 3.9, B can be viewed from a different perspective, 
i.e. as a graph characterizing the colour intensity histogram profile for all 
pixels of a two colour image. It is from this latter concept that JACoP takes 
advantage of to determine co-localization. To briefly explain the analysis, the 
x, y coordinates of a single (red; green) pixel on a histogram depend on the 
intensity values for both individual colours. This dependence can be 
measured by the Pearson Correlation Coefficient (denoted r). Pixels with 
similar colour intensities are given correlation values towards 1 and plot in a 
liner fashion, while weaker correlated pixels (where colour intensities differ) 
plot in a less linear fashion and are given an r value towards 0. Given that a 
pixel represents an original illumination point (such as a segment of two 
fluorescently labelled proteins), protein co-localization is quantified by pixel 
correlation. However, background areas are also pixilated and can contain 
correlated colours intensities. Therefore including these in the co-localization 
analysis would undoubtedly alter the correlation analysis in such a way that 
is not a direct representation of what is under examination. Therefore, to 
exclude background pixels and weakly correlated pixels that lack significant 
co-localization, threshold levels are set to exclude these regions. Figure 3.9, 
B signifies correlated pixels (on the trend line) and uncorrelated or 
background pixels in the red and green or black areas respectively.  
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Figure 3.9: The colour spectrum of a pixel in a digital image 
Pixels that build an image contain the primary colours red, green and blue. 
Different colour intensities, which are based on the colour of what a pixel is 
meant to represent can range anywhere in the block illustrated A. Confocal 
images used in this thesis are constructed from the two red and green colour 
channels, with blue removed. The colour spectrum of a single pixel with blue 
removed is illustrated in B. On a wider note, the graph B can also represent a 
2D histogram plot of pixels from a two coloured (red, green) image. 
Histogram plots used in this thesis are 2D and focus on red and green 
colours only.     
 
 
 
 
 
Background was estimated as the threshold colour intensity levels that 
provided pixel correlation values equal to zero. These threshold levels were 
calculated by i) setting levels to include all pixels; ii) determining the 
correlation and then iii) systematically reducing the threshold levels by 
decrements of one until a threshold intensity value is reached where 
correlation equals zero. The efficiency of this approach is illustrated in Figure 
3.10. Platelets adhered to fibrinogen for 5 minutes (A1) and 45 minutes (B1) 
were analyzed for pixel correlation (A2) and (B2) respectively; with 
background (Pearson Correlation) and without background (Costes’ 
Correlation). Figure 3.10; panel C, demonstrates the correlation values for 
co-localized pixels from images A1 and B1 over a range of threshold levels. 
B A 
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In addition, the significance of the original histogram analysis is inspected by 
randomly scrambling pixel blocks of a representative colour (i.e. red) and 
overlaying them onto the unscrambled opposing colour (i.e. green) and re-
calculating the correlation. Image A1 was used as a representative example. 
5000 pixel randomization rounds were preformed for all images analyzed 
with one randomized round displayed in panel A3. The distributed probability 
of getting an r value above or below zero for the randomized images is 
calculated (Figure 3.10, A4). All images selected for analysis showed zero 
correlation following random scrambling. In conclusion, the JACoP tool 
provides a non-biased method for removing background levels to determine 
co-localization based on pixel correlation. Moreover, the efficiency of this 
approach is recognized by determining the probability that the co-localization 
is due to a random affect.    
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Figure 3. 10: Colour intensity threshold limits from selected fluorescent 
images changes the correlation values between analyzed pixels 
The two separate images representing platelets adhered to fibrinogen for 5 minutes 
in A1 and 45 minutes in B1 which were immunostained for RNF181 and platelet 
integrin (as described in figure 3.3) were compared for co-localization analysis by 
determining the Pearson Correlation Coefficient of their respective pixel histograms 
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(A2 and B2). In addition, the significance of the histogram representing the 5 
minutes platelet adhesion image (A2) was determined by randomly scrambling the 
pixels from one colour channel and overlaying on to the unscrambled image, which 
was then re-analyzed for correlation. One example of a randomized image of A1 is 
illustrated in A3. 5000 randomization rounds were carried out. Zero correlation was 
estimated for the randomization. Furthermore, the probability for the correlation 
distribution of randomized images to obtain an r value above zero is described in 
the graph A4. Graph C compares and describes the procedure for estimating colour 
threshold intensities to determine correlation values for co-localized pixels from 5 
minutes adhesion (green bar) and 45 minutes adhesion (red bar) that fall below zero 
from the original histogram plot A2 and B2 respectively.     
 
 
 
 
 
 
 
 
 
3.9: Pearson correlation estimates a reduction in RNF181 and integrin 
αIIbβ3 co-localization in platelets spreading on fibrinogen 
Images co-immunostained for RNF181 and integrin αIIbβ3 were processed 
with and without correcting threshold colour intensity levels to adjust 
background; as previously described in Figure 3.10. The purpose of carrying 
out this analysis was to determine if there were any differences in the 
correlation values for co-localized pixels over the various platelet adhesion 
times to fibrinogen. A total of thirty different images per adhesion time (45 
minutes to BSA and 5, 15, 30 and 45 minutes to fibrinogen) were selected 
from four separate experiments and analyzed with and without threshold 
correction for background. The mean correlation values for each treatment 
were gathered from four data sets and compiled to give a mean (average) 
correlation value with standard deviations from the mean (M±SD), which are 
represented by the error bars. Figure 3.11 represents the mean correlation 
for co-localized pixels with background included whilst Figure 3.12 
represents the mean co-localized pixel correlation with threshold color 
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intensity levels being set to remove background. Co-immunostaining 
between actin and integrin αIIbβ3 was included as a control analysis.  
 
In Figure 3.11 the strongest measurements for co-localization were detected 
in the resting and 5 minutes spreading samples (average r = 0.87367 and 
0.80527 respectively). There was reduction in co-localization as the platelets 
spread on fibrinogen for longer times of 15, 30 and 45 minutes (average r = 
0.70952, 0.64871 and 0.5929) with significant differences between the initial 
and final two time points; according to one-way ANOVA (p<0.001** and 
p<0.0001*** respectively). Co-localization of actin and integrin αIIbβ3 was 
also analyzed with an average correlation value of 0.56. Because actin and 
integrin are known not to physically interact, its inclusion in the analysis 
provides high-quality supporting evidence to demonstrate correlation values 
of a non-co-localizing protein. Given that its r value is especially similar to 
that observed in the 45 minute platelet adhesion time point examining 
RNF181 and integrin co-localization, this strongly implies that RNF181 
dissociates from integrin following prolonged spreading on fibrinogen. 
  
After altering threshold levels to exclude background (Figure 3.12), the 
overall correlation of co-localized pixels were reduced (average r = 0.74286 
resting; 0.59869 - 5 minute spreading; 0.34921 – 15 minute spreading; 
0.30081 - 30 minute spreading; 0.29077 - 45 minute spreading). However, 
the significant differences in co-localization between the resting and 5 
minutes adhesion times with the remaining data sets became far greater 
when background was excluded. Moreover, estimation of co-localization 
between actin and integrin αIIbβ3 reduced to definitive levels of a non-
interacting nature (r= 0.08). In contrast to Figure 3.11, these correlation 
values were significantly less than that observed at the 45 minute platelet 
adhesion time point examining RNF181 and integrin co-localization (Figure 
3.12) eventhough correlation was considerably low (r = 0.29077). In 
summary, these results indicate the time dependence for co-localization as 
platelets spread on fibrinogen with RNF181 having an attraction for integrin 
at early activation times.    
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Figure 3.11: Pearson correlation analysis detects changes in co-localization 
between RNF181 with αIIbβ3 during platelet spreading. 
Washed platelets that were visually inspected for co-localization between RNF181 
and integrin αIIbβ3, such as those illustrated in fig 3.9, were examined by pixel 
correlation to improve data interpretation. Resting platelets were adhered to BSA 
surface (for 45 minutes) or fibrinogen coated surface (for 5, 15, 30 and 45 minutes) 
and immunostained for RNF181 and integrin, or actin and integrin. Co-localization 
of the fluorescently labeled proteins RNF181 and integrin αIIbβ3 was measured by 
calculating pixel correlation. The average r value for co-localization between 
RNF181 and integrin αIIbβ3 was estimated to give a mean co-localization value for 
each treatment, compiled from four data sets. The mean values were estimated: 
0.87367 – resting; 0.80527 - 5 minute spreading; 0.70952 – 15 minute spreading; 
0.64871 - 30 minute spreading; 0.5929 - 45 minute spreading. The correlation 
between RN181 and αIIbβ3 was significantly different in resting platelets compared 
to platelets incubated with fibrinogen for 30 and 45 min according to one-way 
ANOVA (** p<0.001 and *** p<0.0001 respectively). Pixel correlation analysis of 
actin and integrin αIIbβ3 estimated an r value = 0.56. Error bars represent standard 
deviations from the mean from 30 images acquired from four separate experiments. 
 
 
 
 
 
***
***
**
RN181/αIIbβ3 Actin/αIIbβ3
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Figure 3.12: Removing background pixels enhances co-localization 
differences of RNF181 and integrin αIIbβ3 during platelet spreading. 
The calculation of correlated pixels from platelet images representing 
RNF181 and integrin αIIbβ3 immunostaining were scrutinized further by 
altering colour intensity threshold levels to remove background  according to 
methods described in figure 3.10. Co-localization analysis by this method 
estimated a significantly greater difference in co-localization between RN181 
and αIIbβ3 in both resting and platelets spreading for 5 minutes compared to 
platelets adhered to fibrinogen for 15, 30 and 45 min; according to one-way 
ANOVA (***p<0.0001). Average r = 0.74286 resting; 0.59869 - 5 minute 
spreading; 0.34921 – 15 minute spreading; 0.30081 - 30 minute spreading; 
0.29077 - 45 minute spreading. Pixel correlation analysis of actin and integrin 
αIIbβ3 estimated an r value = 0.08. Error bars represent standard deviations 
of each sample from the mean taken from 30 images acquired from four 
separate experiments. 
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3.10: RNF181 and integrin αIIbβ3 co-localization in CHO cells 
To further investigate the capacity for RNF181 and integrin αIIbβ3 to co-
localize under different integrin activation states, CHO-FF and CHO-AA 
adhered to BSA or fibrinogen coated surfaces were fluorescently stained for 
the proteins and examined by confocal microscopy. CHO-FF cells adhered 
to a BSA substrate appeared to comprise of low levels of co-localization 
(Figure 3.13, panel A3), especially when analyzed by the pixel colour 
intensity profile (panel A4; r = 0.624) even though cellular expression of both 
RNF181 and integrin are closely located (panels A1 and A2). After 5 minutes 
spreading on fibrinogen, CHO-FF cells exhibit an enhancement of co-
localization between RNF181 and integrin αIIbβ3 (Figure 3.13, panel B3) 
when analyzed for pixel correlation (panel B4; r = 0.834). However, this co-
localization profile reduces as CHO-FF cells spread on fibrinogen for 
increasing times of 15 to 45 minutes (panels C; r = 0.777 and D; r = 0.703 
respectively).  
 
Images representing RNF181 and integrin αIIbβ3 fluorescence in CHO-AA 
cells adhered to BSA or fibrinogen for 45 minutes are displayed in figure 
3.14 panels A and B respectively. Subcellular areas of the CHO-AA cells 
adhered to BSA (Figure 3.14, panel A1) illustrate co-localization between the 
proteins, additionally highlighted by specific regions of interest within the 
histogram plot (Figure 3.14, panels A2 – A3). However, this co-localization 
profile declines as CHO-AA cells spread on fibrinogen for 45 minutes (Figure 
3.14, panels B1 and B2) with the additional histogram plot (B3) representing 
the image in panel B2. In summary, RNF181 has the strongest capacity to 
co-localize with integrin αIIbβ3 in CHO-FF cells adhered to fibrinogen at an 
early time and CHO-AA cells adhered to BSA, but not to fibrinogen thus 
demonstrating that there is a specific conformational stage of an active 
integrin attractive to RNF181. To conclude, CHO-FF and CHO-AA cells 
indicate that the activation state demonstrating co-localization between 
RNF181 and integrin αIIbβ3 appears to be immediately post-activation but as 
adhesion time progresses and the integrin conformation states become more 
active, the co-association lessens.  
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Figure 3.13: Co-localization between RNF181 and αIIbβ3 in CHO–FF cells 
adhered to BSA and fibrinogen 
CHO-FF cells were adhered to a surface coated with 1.5% BSA (panel A) and 
25µg/ml of fibrinogen for 5 minutes, 15 minutes and 45 minutes for panels B, C and 
D respectively. Immunostaining for the proteins RNF181 (green) and integrin αIIbβ3 
(red) was carried out as previously described in figure 3.3. Co-localization was 
measured by Pearson correlation with thresholds for each histogram set to reduce 
background, using the histogram displayed to the right of each panel. r-values 
determining co-localization were 0.624, 0.834, 0.777, 0.703 for resting, 5 minute ,15 
minutes and 45 minute adhesion respectively. Colocalization was determined by 
evaluating images of integrin positive CHO cells from at least seven adjacent 
positions for each condition from three separate experiments. Scale bars represent 
10µm. Images are representative of three separate experiments.  
A1 A2 A3 
B1 B2 B3 
C1 C2 C3 
A4 
B4 
C4 
D1 D2 D3 
D4 
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Figure 3.14: CHO-AA cells adhered to BSA exhibit more co-localization than 
CHO-AA cells spreading on fibrinogen 
CHO-AA cells were adhered to surfaces coated with 1.5% BSA (panels A) or 
25µg/ml of fibrinogen (panels B) for 45 minutes. Immunostaining for the proteins 
RNF181 (green) and integrin αIIbβ3 (red) was carried out as previously described in 
figure 3.3. CHO-AA cells in panel A1 were analyzed for specific regions of interest 
by the histogram (A2) where co-localized pixels would plot. Pixels within this region 
are highlighted white (panel A3). CHO-AA cells adhering to fibrinogen 45 minutes 
are illustrated in panels B1 and B2 with a histogram plot (B3) representing colour 
intensity pixel distribution for the image in B2. After acquiring images from at least 
seven adjacent positions from each condition, the CHO cells were evaluated for co-
localization.  Images are representative of three separate experiments. Scale bars 
represent 10µM. 
 
 
 
 
 
 
 
 
 
 
 
A1 A2 A3 
B2 B3 B1 
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3.11: Immunostaining HIC-5 and integrin αIIbβ3 during platelet spreading 
At the time of this investigation a lab colleague was carrying out research on 
the binding nature between HIC-5 and the integrin αIIbβ3. Therefore, to 
compare and contrast the co-localization profile of an alternative potential 
integrin binding protein’s capacity to co-localize with αIIbβ3, HIC-5 was 
selected. To investigate co-localization between the two proteins, platelets 
were adhered to BSA or fibrinogen surfaces for times up to 45 minutes 
(Figure 3.15). Resting platelets adhered to BSA exhibit equal fluorescent 
intensity between HIC-5 and integrin staining (panels A1 – A3). After 5 
minutes adhesion to fibrinogen, and as the platelet’s surface areas enlarge 
(as indicated by the distribution of αIIbβ3 fluorescence), HIC-5 remains more 
localized to the central region of adhesion (panels B1 – B3). Following 15, 30 
and 45 minutes adhesion, the platelets undergo greater spreading 
dimensions with the distribution of integrin molecules throughout the cells. 
However, the detection of HIC-5 lessens significantly (panel C, D and E 
respectively). Indicated in white arrows are platelets achieving maximum 
spreading with a reduction in HIC-5 levels, while blue arrows indicate 
platelets minimally spread with detectable levels of HIC-5. These results 
indicate that HIC-5 expression levels are directly regulated by the level of 
spreading / activation of platelets.  
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HIC-5, green and integrin αIIbβ3, red in platelets on BSA for 45 minutes 
   
 
HIC-5, green and integrinαIIbβ3, red in platelets on fibrinogen for 5 minutes 
   
 
HIC-5, green and integrinαIIbβ3, red in platelets on fibrinogen for 15 minutes 
   
HIC-5, green and integrinαIIbβ3, red in platelets on fibrinogen for 30 minutes 
   
 
 
A1 
B1 B2 B3 
C1 C2 C3 
D1 D2 D3 
A2 A3 
 95 
HIC-5, green and integrinαIIbβ3, red in platelets on fibrinogen for 45 minutes 
   
 
Figure 3.15: HIC-5 staining is dramatically reduced in platelets extensively 
adhered to immobilized fibrinogen 
Washed platelets were adhered for the times indicated to a surface pre-coated with 
1.5% (w/v) BSA substrate (panels A) or 25µg/ml of fibrinogen (panels B - E). Panels 
A - 45 minutes adhesion; B – 5 minutes; C – 15 minutes; D – 30 minutes; E - 45 
minutes adhesion to fibrinogen. Platelets were fixed, permeabilised and incubated 
with rabbit anti-HIC-5 and mouse anti-integrin αIIbβ3 antibodies at 1:500 and 1:1000 
dilutions respectively. Alexa-fluor488 conjugated goat anti-rabbit and alexa-fluor546 
conjugated goat anti-mouse antibodies (at 1:500 dilution) were subsequently added 
to the cells for 1 hour. Slide was then covered and images were acquired using a 
LSM510 microscope. White arrows indicate platelets achieving maximum spreading 
with a reduction in HIC-5 levels. Blue arrows indicate platelets minimally spread with 
detectable levels of HIC-5. Scale bars represent 10µm. Images represent 3 
separate experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
E1 E2 E3 
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3.12: Co-localization of HIC-5 with integrin αIIbβ3 in CHO cells  
Because HIC-5 underwent a reduction in fluorescence in platelets spreading 
on fibrinogen, it was difficult to estimate any levels of co-localization with 
αIIbβ3. Therefore, the larger cell type; CHO-FF and CHO-AA were examined 
by dual staining for HIC-5 and integrin αIIbβ3. Representative images of CO-
FF cells are illustrated in Figure 3.16. CHO-FF cells adhered to BSA for 45 
minutes reveal a lack of co-localization between HIC-5 and integrin αIIbβ3 
(panels A1 and A2). However, co-localization between HIC-5 and integrin 
αIIbβ3 becomes detectable following adhesion to fibrinogen and prominent in 
the central region of the cells (panels B and C). In contrast, CHO-AA cells 
adhering to BSA display co-localization between HIC-5 and integrin in the 
specific areas indicated with arrows (Figure 3.17, Panels A1 – A3). Due to 
the smaller morphology, the lesser distribution of proteins and to rule out the 
possibility that co-localization is due to pixel overlap, co-localization was 
examined in more detail by z-stacks (Figure 3.17, panels B1- B3). The 
sequential images which capture consecutive z-planes of the CHO-AA cell 
that is illustrated in Figure 3.17, panel A3 demonstrate co-localization 
between the two proteins while adhered to BSA (panel B3). Colour intensity 
maps reveal a distinct similarity in the intensity profile of each colour in 
similar regions of the cell (figure 3.17, C1 – C3) where red intensity indicates 
that there is strong protein concentration in that region while blue indicates 
weaker levels. HIC-5 and integrin αIIbβ3 are marked red in identical sub-
cellular regions of the CHO-AA cell in identical planes when analyzed by 
colour intensity maps. This profile is an indication of true co-localization. The 
z-stack image was also analyzed by the range indicator (figure 3.16.2, D1 – 
D3) to demonstrate that fluorescent detection was carried out to an optimum 
standard.  
 
CHO-AA cells that were adhered to fibrinogen display a lack of co-
localization between HIC-5 and integrin αIIbβ3 subsequent to spreading 
(Figure 3.18, panels A – C). In these selected frames (panels A and B) 
representing CHO-AA cells spreading for 15 minutes, there are both spread 
and unspread cells in view. In the unspread CHO cells co-localization is 
apparent (single white arrows). However, as the cells undergo shape 
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change, the two proteins become separated in their regions (indicated with 
double blue arrows). As CHO-AA cells spread on fibrinogen for 45 minutes a 
greater degree of separation is observed between the two proteins HIC-5 
and integrin αIIbβ3. 
 
 
 
 
 
Figure 3.16: Integrin αIIbβ3 and HIC-5 co-localize in CHO-FF cells 
adhered to fibrinogen but not BSA 
CHO cells expressing wild type integrin αIIbβ3 were examined for HIC-5 and 
integrin αIIbβ3 co-localization. The CHO-FF cells were adhered to a surface 
pre-coated with 1.5% BSA (panel A) or 25µg/ml fibrinogen (remaining 
panels, B and C) for 45 minutes. Dual staining was carried out for HIC-5 (in 
green) and integrin αIIbβ3(in red), which is described in detailed in figure 3.15. 
CHO-FF cells adhered to BSA display little co-localization between HIC-5 
and integrin αIIbβ3 (A3). Although integrin αIIbβ3 is distributed unequally 
around the spreading CHO cells, co-localization is captured in a more central 
region between integrin and HIC-5 (B3 and C3). To determine the extent of 
co-localization, at least five adjacent images for each treatment were 
acquired from three separate experiments. Displayed images are 
representative of these three experiments. Scale bars represent 10µm. 
A1 
B1 B2 B3 
C1 C2 C3 
A2 
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HIC-5 intensity map  αIIbβ3 intensity map  Merged  
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Figure 3.17: Z-stacks and intensity colour maps indicate co-localization between integrin and 
HIC-5 in CHO-AA cells adhered to BSA.    
A selection of representative images in panels A1 – A3 illustrates co-localization between integrin 
(red) and HIC-5 (green) in CHO-AA cells adhered to a BSA surface. Immunostaining was carried out 
as described in the figure, 3.15. To examine the co-localization in more detail, Z-stacks of the CHO-
AA cell displayed in image A3 were acquired to estimate the localization regions of HIC-5 and 
integrin αIIbβ3. 20 consecutive slices were captured in the z-plane of the cell with a depth of 0.70μm 
and sequential slices were overlapped by 0.20μm. Panel B1 and B2 show the z-stacks of HIC-5 and 
integrin αIIbβ3 respectively. B3 is a merger of B1 and B2. C1 – C3 are the representative intensity 
colour maps for B1 – B3 which indicate the level of protein detected from each z-plane. D displays 
the colour intensity profile. E1 – E3 represent the range indicator of the images displayed in B1 – B3 
respectively. Scale bars represent 10µm. Images are representative of three separate experiments. 
D 
B1 B2 B3 
C1 C2 C3 
E1 E3 E2 
A1 A2 A3 
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Figure 3.18: HIC-5 and integrin αIIbβ3 staining in CHO-AA cells adhered 
to fibrinogen reveal weak co-localization 
CHO-AA cells were examined for HIC-5 and integrin αIIbβ3 co-localization 
following adhesion to fibrinogen for 15 minutes (panels A and B) and for 45 
minutes (panels C). Following adhesion the cells were treated to 
immunostaining for HIC-5 (shown in green) and integrin αIIbβ3 (shown in red) 
as described in Fig 3.15. Panels A3 and B3 display both spreading and non-
spreading cells in each frame. The non-spreading cells reveal co-localization 
(indicated by single white arrows) while the spread cells exhibit no co-
localization (blue double arrows). Scale bars represent 10µm and images are 
representative of three independent experiments.  
 
 
 
A1 A2 A3 
B1 B2 B3 
C1 C2 C3 
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3.13: The absence of HIC-5 staining in CHO MOCK cells 
The presence of HIC-5 protein in CHO-FF and CHO-AA cells is evident. 
However, its gene expression is repressed in CHO Mock cells (i.e. CHO 
cells not expressing integrin αIIbβ3). CHO MOCK cells were examined by 
immunofluorescence for the proteins; integrin αIIbβ3, RNF181 and HIC-5 
(Figure 3.19). No fluorescence of integrin was detected (panel A) as CHO 
cells do not naturally express the protein. The presence of RNF181 is 
prominent (panel B) as this protein is naturally expressed in CHO cells. 
However, the HIC-5 expression is nullified (panel C), implying that the cell 
line do not naturally express the protein. Moreover, the proteomic databases 
for CHO cells which are available at the online resources www.uniprot.org 
and www.chogenome.org revealed no findings for HIC-5 at a protein level or 
mRNA level. In addition, when searching for HIC-5 using the alternative 
alias; hydrogen peroxide-inducible gene, no findings were revealed (Figure 
3.20, panels A and B). In addition to the previous results in Section; 3.12, 
these images indicate the reliance that integrin αIIbβ3 expression has for the 
protein HIC-5.  
 
 
 
 
Figure 3. 19: CHO MOCK cells reveal negative staining for HIC-5 protein 
CHO MOCK cells were examined for HIC-5 protein staining. Initially, the cells 
were adhered to BSA for 45 minutes and fluorescently labelled for the 
proteins; integrin αIIbβ3 (A), RNF181 (B) and HIC-5 (C). Immunostaining was 
carried out for the specific proteins as described in Figure 3.3 and Figure 
3.15. As expected, CHO MOCK cells display negative fluorescence for 
integrin αIIbβ3. (panel A). RNF181 is naturally expressed in CHO cells as 
revealed with immunostaining (panel B).HIC-5 fluorescence is absent in 
CHO MOCK cells (panel C). . Scale bars represent 10µm.  Images represent 
staining from two independent experiments.   
  
A B C 
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Figure 3. 20: HIC-5 protein is not identified in online protein databases 
Due to the negative fluorescence of HIC-5 in CHO MOCK cells following 
immunostaining, the proteomic databases at uniprot.org and chogenome.org 
were searched to determine if HIC-5 protein was contributed to the CHO cell 
genome. A screen shot displaying the search results from uniprot.org for 
HIC-5 when specifying to search in CHO cells (cricetulus griseus) revealed 0 
results (panel A). A screen shot of the online source at chogenome.org 
revealed 0 results when searching for HIC-5 protein or HIC-5 gene. 
 
 
 
 
 
 
A 
B 
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3.14: Dual staining for the two integrin αIIb binding proteins; RNF181 
and HIC-5 
Confocal microscopy analysis of platelets and CHO cells adhering to BSA 
and fibrinogen described above revealed that a substantial amount of 
RNF181 and HIC-5 co-localize with Integrin αIIbβ3 thereby, somehow 
regulating its activation state. Therefore, the possibility of RNF181 co-
localizing with HIC-5 was considered. To investigate this, CHO-FF and CHO-
AA cells were adhered to BSA or fibrinogen and examined by microscopy 
using immunostaining techniques. Image acquisition illustrates that the in 
both CHO-FF and CHO-AA cells, the two cytoplasmic proteins present 
themselves in different regions within the cells under normal adhesion 
conditions to BSA (images A1 and B1: CHO-FF and CHO-AA respectively) 
and spreading on fibrinogen (images A2 and B2: CHO-FF and CHO-AA 
between RNF181 and HIC-5 with integrin αIIbβ3. 
 
 
  
Figure 3. 21: The two integrin αIIb binding proteins RNF181 and HIC-5 show no 
physical association in CHO cells 
CHO-FF and CHO-AA cells were examined for co-localization between the two 
proteins RNF181 and HIC-5, which both co-localize with αIIbβ3. The cells were 
adhered to a surface pre-coated 1.5% (w/v) BSA or 25µg/ml fibrinogen for 45 
minutes and stained for RNF181 (in green) and HIC-5 (in red) as described in figure 
3.3 and figure 3.15 respectively. Panels A display CHO-FF cells adhered to BSA 
(A1) and fibrinogen (A2). Panels B display CHO-AA cells adhered to BSA (B1) and 
fibrinogen (B2). Scale bars represent 10µm. Images are representative of 3 
separate experiments.  
A1 A2 
B1 B2 
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3.15: Discussion 
Since indentifying the potential binding partnership between the proteins, 
RNF181 and platelet integrin αIIbβ3, various methods and personnel have 
been employed in our lab to understand the nature of the interaction. Using 
confocal microscopy this chapter is aimed at using co-localization to indicate 
if an interaction between RNF181 and integrin αIIbβ3 was likely during 
fibrinogen mediated integrin αIIbβ3 activation. More specifically, to simulate a 
thrombotic condition that would induce various stages of integrin activation, 
washed platelets and CHO cells expressing integrin αIIbβ3 were adhered to 
either a BSA or fibrinogen surface over a range of times. Immunostaining 
was carried out for various target proteins implicated in integrin regulation, 
namely; talin, actin, HIC-5 and RNF181, in order to determine integrin 
activation dependent co-associations. Talin has been implicated in integrin 
regulation, with a defined role of binding directly to the integrin cytoplasmic 
domains and inducing activation. Co-immunostaining with talin and integrin 
illustrated specific regions in the periphery of the spreading platelet where 
co-localization occurred. Even though the precise conformation of the 
integrin protein in these specific areas is undefined, talin co-localization does 
indicate towards structurally active integrin molecules. Interestingly, co-
immunostaining carried out with RNF181 and integrin αIIbβ3 resulted in a co-
localization profile similar to that observed with talin, whereby the two 
proteins had a stronger tendency to localize in the periphery of the spreading 
platelet. Nevertheless, it was difficult to define any specific stage of platelet 
spreading as having a stronger co-localization profile between RNF181 and 
integrin αIIbβ3. However, subjecting the images to pixel correlation analysis 
indicated that co-localization was strongest when the platelets adhered to 
BSA. In addition, subsequent images showed significantly strong co-
localization when measured by pixel correlation, particularly in early stages 
of platelet spreading (5 minutes) with a measurable but reduced amount in 
the later times of adhesion to fibrinogen. The additional analysis of actin – 
integrin co-immunostaining confirms the co-localization profile of RNF181 
with the platelet integrin. Overall, these results imply that RNF181 co-
localizes with integrin particularly in a resting or an early activation 
conformation and that this tendency was then significantly reduced as the 
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platelets underwent longer conditions of spreading on fibrinogen. However, 
even though washed platelets adhered to BSA are considered to be in a 
resting condition, their true activation status is questionable. The reason for 
this query lies in the preparation of washed platelets from whole blood.  
 
By their nature, platelets are highly sensitive cells to their surrounding 
environment and during the washed platelet preparation the cells are 
processed through a vigorous method of repeated centrifugation and cell 
resuspension. Throughout this treatment, it is possible that small quantities 
of ADP are secreted from platelet granules. Therefore during washed 
platelet preparations, PGE1 is given to maintain platelets in a suppressed 
condition by causing cAMP production. This receptor occupation would 
counteract ADP occupied P2Y12 receptor signalling. However, the thrombotic 
molecule (ADP) is still capable of occupying alternative receptors unaffected 
by PGE1 induced signalling (namely P2Y1) which also have a downstream 
affect on integrin activation. Therefore, declaring integrin αIIbβ3 as being 
completely inactive in resting washed platelet preparations is a questionable 
topic.  
 
As a result, examining integrin in a true resting conformation and various 
stages of an active conformation was performed in the form of CHO-FF and 
CHO-AA cells. CHO-FF cells adhered to BSA indeed have a true resting 
integrin. In contrast, CHO-AA cells adhered to BSA would represent one 
possible intermediate stage of integrin activation, prior to fibrinogen binding 
but post; agonist induced inside-out signalling. Results illustrate that RNF181 
has a weak capacity to co-localize with resting integrin (in CHO-FF cells 
adhered to BSA). However, following 5 minutes adhesion to fibrinogen the 
co-localization in the CHO-FF cell profile improves substantially, and 
similarly to platelets, it reduces following longer adhesion times. In contrast, 
integrin that is in an active conformation but that has not been bound by 
fibrinogen (CHO-AA cells adhered to BSA), reveals strong co-localization 
between the two proteins; RNF181 and integrin αIIbβ3. Moreover, co-
localization reduces dramatically following CHO-AA adhesion to fibrinogen in 
a similar fashion to that observed by immunostaining for RNF181 and 
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integrin αIIbβ3 in platelets adhered to fibrinogen for 90 minutes. From these 
results it can be concluded that RNF181 co-localizes with integrin αIIbβ3 
during the early stages of activation and that under longer influences of 
thrombotic conditions, this interaction diminishes.  
 
Even though the position of HIC-5 is undefined with respect to binding to the 
integrin αIIb cytoplasmic tail and therefore does not merit the status as a 
comparative protein in relation to RNF181 - integrin co-localization, it’s 
inclusion in this section revealed some interesting findings. Initial 
investigations with HIC-5 in platelets revealed that the protein’s expression 
levels were dramatically reduced following platelet spreading. However, 
subsequent experiments in CHO-FF cells demonstrated that HIC-5 co-
localized with integrin following adhesion to fibrinogen. CHO-AA cells 
adhered to BSA also demonstrated co-localization between HIC-5 and 
integrin, but that this co-localization profile reduced as CHO-AA cells spread 
on fibrinogen. These adhesion conditions were identical to the manner in 
which RNF181 co-localized with integrin in CHO-FF and CHO-AA cells. 
Although, co-localization did appear in alternative subcellular regions. Most 
interesting is the subsequent analysis in which CHO-FF and CHO-AA cells 
that were adhered to BSA and fibrinogen were subject to RNF181 and HIC-5 
immunostaining. These analyses display a total lack of engagement between 
RNF181 and HIC-5. Overall, these images confirm that RNF181 and HIC-5 
co-localize with integrin αIIbβ3 in an independent fashion and that due to the 
manner of co-localization, their potential integrin regulatory roles must differ 
greatly. On a separate note, CHO-MOCK immunostaining with HIC-5 and 
proteomic database searches indicated striking evidence of the 
interdependency that exists between integrin αIIbβ3 and HIC-5 expression, 
whereby a lack of integrin αIIbβ3 in a cell system does not register the 
capacity for that cell to express HIC-5. Determining a functional role for a 
particular protein is the forefront of protein biochemistry. However, it is a 
difficult task to accomplish by simply carrying out cell adhesion and confocal 
microscopy studies. Attempts were made to do so nonetheless.  
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By drawing on as much evidence as possible it can be concluded that;  
A) RNF181 has a tendency to localize with integrin αIIbβ3 in platelets 
spreading on fibrinogen. 
B)  This co-localization is activation dependent and reduces over longer 
adhesion times.  
C) CHO-FF cells expressing integrin αIIbβ3 in its wild-type status revealed 
little interaction between RNF181 and integrin under resting conditions, 
but during spreading, co-localization increased dramatically. In addition 
CHO-AA cells (expressing integrin αIIbβ3 in an activated conformation) 
adhered to BSA displayed co-localization. 
D) CHO-AA cells adhered to fibrinogen revealed no RNF181 – integrin co-
localization.  
E) Co-localization studies therefore demonstrate that RNF181 does not bind 
to a resting or fully active integrin molecule, but to a transitional 
conformation, thus indicating that the RNF181 has a transient role in 
regulating integrin activation.     
 
It must be noted that the resolution of platelet and CHO cells examined by 
confocal microscopy in this chapter is extremely limited and does not entirely 
demonstrate but merely indicates a direct protein interactions when 
measured by co-localization. Therefore, further investigations into the 
binding relationship between RNF181 and the integrin αIIbβ3 protein will be 
explored in the subsequent chapter.   
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Chapter 4 
 
Directly measuring a  
Protein – protein interaction 
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4.1: Introduction 
Previously in our labs, the novel ubiquitin, E3 ligase; RNF181 was identified 
as a potential integrin-binding protein in platelets (Brophy et al. 2008). The 
potential for a protein involved in ubiquitination, to regulate integrin αIIbβ3 
function is intriguing. In the previous chapter, confocal imaging was used to 
demonstrate supporting evidence for the co-association of the platelet integrin 
αIIbβ3 with RNF181. In addition, temporal analysis suggested that the co-
association of these proteins was transiently related to the spreading profile of 
platelets on fibrinogen, and therefore, the activation status of the integrin 
αIIbβ3 complex. This chapter therefore aimed to confirm a direct interaction 
between the two proteins and investigate the binding dynamics. In particular, 
any specific region of RNF181 protein that is responsible for co-ordinating the 
binding to integrin was examined. Methods employed to investigate such 
binding parameters included co-immunoprecipitation (CO-IP), peptide 
microarrays and isothermal calorimetry (ITC), pull down experiments and 
bioinformatics.  
 
Co-immunoprecipitation (Co-IP) assays are generally used to identify if 
binding occurs between proteins under specific stages of cellular activity. 
However, it cannot always distinguish between direct or indirect interactions. 
Moreover, it is difficult to detect transient or low affinity binding interactions by 
co-immunoprecipitation, as previously found out, when looking at ICln 
interactions with the platelet integrin (Larkin et al, 2004). In contrast, ITC is a 
more quantitative technique which can specifically measure direct protein 
interactions between two partners. In addition, ITC is sufficiently sensitive at 
measuring low affinity or transient interactions. Thus the two techniques (Co-
IP and ITC) can work in a complimentary fashion to each other during the 
assessment of protein: protein interactions. Therefore they were extensively 
used to investigate the relationship between RNF181 and integrin. In addition 
to being able to measure direct interactions, array technology can specify the 
precise sequences of a protein that mediate binding. RNF181 membrane 
PepSpot arrays, in conjunction with bioinformatics were therefore employed 
to establish sequences within RNF181 responsible for direct binding to the 
integrin motif. Furthermore, peptide pull-down experiments and ITC analyses 
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were subsequently utilized to corroborate any results observed. Overall this 
chapter aimed to determine if the interaction between the cytoplasmic protein 
RNF181 and the transmembrane platelet receptor; integrin αIIbβ3 is direct or 
indirect. In addition, the nature of the interaction between these two proteins 
was further explored. 
 
 
 
 
Results 
4.2: Co-immunoprecipitation of RNF181 with Integrin αIIb in washed 
platelets  
Immunoprecipitation experiments were carried out to investigate if an 
interaction between RNF181 and integrin αIIbβ3 could be detected in platelets. 
To examine this, washed platelets were prepared as described in section 
2.2.1. Platelet lysates were generated from the platelets and samples were 
incubated with selected antibodies. Using protein G conjugated agarose 
beads, mouse monoclonal antibodies targeting integrin αIIb (SZ22) or non 
specific mouse monoclonal antibodies were separately incubated with platelet 
lysates from resting and Thrombin receptor activating peptide (TRAP) 
activated samples. This method was to determine if the proteins had an 
interaction based on the activation status of the platelets and therefore the 
activation status of the integrin αIIbβ3. Multiple IP experiments were performed 
to investigate if resting or a TRAP-activated integrin was bound by RNF181. 
However, reproducing a specific moment of platelet activity during which the 
protein RNF181 had an affinity for integrin αIIbβ3 was difficult to achieve. On 
some occasions, RNF181 was found to co-immunoprecipitate with the 
integrin in lysates generated from resting platelets but not those from 
activated platelets (Figure 4.1; panel A). On other occasions, RNF181 bound 
only to the integrin from activated platelets (Figure 4.1, panel B) and 
sometimes co-immunoprecipitation was observed in both resting and TRAP 
activated samples from the same platelet preparation. Finally, sometimes no 
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positive interaction was observed. Thus no definitive conclusion could be 
made about the activation state of the platelet with the tendency for co-
association of the two proteins. A total of approximately 20 similar 
experiments were performed. But, because the reproducibility of these 
experiments proved difficult, an investigation into why there was such a 
problem was carried out by incrementally changing a variety of the 
experimental conditions. The stability of the proteins in platelet lysates during 
the overnight incubation of the experiments was examined by including / 
excluding protease inhibitor cocktails in the lysis buffer or by adding a 
proteasome inhibitor drug (Bortezomib) to prevent protein degradation. To 
coincide with this, the incubation times between the platelet lysates and the 
protein G / antibody complex were varied between 1 and 24 hours. In 
addition, wash steps during the immunoprecipitation protocol were addressed 
by altering the salt concentrations of the wash buffer between 70mM and 
1000mM. Finally, alternative platelet agonists (Thrombin, ADP, collagen and 
U46619) were examined for their effect on the co-immunoprecipitation assay. 
However, these investigations did not improve to overall reproducibility for the 
co-immunoprecipitation of RNF181 with integrin αIIbβ3 in washed platelets. 
This implied that the interaction between the proteins RNF181 and integrin is 
highly transient in nature or that it is modified by experimental conditions 
beyond our control. Therefore alternative methods were employed to examine 
the characteristics of the interaction.  
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Figure 4.1: RNF181 co-immunoprecipitation with integrin αIIbβ3 from resting and TRAP 
activated platelets 
RNF181 was examined for co-immunoprecipitation with integrin αIIb from washed platelet 
lysates. Lysates were generated from resting platelets and platelets activated for 3 minutes 
by 10μM TRAP. Samples were then incubated overnight at 4° C, with 1μg of either the 
normal mouse antibody (for negative control) or mouse anti-αIIb antibody (SZ22) plus 25μl of 
protein G agarose beads. After incubation, the beads were washed, mixed with 2X sample 
buffer and heated to 95°C. The eluted protein samples were loaded into 2D (14% – 2%) 
gradient gels and analyzed by western blot for integrin αIIb immunoprecipitation and RNF181 
co-immunoprecipitation. Western blot results in Panels A and B are from two experiments 
representing co-immunoprecipitation of RNF181 with integrin αIIb from platelet lysates. 
Lanes in panel A are as follows; 1) resting lysate; 2) TRAP activated lysate; 3) IP with anti-
αIIb IgG from resting lysate; 4) IP with anti-αIIb from TRAP activated lysate; 5) IP with normal 
mouse IgG from resting lysate. Lanes in panel B are as follows; 1) resting lysate; 2) TRAP 
activated lysate; 3) IP with normal mouse IgG from resting lysate; 4) IP with anti-αIIb IgG 
from resting lysate; 5) IP with anti-αIIb from TRAP activated lysate. Western blots in panel A 
demonstrate the CO-IP of RNF181 with the integrin αIIbβ3 from platelets in resting conditions 
only. In contrast the CO-IP of RNF181 with the integrin αIIbβ3 from resting platelets and 
TRAP activated platelets is demonstrated by the western blots in panel B. These 
experiments were carried out at least 20 times, however the results were variable. 
1 2 3 4 5 
A 
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4.3: Co-immunoprecipitation of RNF181 with Integrin αIIb from CHO cells 
As discussed in chapter 3, the true state of the integrin αIIbβ3 following 
washed platelet preparation is uncertain due to the rigorous treatment the 
cells receive during the preparation process. Therefore, the co-
immunoprecipitation of RNF181 with integrin αIIbβ3 was examined in CHO-FF 
and CHO-AA cells. Despite the fact that the reproducibility of the IP 
methodology had proven difficult with platelet lysates, it was rationalized that 
the CHO cells could provide a cleaner system in which to observe the 
interactions because it would be expected that the transfected integrin αIIbβ3in 
these cells would most likely represent a single conformation status of the 
protein complex, due to the absence of platelet receptor induced signaling 
networks. Significantly less integrin is present in the CHO-AA cells than in the 
CHO-FF cell lysates (Figure 4.2; lanes 7,8 respectively). Accordingly, less 
integrin immunoprecipitates from the CHO-AA cell lysates than from the 
CHO-FF cell lysates (Figure 4.2; lanes 2, 3 respectively). As expected, CHO 
MOCK cells contained no integrin (lanes 4 (IP) and lane 9 (lysate)). RNF181 
co-immunoprecipitates with integrin αIIbβ3 from lysates generated from CHO-
FF and CHO-AA cells. The large differences in the amounts of integrin protein 
present in the two cell lines makes it is difficult to quantify the relative 
interactions. However, given that an equal amount of RNF181 protein 
immunoprecipitates from the CHO–AA cells with a relatively small quantity of 
CHO-AA integrin (compared with the higher density of CHO-FF integrin), is 
strongly suggestive of a preference for an interaction of RNF181 for the 
activated state of the integrin found in CHO-AA cells. The experiments were 
performed up to five times (with only one experiment demonstrating a specific 
co-immunoprecipitate between the proteins). Again, there were issues with 
the reproducibility of results. Based on the failure to determine optimal CO-IP 
conditions between RNF181 and integrin αIIbβ3 in washed platelets, a lesser 
time was committed to the CHO cell investigation. Western blot is displayed 
as white bands on a black background as it gives a clearer indication of the 
differences in protein intensity between lanes 2 and 3, for both panels A and 
B. 
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Figure 4.2: Co-immunoprecipitation of RNF181 in CHO cells expressing 
integrin αIIbβ3 
RNF181 was examined for its capacity to co-immunoprecipitation with integrin 
αIIbβ3 from both CHO-FF and CHO-AA cell lysates. 1ml of cell lysates were 
pre-cleared for non-specific binding components and incubated overnight at 
4°C with 1μg of the indicated antibodies (either mouse anti-αIIb (SZ22) or 
normal mouse IgG antibodies)in combination with 25μl of protein G agarose 
beads. Beads were then washed, mixed with 25μl of 2x sample buffer and 
heated to 95°C for 3 minutes to elute bound protein. Samples were loaded 
into 2D gels and analyzed by western blot for integrin αIIb (panel A) and 
RNF181 (panel B). Lanes for both gels represent either free antibody loading, 
immunoprecipitation samples or cell lysates and are equally represented as 
follows; Lane 1 - 2μg of SZ22 antibody; 2 – IP from CHO-AA cell lysate using 
SZ22; 3 – IP from CHO-FF cell lysate using SZ22; 4 – IP from CHO-MOCK 
cell lysate using SZ22; 5 –IP from CHO-AA cell lysate using normal mouse 
IgG; 6 – IP from CHO-FF cell lysate using normal mouse IgG; 7 – CHO-AA 
cell lysate; 8 – CHO-FF cell lysate; 9 – CHO MOCK cell lysate. Western blots 
are representative of two separate experiments.  
 
 
 
 
1 2 3 4 5 6 7 8 9 
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4.4: Recombinant RNF181 purification from E.Coli 
To assess the potential for protein interactions in vitro, a recombinant version 
of RNF181 was generated from an E. Coli construct expressing the human 
RNF181 gene (Brophy et al. 2008). Purification of RNF181 from E-Coli was 
carried out as described in the materials and methods section (2.2.14). The 
purification of His-tagged RNF181 is demonstrated by the single protein band 
in lanes 4 - 6 of the coomassie stained gel following elution from Ni+ agarose 
beads.  
 
 
 
Figure 4.3: Coomassie stain representing recombinant RNF181, 
expressed in E.Coli cells and purified by column filtered 
chromatography and dialysis 
E-Coli expressing His-RNF181 were induced to over express the recombinant 
protein using the stimulant, Isopropyl β-D-1-thiogalactopyranoside (IPTG). A 
sample of lysate from these cells was added to the gel (lane 1); the lysate of 
the cultured bacteria was incubated with Ni-NTA (nickel-nitrilotriacetic acid) 
agarose beads for an hour and the passed through a column. The initial flow 
through from this column contains no RNF181 protein (lane 2). The column 
was washed extensively with 100mls of wash buffer and a fraction of the elute 
was examined for the presence of protein (lane 3); RNF181 was eluted using 
imidazole (Lane 4) until no more protein was observed (lane 5); protein-
positive fractions were pooled and dialysed overnight (lane 6). Lane 7 is 
blank. Bovine serum albumin was prepared and loaded into the gel at various 
concentrations (lane 8 – 1mg/ml; lane 9 – 2mg/ml; lane 10 – 5mg/ml) to 
indicate the quantity of RNF181 expressed. Data is shown as a coomassie 
stained protein gel from one experiment, but represents at least 5 separate 
experiments .  
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4.5: Microscale thermophoresis detects direct binding between RNF181 
and αIIbβ3 
The reliability of the Co-IP data in the previous section posed the question of 
whether to carry on the investigation into the relationship between RNF181 
and integrin. However, a previous PhD student in the RCSI lab illustrated that 
the protein RNF181 had a direct affinity for both purified integrin αIIbβ3 and 
native integrin in platelet lysates. In addition, a peptide derived from the motif 
of the integrin αIIb cytoplasmic tail (
989KVGFFKR995) inhibited RNF181 - 
integrin αIIbβ3 binding, indicating that the protein: protein interaction was 
mediated through this conserved sequence of the integrin αIIb cytoplasmic tail 
(Brophy et al. 2008). To confirm the relevancy of the study, a protein 
interaction study was carried out between recombinant RNF181 and purified 
integrin through microscale thermophoresis (MST).    
 
Thermophoresis (Soret effect) is the effect of a temperature gradient on the 
rate and direction of movement of a solubilised structure (such as a protein) in 
solution. The movement depends on the solvation properties of the protein 
which inevitably changes when forming complexes with a binding partner (as 
illustrated in Figure 4.4). Microscale thermophoresis (MST) is an advanced 
technique that takes advantage of the Soret effect to determine if two proteins 
of interest have the potential to interact. By fluorescently labelling one protein 
(the target) and measuring its rate of movement in a temperature gradient in 
the presence of increasing concentrations of its partner (the ligand), MST can 
measure if ligand - target complexes have formed.   
 
Using MST the binding of fibrinogen and RNF181 to fluorescently labelled 
integrin αIIbβ3 was measured in separate, single experiments. This analysis 
was performed when the dealer of the commercial MST device (Dr. Moran 
Jerabek-Willemsen) ran a single demonstration in our lab. Firstly the binding 
of the ligand; fibrinogen to its receptor; integrin αIIbβ3 demonstrated the 
capacity for this technique to detect physiologically-relevant interactions. MST 
analysis of integrin αIIbβ3 interaction in the presence of fibrinogen yielded a Kd 
value of 150nM (Figure 4.5, A). Secondly, RNF181 binding to integrin αIIbβ3 
was measured to have a Kd value of 2.5μM (Figure 4.5, B). The binding of 
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RNF181 to integrin αIIbβ3 indicated to us that the ineffectiveness of the CO-IP 
experiments may be, in part, due to the low affinity observed. Furthermore, it 
is well established that soluble fibrinogen does not bind to integrin αIIbβ3 that 
is in a resting conformation. But since MST measured direct binding between 
fibrinogen and the integrin αIIbβ3, it strongly suggested that the purified protein 
is in an active conformation. Given that RNF181 also binds to this purified 
integrin, it strongly suggests that RNF181 binds to the active conformation of 
integrin αIIbβ3. As a result, the role of RNF181 in integrin function is becoming 
increasingly established.  
 
 
 
 
 
Figure 4.4: The solvation effect of water on two interacting partners 
The ability for water to dissolve a physical substance into solution depends on 
the solvation effect of that substance. Water acts as a solvent by forming a 
hydration shell around each individual particle, such as the ligand and the 
substrate in Figure A. Upon binding, the two partners displace some water 
molecules to allow for non-covalent interactions between the substances. 
This interaction creates a larger product with different solvation properties as 
described in Figure B. Methods such as thermophoresis have taken 
advantage of this effect to determine if two molecules interact by labelling the 
target molecule and measuring its movement in a temperature gradient 
environment in the presence of increasing concentrations of a ligand.  
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B
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Figure 4.5: Microscale thermophoresis measures protein interactions 
with integrin αIIbβ3 
The platelet integrin αIIbβ3protein was examined for its capacity to bind to 
fibrinogen (panel A) and RNF181 (panel B) under thermophoretic conditions. 
Purified integrin was prepared inan MSTbuffer(50mM Tris, 150mM NaCl, 
1mM CaCl2, 0.05 % tween-20, pH 7.6). The integrin was labelled with a NT-
647 dye using NanoTemper’s protein labelling kit RED. The concentration of 
integrin was kept constant at 20nM. The protein concentration of fibrinogen 
and RNF181 varied from 25µM to 0.2µM for fibrinogen and 100µM to 0.78µM 
for RNF181. 10μl of each sample were loaded into standard treated MST-
grade glass capillaries and after fifteen minutes, an MST-Analysis was 
performed using the Monolith NT.115. The molar concentration of the ligand 
is plotted on the X axis. Graphs represent one single experiment. 
 
 
 
A 
B 
 118 
4.6: Isothermal titration calorimetry explores the interaction dynamics 
between RNF181 and integrin αIIbβ3 
Since the MST analysis was explored by only a single experiment, an 
alternative approach was taken to measure the interaction between the 
proteins; namely by Isothermal titration calorimetry (ITC). This is a sensitive, 
label free technique that allows analysis of molecular interactions in solution. 
Briefly; changes in the thermal environment are recorded in response to 
incremental injections of a binding molecule (ligand) into a target molecule 
(and separately into a buffer). By measuring the heat change following each 
injection, the addition of a ligand to its target results in an initial thermal effect 
with successively weaker responses following each subsequent injection until 
a final saturation effect is seen as illustrated in Figure 4.6, A and A1.  
 
Thermodynamic parameters that can be gathered from ITC experiments 
include; estimation of the binding affinity (Ka = 1/Kd)) between a ligand and its 
target. This can indicate whether an interaction is feasible or biologically 
relevant. The ligand: target binding ratio (n) can also be estimated by ITC (i.e. 
how many ligand molecules bind to a single target). The free energy change 
(ΔG) can be calculated from the changes in enthalpy (ΔH) and entropy (ΔS) 
of an experiment where ΔH equals the total heat change of a system and ΔS 
equals a change in order of a system. ΔG is a measure how much energy is 
required by a system for a particular reaction and indicates whether the 
reaction is spontaneous or forced. A reaction with negative ΔG is said to be 
spontaneous and favourable. On the contrary, if ΔG is positive, a reaction is 
said to non-spontaneous (forced) and non favourable.  
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Figure 4.6: Isothermal titration calorimetry is a method for analyzing ligand 
titration into a target molecule 
The diagram (A) describes the method of how ITC detects temperature changes in 
the sample cell following the injection of a ligand (red dots in the syringe and the 
sample cell) into a target protein (green shape in the sample cell). The effect of any 
heat generated as a result of an interaction between the ligand and its target are 
detected by using the reference cell (that contains water or buffer) as an indication 
for the variation in temperature (ΔT). A1 shows an example of an exothermic 
response from titrating a ligand into a target. The titration of ligand into buffer is also 
depicted in Figure B. As a result of having no target present in the sample cell, the 
titration of ligand into buffer would not produce a significant change in temperature. 
An example of the exothermic effect of titrating ligand into buffer is described in B1. 
 
 
 
 
 
 
 
 
ΔT
Sample cell Reference cell
Injection syringeA
ΔT
Sample cell Reference cell
Injection syringeB
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To standardize the ITC assay system, a known set of interaction partners 
were used, namely calcium and the metal chelator, EDTA. These compounds 
have a strong affinity for each other that can be quantified by ITC. During the 
titration, the ligand was EDTA and the target molecule was calcium. Figure 
4.7 displays the raw thermogram and the binding isotherm generated as a 
result of the measured interaction between calcium and EDTA (stoichiometric 
analysis is presented in Table 4.1).  
 
 
Figure 4.7: Quantification of calcium binding to EDTA by ITC 
EDTA and calcium chloride have an attractive force in solution based on EDTA’s 
chelating properties for metal ions such as calcium (Ca2+). This molecular interaction 
was routinely used to practice and improve ITC skills and to ensure the system was 
fully operational. The compounds EDTA and calcium chloride were solubilised in an 
ITC buffer containing 10mM MES, pH 5.6. Subsequently, 26 x 1.5µl of 0.5mM EDTA 
was titrated into 0.05mM calcium chloride. The raw thermogram from the analysis of 
EDTA titration into calcium chloride is displayed in A. The binding isotherm from the 
integrated peaks generated by the reaction was analyzed using the one site binding 
model provided by Origin (B). The data shown is representative from four 
experiments.  
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To examine the sensitivity of ITC at measuring protein - protein interactions, a 
second control system was explored. This contained the proteolytic enzyme; 
trypsin and a substrate; BSA. The thermodynamic properties of this reaction 
were measured (Figure 4.8) with a full profile given in Table 4.1. 
 
 
Figure 4.8: Quantification of Trypsin binding to BSA by ITC 
Trypsin and BSA were dissolved in an ITC buffer containing TRIS (10mM) 
and NaCl (50mM) at pH 7.4. The trypsin (1mM) was titrated into BSA (0.1mM) 
in 23 sequential 1.75µl injections. The raw thermogram displaying the titration 
of trypsin into BSA is displayed (A) and the binding isotherm is analyzed 
using the one site binding model provided in Origin (B).Data represents one 
experiment from a total of two experiments.   
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The final set of ITC experiments carried out in this section investigated if 
RNF181 was capable of binding to integrin αIIbβ3. The assays were performed 
by titrating full length, recombinant RNF181 protein into purified integrin αIIbβ3. 
One control for this experiment was the parallel titration of Lysozyme into 
integrin αIIbβ3.  A second control experiment simply titrated the ligand 
(RNF181) into ITC titration buffer. Large exothermic spikes were generated 
following the titration of RNF181 into integrin αIIbβ3 (Figure 4.9, A). In 
comparison, the titration of lysozyme into integrin αIIbβ3, or RNF181 into ITC 
buffer measured minimal changes in heat capacity (represented in Figure 4.9, 
panel B by solid stars and solid triangles respectively). Thermodynamic 
analysis for the RNF181 – integrin αIIbβ3 interaction revealed a binding ratio 
close to 1, a Kd value in the low micromolar range(10µM) and a free energy 
change (-30.75kca/mol) driving towards conditions of favourable reaction. 
 
It is worth noting that the titration of recombinant RNF181 into purified integrin 
αIIbβ3, prepared in a calcium deficient buffer showed titrations with minimal 
changes in heat capacity, similar to that observed during the titration of 
RNF181 into ITC buffer only (data not shown). This suggests that the binding 
of RNF181 to integrin is calcium-dependent or more reasonably; integrin 
activation dependent. Stoichiometric analysis for the reaction is presented in 
table 4.1 
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Figure 4.9: Quantification of the binding of recombinant RNF181 to 
integrin αIIbβ3 by ITC 
Purified integrin αIIbβ3 and recombinant RNF181 were dialyzed into an ITC 
buffer substituted with CaCl2 (1mM), 0.1 % Triton 100X, pH 7.4. Their 
concentrations were assessed by protein assay and prepared. RNF181 
(180μM) was titrated into 18μM of integrin αIIbβ3. Panel A displays the 
thermogram from the reaction between the proteins. Panel B displays the 
binding isotherm (in solid squares) that was generated by Origin.  In addition, 
the binding isotherms that were generated from titrating 1) 180μM RNF181 
into ITC buffer alone (triangles) and 2) titrating 180μM lysozyme into 18μM of 
integrin αIIbβ3 (stars) are displayed. Graphs are representative of three 
independent experiments. 
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Table 4.1: Stoichiometric analysis of protein interactions carried out by 
ITC show favourable measurements for binding 
Recombinant RNF181 and purified integrin αIIbβ3 were measured by ITC to 
assess their capacity to interact. In addition, the binding partners EDTA with 
calcium and bovine serum albumin (BSA) with trypsin were measured by ITC. 
Following analysis, their stoichiometric profile was determined which are 
indicated below. Binding partners are described in the left column with their 
respective binding ratio (n), binding affinity (Kd), enthalpy change (ΔH), 
entropy change (ΔS) and calculated free energy change (ΔG) displayed in 
rows on their right. Values represent the mean ± standard deviations 
calculated from three separate experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Binding partners 
 
 
n 
 
 
Kd (µM) 
 
ΔH 
(kcal/mol) 
 
ΔS 
(kcal/mol/deg) 
 
ΔG 
(kcal/mol) 
 
1 
 
 
EDTA v’s CaCl2 
 
0.902 ± 0.07 
 
0.415 ± 0.035 
 
-4.1±0.25 
 
0.015 ± 0.001 
 
-8.72 ± 0.06 
 
2 
 
Trypsin v’s BSA 
 
0.9 ± 0.4 
 
18 ± 12 
 
-211 ± 127 
 
-0.69 ± 0.4 
 
-6.5 ± 0.4 
 
3 
 
RNF181 v’s αIIbβ3 
 
1.4 ± 0.4 
 
11.1 ± 0.9 
 
-271 ± 17 
 
-0.89 ± 0.06 
 
-6.47 ± 0.37 
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4.7: Bioinformatics analysis of the interaction between RNF181 and the 
integrin IIb cytoplasmic tail 
The Protein Data Bank (PDB) is an online archive that contains the predicted 
structures of many identified proteins. Within this database are a variety of 
predicted 3D models of integrin IIb cytoplasmic tails. Specifically; four models 
are available which include one short representation of the integrin IIb chain; 
with protein data bank identification code (PDB ID) - 1KUP (Weljie, Hwang, 
and Vogel 2002); displayed in Figure 4.10, A; and three longer 
representations of the integrin IIb cytoplasmic tails which include one 
modified structure (PDB ID – 1DPQ (Vinogradova et al. 2000) (Figure 4.10, 
B)) and two native structures (PDB ID – 1DPK (Vinogradova et al. 2000) 
(Figure 4.10, C)) and  PDB ID -1S4W (Vinogradova et al. 2004) (Figure 4.10, 
D). Complimentary to the protein data bank is the protein: peptide interaction 
tool - Pepsite2 (Trabuco et al. 2012). This software tool is capable of 
predicting binding sites for any peptide sequence of a limited size onto the 
surface of protein structures sourced from the PDB. Therefore, Pepsite2 was 
utilized to examine if binding motifs could be identified from RNF181 that 
appeared to mediate its interaction with predicted models of the four integrin 
αIIb cytoplasmic tails, which are illustrated in figure 4.10. To carry this out, 49 
sequential peptides representing RNF181’s amino acid sequence were 
systematically docked onto each PDB integrin model, described above, 
namely; 1KUP, 1DPQ, 1DPK and 1S4W. Starting at the C-terminal and 
ending at the N-terminal of RNF181’s primary structure, the peptide 
sequences were nine amino acids in length and overlap by six residues 
(illustrated in Table 4.2).  Also illustrated in Table 4.2 are the predicted 
binding scores for each docking event, which are provided as significant p-
values. Peptides which are predicted to be highly significant at binding onto 
the integrin cytoplasmic tails are scored with p-values closer to zero (in red), 
while peptides with a moderate binding significance are scored in yellow. 
Understandably, peptides not predicted to bind are given a significance score 
closer or above 0.2, in white. After docking the selected peptides onto the 
integrin models, two regions of RNF181 appeared to have an affinity for the 
integrin tails.  
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The sequence 129HRRDKARKQQQQHRLENL146 was a more outstanding 
repeatedly predicted region of RNF181 to bind to the integrin models with 
significance, while the 46WDHHLPPPAAKTVVE60 was also predicted to bind, 
but with less significance. A full list of peptides and their predicted scores for 
binding to the individual PDB structures of the integrin tails are given in Table 
4.2.  
 
 
 
         
 
         
 
Figure 4.10: The secondary structures of integrin αIIb cytoplasmic tails 
from a variety of sources within the protein data bank 
Structures were predicted by the hydrogen bond estimation algorithm (DSSP) 
using the experimental information provided by the sources (Weljie, Hwang, 
and Vogel 2002) for A - 1KUP; (Vinogradova et al. 2000) for B – 1DPQ; and 
for C – 1DPK; (Vinogradova et al. 2004) for D – 1S4W. These structures 
represent those subject to the docking studies in Table 4.1 below.  
 
 
 
A: 1KUP B: 1DPQ 
C: 1DPK D: 1S4W 
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Table 4.2: A unique region of RNF181 that binds to the integrin αIIb 
cytoplasmic  
Four alternative structures for the integrin αIIb cytoplasmic tail were obtained 
from the RCSB protein data bank. Using the pepsite2 docking tool (developed 
by (Trabuco et al. 2012)) sequential RNF181-derived peptide sequences 
(which were 9 amino acid residues in length and overlapped by 6 residues) 
were examined for their probability to bind to the computational structures of 
the integrin αIIb cytoplasmic tail domain. The PDB models are defined by the 
PDB ID codes; 1KUP, 1DPQ, 1DPK and 1S4W. Each value from the table 
represents the binding prediction of each peptide onto each of the models. 
The scores are a measure of binding probability and are colored according to 
statistical significance (red = highly significant; yellow = moderately 
significant; white = not significant).  
 
Top significance score of predicted 
binding 
  
Top significance score of predicted 
binding 
 Protein data bank ID 
  
Protein data bank ID 
Peptide 
sequence  1KUP 1DPQ 1DPK 1S4W 
 
Peptide 
sequence 1KUP 1DPQ 1DPK 1S4W 
MASYFDEHD 0.4481 0.2839 0.7378 0.3543 
 
SPVSLLEFE 0.5197 0.402 0.6382 0.5361 
YFDEHDSEP 0.4589 0.4244 0.7999 0.4554 
 
SLLEFEEEE 0.6794 0.5877 0.9033 0.5496 
EHDSEPSDP 0.3969 0.3354 0.6181 0.3736 
 
EFEEEETAI 0.5644 0.4599 0.8551 0.509 
SEPSDPEQE 0.338 0.3764 0.4184 0.3496 
 
EEETAIEMP 0.4328 0.3244 0.55 0.3776 
SDPEQETRT 0.3902 0.2028 0.3687 0.3197 
 
TAIEMPSHH 0.3591 0.245 0.4568 0.2455 
EQETRTNML 0.2799 0.2941 0.5598 0.245 
 
EMPSHHLFH 0.3148 0.2949 0.4847 0.3086 
TRTNMLLEL 0.3811 0.3197 0.5728 0.3534 
 
SHHLFHSSS 0.4613 0.3588 0.6996 0.3657 
NMLLELARS 0.3311 0.3067 0.6671 0.3975 
 
LFHSSSILP 0.4118 0.3112 0.666 0.298 
LELARSLFN 0.3597 0.328 0.7382 0.3334 
 
SSSILPWLS 0.3255 0.3609 0.4944 0.3672 
ARSLFNRMD 0.3046 0.2177 0.5335 0.3131 
 
ILPWLSKTN 0.2361 0.2338 0.5651 0.311 
LFNRMDFED 0.3337 0.2675 0.5701 0.3205 
 
WLSKTNSSP 0.2977 0.3558 0.6069 0.378 
RMDFEDLGL 0.363 0.2769 0.697 0.455 
 
KTNSSPLSR 0.2936 0.2441 0.5391 0.3429 
FEDLGLVVD 0.5965 0.493 0.8053 0.4919 
 
SSPLSRYEL 0.4826 0.393 0.6382 0.4801 
LGLVVDWDH 0.4128 0.2887 0.6996 0.3308 
 
LSRYELPTD 0.4847 0.3487 0.5523 0.3275 
VVDWDHHLP 0.2694 0.2594 0.6452 0.2928 
 
YELPTDDDT 0.3639 0.2711 0.6525 0.387 
WDHHLPPPA 0.172 0.2651 0.3137 0.1395 
 
PTDDDTYEE 0.4491 0.3027 0.671 0.3411 
HLPPPAAKT 0.267 0.02752 0.3011 0.2969 
 
DDTYEEHRR 0.2498 0.3603 0.8088 0.3504 
PPAAKTVVE 0.1842 0.3161 0.3161 0.2941 
 
YEEHRRDKA 0.303 0.3531 0.6679 0.4098 
AKTVVENLP 0.378 0.3112 0.5969 0.3845 
 
HRRDKARKQ 0.1602 0.1974 0.423 0.2468 
VVENLPRTV 0.4673 0.3921 0.4858 0.3169 
 
DKARKQQQQ 0.0785 0.1624 0.226 0.1433 
NLPRTVIRG 0.3836 0.2629 0.5212 0.2627 
 
RKQQQQHRL 0.1114 0.2078 0.1909 0.1516 
RTVIRGSQA 0.4046 0.2564 0.4758 0.2622 
 
QQQHRLENL 0.1561 0.1946 0.2852 0.1576 
IRGSQAELK 0.3275 0.3377 0.5826 0.3899 
 
HRLENLHGA 0.2854 0.3576 0.6444 0.3011 
SQAELKSPV 0.2962 0.2302 0.5451 0.3549 
 
ENLHGAMYT 0.2627 0.2951 0.6355 0.315 
ELKSPVSLL 0.425 0.4669 0.6185 0.5402 
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4.8: Peptide array identifies the structural region of RNF181 that 
interacts with the integrin αIIb motif 
Since the bioinformatic approach identified short linear motifs mediating 
RNF181’s interaction with integrin, it deemed appropriate to examine the 
binding region by using wet laboratory conditions. To investigate the 
interaction parameters, membranes peptide arrays (PepSpot membrane 
arrays) that carried short linear peptides originating from the primary 
sequence of full length RNF181 protein were generated (by JPT technologies, 
Germany). In the first array (PepSpot membrane 1); 49 peptides were 
synthesised that corresponded to the entire length of the RNF181 protein. 
Starting from the N-terminus and ending at the C-terminus, these peptides 
were constructed nine amino acids in length and overlapped by six residues. 
Each peptide was covalently anchored onto the cellulose membrane at the C-
terminus. The membrane was probed with the integrin αIIb derived peptide 
(985LAMWKVGFFKR995); representing the αIIb motif that was originally used to 
identify RNF181 as an integrin-binding protein. In addition, this targeting 
peptide was modified with a biotin molecule, to enable binding site 
identification using a FITC Streptavidin method; as detailed in the Materials 
and Methods section. Data analysis identified the RNF181 derived peptides to 
be targeted by the αIIb motif were at positions 10, 21, 22, 37, 44, 45 and 46 
(Figure 4.11, A). These positions corresponded to RNF181 derived peptide 
sequences; ARSLFNRMD, NLPRTVIRG, RTVIRGSQA, KTNSSPLSR, 
HRRDKARKQ, DKARKQQQQ and RKQQQQHRL respectively (Table 4.3, B). 
Thereafter, the second array (PepSpot 2) was generated to contain 37 
peptides representing the entire sequence of RNF181. To confirm that the 
binding observed in PepSpot 1 was a factor of specificity, the primary 
structure of RNF181 was alternatively diced into 10 amino acid residues in 
length, overlapping by 6 residues, starting from the N-terminus and ending at 
the C-terminus. Furthermore, an additional group of peptides corresponding 
to the structures that had been positive for binding on PepSpot 1 were 
replicated onto PepSpot 2 (at positions 38 -46). These additional 9 peptides 
were also spotted in a disordered way from their original anchorage in 
PepSpot 1 (i.e. sequential sequences were not directly next to each other), to 
reduce the re-occurrence of non-specific interactions. In addition, a modified 
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peptide (DKAAAAQQQ) representing one that had been positively targeted in 
PepSpot 1 (DKARKQQQQ; position 45) was also generated on to PepSpot 2 
at position 47. The PepSpot 2 was again incubated with a peptide 
corresponding to the conserved integrin αIIb motif; LAMWKVGFFKR and 
measured for binding (Figure 4.11, B). In addition, a control peptide 
(MRDKAPGQ) which was modified with a biotin molecule was used to probe 
a second PepSpot 2 membrane, in order to identify non-specific binding 
regions (Figure 4.11, C). Sequences bound in PepSpot 2 by 
LAMWKVGFFKR were at positions 1, 10, 11, 33, 34, 40, 41, 44 and 46 
(Figure 4.7, B). There was substantial overlap in the results from the PepSpot 
1 and PepSpot 2 membranes that clearly identified potential binding sites for 
the conserved integrin LAMWKVGFFKR sequence. However, some RNF181 
peptide sequences were also bound by the control peptide.  
 
Overall, the peptides which showed specificity for integrin αIIb were identified 
at positions 44, 45 and 46 of PepSpot 1 and positions 33, 34, 40, 44 and 46 
of PepSpot 2. These regions on the PepSpot membrane collectively 
correspond to the amino acid residues; 128EHRRDKARKQQQQHRL143 of 
RNF181. The sequences of all peptides in PepSpot membrane 1 and 2 are 
given in Table 4.3. A. 
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Table 4.3: Amino acid sequences of RNF181 and the peptide fragments 
arrayed on the PepSpot membranes 1 and 2 
The full length amino acid sequence of RNF181 obtained from UniProtKB/Swiss-
Prot (Q9P0P0 (RN181_HUMAN) is displayed (A). Starting at the N-terminus and 
ending at the C-terminus, the entire primary structure sequence of RNF181 was 
diced into short linear overlapping peptides. These sequences were synthesised 
and arrayed onto nitrocellulose membranes (PepSpot arrays) at positions 
described in B. The PepSpot membrane 1 has 49 peptides; nine amino acids 
long, overlapping by six residues. PepSpot membrane 2 has 37 peptides derived 
from RNF181 that are ten amino acids in length and overlap by six. In addition, 
ten peptides from PepSpot 1 are arrayed on PepSpot 2 at position 38 – 46, plus 
a modified peptide at position 47. Specifically highlighted are the sequences that 
demonstrated an interaction with the integrin-derived peptide LAMWKVGFFKR 
(green) or sequences that interacted with the control peptide (MRDKAPGQ; 
highlighted in grey).   
 
 
RNF181 protein sequence 
MASYFDEHDCEPSDPEQETRTNMLLELARSLFNRMDFEDLGLVVDWDHHLPPPAAKTVVENLPRTVIRGSQA
ELKCPVCLLEFEEEETAIEMPCHHLFHSSCILPWLSKTNSCPLCRYELPTDDDTYEEHRRDKARKQQQQHRLE
NLHGAMYT 
 
         
PepSpot membrane 2 
 
 
 
 
PepSpot membrane 1 
01 MASYFDEHD 11 LFNRMDFED 21 NLPRTVIRG 31 EMPSHHLFH 41 PTDDDTYEE 
02 YFDEHDSEP 12 RMDFEDLGL 22 RTVIRGSQA 32 SHHLFHSSS 42 DDTYEEHRR 
03 EHDSEPSDP 13 FEDLGLVVD 23 IRGSQAELK 33 LFHSSSILP 43 YEEHRRDKA 
04 SEPSDPEQE 14 LGLVVDWDH 24 SQAELKSPV 34 SSSILPWLS 44 HRRDKARKQ 
05 SDPEQETRT 15 VVDWDHHLP 25 ELKSPVSLL 35 ILPWLSKTN 45 DKARKQQQQ 
06 EQETRTNML 16 WDHHLPPPA 26 SPVSLLEFE 36 WLSKTNSSP 46 RKQQQQHRL 
07 TRTNMLLEL 17 HLPPPAAKT 27 SLLEFEEEE 37 KTNSSPLSR 47 QQQHRLENL 
08 NMLLELARS 18 PPAAKTVVE 28 EFEEEETAI 38 SSPLSRYEL 48 HRLENLHGA 
09 LELARSLFN 19 AKTVVENLP 29 EEETAIEMP 39 LSRYELPTD 49 ENLHGAMYT 
10 ARSLFNRMD 20 VVENLPRTV 30 TAIEMPSHH 40 YELPTDDDT   
 
PepSpot membrane 2 
01 MASYFDEHDC 11 GLVVDWDHHL 21 LEFEEEETAI 31 PTDDDTYEEH 38 ARSLFNRMD 
02 FDEHDCEPSD 12 DWDHHLPPPA 22 EEETAIEMPC 32 DTYEEHRRDK 39 NLPRTVIRG 
03 DCEPSDPEQE 13 HLPPPAAKTV 23 AIEMPCHHLF 33 EHRRDKARKQ 40 HRRDKARKQ 
04 SDPEQETRTN 14 PAAKTVVENL 24 PCHHLFHSSC 34 DKARKQQQQH 41 MASYFDEHD 
05 QETRTNMLLE 15 TVVENLPRTV 25 LFHSSCILPW 35 KQQQQHRLEN 42 RTVIRGSQA 
06 TNMLLELARS 16 NLPRTVIRGS 26 SCILPWLSKT 36 QHRLENLHGA 43 KTNSSPLSR 
07 LELARSLFNR 17 TVIRGSQAEL 27 PWLSKTNSCP 37 LENLHGAMYT 44 DKARKQQQQ 
08 RSLFNRMDFE 18 GSQAELKCPV 28 KTNSCPLCRY   45 ELKSPVSLL 
09 NRMDFEDLGL 19 ELKCPVCLLE 29 CPLCRYELPT   46 RKQQQQHRL 
10 FEDLGLVVDW 20 PVCLLEFEEE 30 RYELPTDDDT   47 DKAAAAQQQ 
01 MASYFDEHDC 11 GLVVDWDHHL 21 LEFEEEETAI 31 PTDDDTYEEH 38 ARSLFNRMD 
02 FDEHDCEPSD 12 DWDHHLPPPA 22 EEETAIEMPC 32 DTYEEHRRDK 39 NLPRTVIRG 
03 DCEPSDPEQE 13 HLPPPAAKTV 23 AIEMPCHHLF 33 EHRRDKARKQ 40 HRRDKARKQ 
04 SDPEQETRTN 14 PAAKTVVENL 24 PCHHLFHSSC 34 DKARKQQQQH 41 MASYFDEHD 
05 QETRTNMLLE 15 TVVENLPRTV 25 LFHSSCILPW 35 KQQQQHRLEN 42 RTVIRGSQA 
06 TNMLLELARS 16 NLPRTVIRGS 26 SCILPWLSKT 36 QHRLENLHGA 43 KTNSSPLSR 
07 LELARSLFNR 17 TVIRGSQAEL 27 PWLSKTNSCP 37 LENLHGAMYT 44 DKARKQQQQ 
08 RSLFNRMDFE 18 GSQAELKCPV 28 KTNSCPLCRY   45 ELKSPVSLL 
09 NRMDFEDLGL 19 ELKCPVCLLE 29 CPLCRYELPT   46 RKQQQQHRL 
10 FEDLGLVVDW 20 PVCLLEFEEE 30 RYELPTDDDT   47 DKAAAAQQQ 
B 
 
 
A 
 131 
 
 
Figure 4. 11: Biotinylated LAMWKVGFFKR peptide binds to specific 
peptides derived from RNF181 on PepSpot membranes 
RNF181 protein sequence was diced into nine amino acid residues (panel A) 
and ten amino acid residues (panels B and C) which overlapped by six 
residues. Peptides were synthesized and covalently immobilized on the 
membrane by JPT technologies, Germany. The membranes were incubated 
with 0.5µM of a biotinylated-LAMWKVGFFKR peptide (panel A and B) and a 
biotinylated control peptide - MRDKAPGQ (panel C) for three hours at room 
temperature. Avidin-HRP was subsequently incubated with the membranes to 
facilitate detection. A table of the amino acid positions for each membrane is 
given in Table 4.3, B.  
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4.9: RNF181 derived peptide extracts integrin IIb3 from solution 
The verify that the peptide regions of RNF181; identified in sections 4.7 and 
4.8 above, were indeed fundamental in mediating the integrin interaction, pull-
down experiments were carried on platelet lysates and solutions of purified 
integrin IIb3 using RNF181 derived peptides. The peptides that were used to 
examine binding included a peptide that was observed by pepsite2 and 
PepSpot arrays as being non-specific for the integrin αIIb tail – 
1MASYFDEHD9; a peptide that was identified (by pepsite2 and PepSpot 
arrays) to be specific for the integrin αIIb tail – 
129HRRDKARKQ137; and finally 
a modified version of 129HRRDKARKQ137, that had alanine substitutions in its 
final four amino acids - 129HRRDKAAAA137. All peptides were biotinylated to 
facilitate the precipitation of peptide: protein complexes using Streptavidin-
conjugated agarose beads. To carry out the experiments, 50µg/ml of each 
peptide was individually incubated with a solution of purified integrin αIIbβ3 
(Figure 4.12, panel A) or with lysates prepared from resting platelets (Figure 
4.12, panel B) for 2 hours. Western blot analysis indicated that the 
129HRRDKARKQ137 extracted purified integrin αIIbβ3 (Figure 4.12, panel A, 
lane1) from solution. Additionally this peptide was able to bind and extract 
integrin αIIbβ3 from platelet lysates (Figure 4.12, panel B, lane 2). The control 
peptide; 1MASYFDEHD9 was unable to pull down integrin αIIbβ3 (Figure 4.12; 
lane 2 - panel A and lane 3 - panel B). Whereas the modification largely 
reduced, but did not abolish the peptide’s (129HRRDKAAAA137) ability to pull 
down purified integrin from solution (Figure 4.12; lane 3 - panel A). In 
conclusion, the amino acid sequence of RNF181; 129HRRDKARKQ137 is 
critical for protein binding to αIIbβ3.  
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Figure 4.12: RNF181 derived peptides bind directly to integrin αIIbβ3 
Biotinylated peptides (50μg/ml)were incubated with a solution of purified 
integrin αIIbβ3 (Panel A)or a lysate prepared from resting platelets (Panel B) 
for 2 hours at 4°C. Streptavidin conjugated agarose beads (30l/ml) were 
then incubated with mixtures overnight. Beads were washed and SDS sample 
buffer was added. Samples were examined by SDS PAGE, transferred to 
nitrocellulose membranes and analyzed for integrin αIIbβ3 by western blot. 
Panel A represents pull down experiments using peptides and purified 
integrin whilst panel B shows pull downs between peptides and platelet 
lysates. The peptides used to pull down protein are in the respective lanes: 
Panel A – 1) HRRDKARKQ, 2) MASYFDEHD, 3) HRRDKAAAA, 4) Blank, 5) 
purified integrin IIb3 load. Panel B:1) platelet lysate load, 2) HRRDKARKQ, 
3) MASYFDEHD, 4) HRRDKAAAA and 5)purified integrin IIb3load. Data 
shown is representative data of 3 similar experiments.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Integrin αIIb
(120 kDa)
Integrin αIIb 
(120 kDa)
1 2 3 4 5
1 2 3 4 5
A
B
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4.10: Isothermal titration calorimetry interaction studies  
Following pull-down of integrin αIIbβ3 by RNF181 derived peptides (described 
in section 4.9), the binding nature of recombinant RNF181 (and its peptide 
derivatives) to an integrin αIIb cytoplasmic tail derived peptide was examined 
using isothermal titration calorimetry (ITC). Firstly, the integrin αIIb derived 
peptide motif was extended to 985LAMWKVGFFKRNRPPLE1001 in order to 
create a more structurally accurate representation of the integrin αIIb 
cytoplasmic tail. A control peptide for the integrin tail sequence was also 
generated with the sequence - RMALEVGAAEENEPPLR. This sequence was 
designed by a control peptide generator software (available at 
http://bioware.ucd.ie/~compass/biowareweb). This peptide was based on the 
original integrin sequence - 985LAMWKVGFFKRNRPPLE1001, but which had its 
positive amino acids replaced with negative residues and additionally had 
hydrophobic regions replaced with alternative hydrophobic regions. Two 
RNF181 derived peptides (29HRRDKARKQ137 and 132DKARKQQQQ140), 
previously identified (in sections 4.7 – 4.9) to be critical at mediating the 
interaction with the integrin cytoplasmic tail were examined for binding to the 
integrin peptides described above. In addition, an RNF181 derived control 
peptide (1MASYFDEHDC10) representing a sequence, non-specific for integrin 
αIIb was also used in the analyses. Peptide: peptide interactions with the 
integrin αIIb motif (
985LAMWKVGFFKRNRPPLE1001) were separately assessed 
against the RNF181 derived peptides 129HRRDKARKQ137 and 
132DKARKQQQQ140.  
 
Figure 4.13 demonstrates an ITC measurement between the integrin αIIb 
peptide and 129HRRDKARKQ137. Panel A illustrates the raw thermogram for 
the peptide; peptide interaction. The binding isotherms displayed in Figure 
4.13, panel B; illustrate the measurements described in panel A, in addition to 
the control titrations for this experiment. Briefly, the αIIb motif and 
129HRRDKARKQ137 are represented by solid squares, while titration of 
129HRRDKARKQ137 into the control peptide, RMALEVGAAEENEPPLR (solid 
circles) and into ITC buffer only (solid stars) are displayed. Finally, the titration 
of the RNF181 derived control peptide (1MASYFDEHDC10) into the integrin 
αIIb derived peptide is represented as solid pentagons. No binding events 
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were detected in the control experiments. The thermodynamic profile for the 
reaction is given in Table 4.4. A molar ratio close to 1, with a Kd value of 105 
± 42µM and a favourable change in free energy of -5.48kcal/mol was 
measured for the reaction.  
 
 
Figure 4.13: Quantification of the binding of RNF181-derived peptide, 
HRRDKARKQ to integrin αIIb derived peptides by ITC 
The peptide sequence HRRDKARKQ from RNF181 (2.5mM) was titrated into a 
solution of integrin-derived peptide LAMWKVGFFKRNRPPLE (0.25mM). The raw 
thermogram for the reaction is displayed in panel A. The binding isotherm generated 
and analyzed by Origins one site binding model is displayed in panel B as square 
symbols and a solid connecting line. Additionally, panel B displays the binding 
isotherms generated from titrating HRRDKARKQ (2.5mM) into a solution of 
RMALEVGAAEENEPPLR (0.025mM) control peptide (circles); or ITC buffer (stars). 
A control RNF181 derived peptide (MASYFDEHDC) was also titrated into the integrin 
αIIb derived peptide; LAMWKVFFKRNRPPLE and is displayed by the binding 
isotherm represented by pentagons. All peptides were solubilised in an ITC buffer 
containing TRIS (10mM) and NaCl (50mM) at pH 7.4. Data is representative of three 
seperate experiments.  
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Subsequently, the peptide 132DKARKQQQQ140 was measured for its binding 
potential to the integrin derived peptide. In comparison to the above analysis, 
a higher affinity was observed between the RNF181 derived peptide 
132DKARKQQQQ140 and the integrin αIIb motif (Figure 4.14) The 
thermodynamic profile for the reaction (given in Table 4.4) shows a binding 
molar ratio (n) close to 1, a binding affinity of 29 ± 16µM and a change in free 
energy (-6.22kcal/mol) suggesting a favourable, spontaneous interaction.  
Control peptides used to determine the specificity of the interactions were 
identical to those used above in Figure 4.13. Again, the experimental controls 
showed no tendency for binding. 
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Figure 4.14: Quantification by ITC of the binding of RNF181-derived peptide, 
DKARKQQQQ, to integrin αIIb derived peptides 
The peptide sequence DKARKQQQQ from RNF181 was titrated at a 2.5mMolar 
concentration into a solution of 0.25mM LAMWKVGFFKRNRPPLE peptide. The raw 
thermogram for the reaction is displayed in panel A. The binding isotherm generated 
and analyzed by Origins one site binding model is displayed in panel B by the lower 
solid squares and solid line. Additionally, panel B displays the binding isotherms 
generated from titrating DKARKQQQQ (2.5mM) into a solution of 
RMALEVGAAEENEPPLR (0.025mM) control peptide (circles); and a solution of ITC 
buffer (upper squares). A control RNF181 derived peptide (MASYFDEHDC) was 
titrated into the integrin αIIb derived peptide LAMWKVFFKRNRPPLE and is displayed 
by the binding isotherm represented by the upper line. Data is representative of three 
independent experiments.  
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Following analysis of peptide – peptide interactions, recombinant full-length 
RNF181 was examined for binding potential with the integrin αIIb derived 
peptide. The reaction was carried out by titrating the integrin-derived peptide 
(LAMWKVGFFKRNRPPLE) into a solution of recombinant RNF181 protein. 
The thermogram and binding isotherm for the reaction is presented in Figure 
4.15. The thermodynamic profile (Table 4.4) shows a binding ratio close to 1 
and a micromolar binding affinity of 10 ± 4µM. The control for this experiment 
was carried out by titrating the integrin derived peptide into ITC buffer alone. 
The isotherm for this titration illustrates minimal changes in heat capacity 
(Figure 4.15, panel B; upper squares). The peptide: peptide and peptide: 
protein interactions, measured by ITC ultimately verified that the sequence of 
RNF181; 129HRRDKARKQQQ139 specifically and directly binds to the integrin 
αIIb tail.   
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Figure 4.15: ITC quantification of binding between recombinant RNF181 and 
the integrin αIIb derived peptide 
The peptide LAMWKVGFFKRNRPPLE was examined by ITC for its binding potential 
to recombinant RNF181. Both peptide (LAMWKVGFFKRNRPPLE; 2mM) and protein 
(recombinant RNF181; 0.075mM) were solubilised in ITC buffer. Then the peptide 
was titrated into RNF181 protein solution. The thermogram from the reaction is 
displayed in panel A. The binding isotherm was generated and analyzed using 
Origin’s one site binding model (panel B) (lower squares). Additionally, the binding 
isotherm generated from the titration of LAMWKVGFFKRNRPPLE peptide (2mM) 
into ITC buffer is displayed by the upper squares in panel B. Data is representative of 
three independent experiments.  
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Table 4. 4: Stoichiometric analysis of peptide interactions carried out by 
ITC show favourable measurements for binding 
Recombinant RNF181 and its peptide derivatives were examined for their 
potential to bind to an integrin αIIb derived peptide in order to determine their 
stoichiometric profile following titration experiments with ITC. Binding partners 
are described in the left column with their respective binding ratio (n), binding 
affinity (Kd), enthalpy change (ΔH), entropy change (ΔS) and calculated free 
energy change (ΔG) displayed in rows on their right. Values represent the 
mean ± standard deviations calculated from three separate experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Binding partners 
 
 
n 
 
 
Kd (µM) 
 
ΔH 
(kcal/mol) 
 
ΔS 
(kcal/mol/deg) 
 
ΔG 
(kcal/mol) 
 
1 
 
HRRDKARKQ  
v’s 
LAMWKVGFFKR 
 
1.1 ± 0.3 
 
105 ± 42 
 
-50.4 ± 35.3 
 
-0.15 ± 0.12 
 
-5.48 ± 0.22 
 
 
2 
 
DKARKQQQQ 
v’s 
LAMWKVGFFKR 
 
1.3 ± 0.1  
 
29 ± 16 
 
-22.3 ± 16.2 
 
-0.054 ± 0.05 
 
-6.22 ± 0.29 
 
3 
 
LAMWKVGFFKR   
v’s  
RNF181 
 
0.95 ± 0.05 
 
10 ± 4 
 
-23.2 ± 7.8 
 
-0.054 ± 0.023 
 
-7.14 ± 0.53 
C 
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4.11: Discussion 
The purpose of this chapter was to determine if RNF181 had a direct binding 
relationship with the platelet integrin αIIbβ3. Multiple techniques were used to 
examine the dynamic binding nature between the proteins. These included 
co-immunoprecipitation, ITC and MST, bioinformatics, peptide arrays and 
pull-down experiments. Co-immunoprecipitation experiments proved difficult 
leading to a conclusion that any interaction was low-affinity, transient or 
dependent on specific cellular conditions. However, experiments using ITC 
and MST demonstrated a direct interaction between full length RNF181 and 
purified integrin αIIbβ3, with a Kd value of approximately 10uM. PepSpot 
microarrays and bioinformatic analysis identified potential interaction sites of 
RNF181 (128EHRRDKARKQQQQHRL143). Subsequently, peptide pull-down 
and ITC experiments corroborated these observations; in particular, the 
integrin αIIb derived peptide and 
129HRRDKARKQQQQ140 amino acid 
sequence of RNF181 displayed a direct and specific affinity for one another.  
 
The lack of reproducibility by the CO-IP experiments was explored in an 
attempt to determine any specific cellular conditions that mediated an optimal 
protein interaction. However the attempts to overcome the limits of CO-IP 
were un-successful. Incubation times of lysates with antibody / bead 
complexes were altered, as was stringency of wash buffers. The possibility of 
protein degradation being the underlying reason was also examined using 
protein inhibitor cocktails and a protease inhibitor drug (Bortezomib), which 
would act to prevent any in-experiment protein degradation. However, the 
levels of RNF181 in platelet lysates or immunoprecipitates were unaltered by 
the presence / absence of protein degradation enzyme inhibitors, suggesting 
that this was not an underlying cause of our failure to demonstrate 
physiological protein co-association. It has been previously shown by our 
group that the integrin binding protein; Icln translocates to the insoluble 
fraction of a platelet lysate following activation. The possibility that this event 
occurs to obstructs CO-IP detection between RNF181 and the integrin needs 
to be examined in future studies. An alternative explanation for the 
reproducibility factor is that the interaction between the two proteins is of 
weak affinity or is highly transient, and therefore difficult to capture by 
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immunoprecipitation methods. Additional experiments examining the CO-IP of 
RNF181 with the integrin over an extensive time course may therefore 
provide additional information to the kinetics of the interaction.  
Subsequently, CHO cells expressing the resting and active forms of integrin 
were examined by immunoprecipitation. Results revealed a greater 
interaction between RNF181 and integrin from CHO-AA cells in comparison 
to CHO-FF cells. The integrin in CHO-AA cells contains a mutation in 2 
phenylalanine residues within the conserved αIIb cytoplasmic tail and appears 
to facilitate a conformation of the integrin that is similar to the activated state. 
However, it is important to note that while the mutated form of integrin 
expressed in the CHO-AA cell is often referred to as ‘activated’; it is not 
physiologically identical to the activated from of the native integrin. 
Nevertheless, this result demonstrated that the proteins bind under conditions 
of a structurally active integrin molecule more than a resting integrin. But 
similar to the CO-IP experiments from platelets, CO-IP’s with CHO cells 
lacked reproducibility. Therefore, to confirm binding between RNF181 and 
integrin; recombinant and purified structures of each protein was measured 
for protein: protein interaction using MST and ITC. Overall, both techniques 
confirmed an interaction between integrin αIIbβ3 and RNF181 with affinities 
between the proteins estimated to have an approximate Kd value within the 
10µM range.  
 
Low-affinity interactions are often mediated by the binding of a domain in one 
protein to a short linear peptide region in another (Diella et al. 2008). With 
regard to this concept and to determine if short linear protein sequences of 
RNF181 were indeed responsible in mediating integrin binding, bioinformatics 
analysis and membrane PepSpot arrays were employed. These two methods 
assessed the capacity for short linear overlapping peptides (derived from 
RNF181) to bind to the integrin αIIb cytoplasmic. The original work that 
identified RNF181 as a potential novel integrin binding protein used a short 
peptide derived from the conserved region of the integrin αIIb cytoplasmic tail; 
989KVGFFKR995 (Larkin et al. 2004). Given that the membrane domain 
(985LAMW988) of the integrin subunit is critical for interactions with alternative 
integrin binding proteins such as CIB1, the subsequent investigations 
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incorporated this additional portion of the integrin subunit onto the peptide 
sequence; 989KVGFFKR995; as these amino acids may also facilitate binding 
to RNF181.  
 
Membrane PepSpot arrays and parallel bioinformatics analysis identified 
numerous peptides regions of RNF181 which had apparent affinities for the 
integrin αIIb derived peptides. Moreover, a specific region 
(129HRRDKARKQQQQHRL143) was repeatedly highlighted by both 
bioinformatic and membrane PepSpot assessments to have a specificity for 
the integrin αIIb cytoplasmic tail. To take this further and examine if this region 
could interact with the full complex of integrin αIIbβ3, a portion of the peptide; 
129HRRDKARKQ137 containing a biotin modification was individually incubated 
with a solution of purified integrin αIIbβ3 and lysates from resting platelets. 
After an incubation of complexes with Streptavidin conjugated agarose beads, 
samples were assessed by western blots to determine if the biotinylated 
peptide could pull-down integrin from solution. In comparison to the native 
and modified (control) peptides, pull-down experiments illustrate the specific 
capacity for the RNF181 derived peptide (129HRRDKARKQ137) to bind and 
extract integrin αIIbβ3 from solution. Moreover, in contrast to native control 
peptide 1MASYFDEHD9, the modification of 129HRRDKARKQ137 to 
129HRRDKAAAA137 did not completely abolish integrin binding capacity. 
Peptide binding studies explored by ITC confirmed an interaction between 
RNF181 and integrin αIIbβ3, specifically at the identified regions. A great deal 
of the work with ITC was carried out to optimize binding parameters. The ITC 
studies demonstrated a direct binding relationship between the RNF181 
derived peptides (129HRRDKARKQ137 and 132DKARKQQQQ140) and the 
integrin peptide (985LAMWKVGFFKRNRPPLE1001). In particular, the 
132DKARKQQQQ140 peptide had an affinity similar to that observed for 
protein: protein interaction with an affinity of 29±16uM.  In addition, ITC 
experiments showed that the integrin peptide; 
985LAMWKVGFFKRNRPPLE1001 could bind to full length, recombinant 
RNF181 protein with an affinity of 10±4uM. In addition to the binding between 
the experimental peptides and proteins being observed as direct, the control 
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peptides and proteins outlined in each figure provided important evidence to 
the study by allowing a definitive conclusion regarding true interactions.  
 
In conclusion, this chapter has demonstrated that RNF181 binds directly to 
integrin αIIbβ3 and that the interaction is mediated via a short linear sequence 
from RNF181; specifically; 129HRRDKARKQQQQ140.  
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Chapter 5 
Functional analyses of RNF181 
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5.1: Introduction 
The biological effect of RNF181 in relation to αIIbβ3 activation in human 
platelets was investigated in this final experimental analysis chapter which 
has been divided into two parts. Firstly, in Part 1 the effect of RNF181 on 
platelet function was assessed while Part 2 aimed to determine the direct 
effect of RNF181 on integrin αIIbβ3 activation.  
 
In part 1, to address the effect of RNF181 on platelet function, peptides 
corresponding to its critical binding site for the αIIb cytoplasmic tail were 
rendered cell permeable by the addition of a palmitoyl group. This 
modification has been previously demonstrated to enable cell permeability of 
biomimetic peptides (Thiam et al. 1999) (Bernard et al. 2009). Since RNF181 
appears to directly interact with the conserved region of the cytoplasmic tail of 
integrin αIIb via the identified sequences in Sections 4.7 – 4.10 
(129HRRDKARKQQQQ140), it was proposed that the palmitoylated RNF181 
derived peptides would therefore modulate integrin activation. To investigate 
this hypothesis, two standard platelet function tests were carried out in the 
presence and absence of RNF181 derived peptides. These tests were (i) 
platelet adhesion to immobilized fibrinogen and (ii) thrombin induced platelet 
aggregation. From a platelet signalling perspective, there is an opposing 
difference for the initiation of integrin activation between the two platelet 
function tests. These differences are that within adhesion to fibrinogen, 
outside - in integrin signalling is the primary stimulant of platelet responses, 
with inside - out signalling, by ADP and TxA2 release being secondary, but 
also essential. Platelet aggregation on the other hand is dependent on inside-
out signalling as the initial primary stimulant with outside - in signalling being 
secondary but again also essential.  
 
Part 2 of this chapter aimed to determine the effect of RNF181 on integrin 
αIIbβ3 function in CHO-FF cells through siRNA targeted knockdown of RNF181 
protein. The rational for this investigation was derived from the fact that CHO-
FF cells undergo integrin αIIbβ3 mediated shape change in response cell 
adhesion to fibrinogen. In light of this, it was proposed that if RNF181 is a true 
regulator of integrin activation, then interference in its cellular concentrations 
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by siRNA molecules would no doubt modulate integrin function and therefore 
integrin mediated CHO-FF cell shape change. Moreover, data could indicate 
whether RNF181 positively or negatively regulates integrin activation.    
 
 
 
 
 
 
Part 1 
5.2: RNF181 derived peptides inhibit platelet spreading and aggregation  
5.2.1: Inhibition of platelet spreading 
Previous chapters examined the dynamic relationship between RNF181 and 
the cytoplasmic tail of integrin αIIb, from an interaction perspective. Amongst 
the binding studies carried out in chapter 4, the linear amino acid region 
(129HRRDKARKQQQQ140) was identified within RNF181 to mediate its 
interaction with integrin αIIb. To examine a physiological role for this binding 
site on platelet function, a set of palmitoyl modified peptides derived from 
RNF181 were examined for their effects on fibrinogen mediated platelet 
spreading. The selected peptides (Pal-HRRDKARKQ and Pal-DKARKQQQQ; 
renamed Pep-HQ and Pep-DQ respectively) represented an overlapping 
amino acid region within RNF181 critical for binding to the conserved motif of 
the integrin αIIb cytoplasmic tail. Two additional palmitoylated peptides were 
generated and included in the study and acted as control peptides. One 
peptide was a modified version of Pal-HQ, with a triple alanine modification at 
the C-terminal (Pal-HRRDKAAAA; renamed Pep-HA), which previously 
caused a significant reduction in the peptide’s binding potential to integrin 
αIIbβ3 (Figure 4.12). The other control peptide (Pal-MASYFEDHD; renamed 
Pep-MD) was native to RNF181 protein but that was observed in Sections 4.7 
– 4.9 as not having a direct interaction with the integrin αIIb cytoplasmic tail.  
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To determine the effects of the above peptides on platelet adhesion to 
fibrinogen, 25µM of each was pre-incubated with preparations of washed 
platelets for 30 minutes. Subsequently, the platelets were added to fibrinogen 
coated microscope slides for 45 minutes, fixed and fluorescently stained for 
integrin αIIbβ3. The images of platelet adhesion acquired following peptide 
treatments are represented in Figure 5.1. Platelet spreading behavior is 
normal in the untreated sample and spread to maximum capacity for the time 
indicated (Figure 5.1 - panel A). The palmitoylated, integrin binding peptides 
(Pal-HQ and Pal-DQ) abolished platelet spreading (Figure 5.1 - panels B and 
C). Previous peptide binding analyses in chapter 4 would suggest that this 
interference in platelet function is due the peptides occupying the conserved 
integrin αIIb motif and therefore interfering with “integrin cytoplasmic domain 
binding proteins” that regulate fibrinogen induced integrin αIIbβ3 activation and 
platelet spreading, such as CIB-1 (Tsuboi 2002), ICln (Raab, Parthasarathi, et 
al. 2010) or even RNF181. Interestingly, the RNF181 modified control peptide 
(Pal-HA) also displayed inhibitory properties to platelet spreading (Figure 5.1 - 
panel D), suggesting that the 137QQQQ140 sequence is not important for 
function. As anticipated, the peptide (Pal-MD) that is derived from RNF181, 
but that was not identified to be directly involved in integrin binding had no 
effect on fibrinogen induced platelet spreading (Figure 5.1 - panel E) 
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Figure 5.1: RNF181 derived peptides block platelet spreading 
To examine the effect of RNF181 derived peptides on platelet / integrin 
function, washed platelets were allowed to adhere to a fibrinogen-coated 
glass surface in the presence and absence of palmitoyl peptides. Initially, 
washed platelets were pre-incubated with JNL buffer (Panel A) or the 
palmitoylated peptides; Pal-HQ (panel B); Pal-DQ (panel C); Pal-HA (panel D) 
and Pal-MD (panel E) for 30 minutes. Subsequently, the platelets were 
allowed to adhere for 45 minutes to glass slides that had been coated with 
25µg/ml of fibrinogen, fixed and fluorescently labeled for the platelet integrin 
αIIbβ3, as described in Figure legend 3.3. Samples were then examined by 
confocal microscopy using a Zeiss LSM510. Five images were acquired for 
each sample, and are representative of two independent experiments.  
 
 
 
 
 
A B C 
D E 
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5.2.2: inhibition of platelet aggregation 
In parallel studies, washed platelet preparations that had been pre-incubated 
with either JNL or various concentrations of peptides were stimulated with 
thrombin (0.2u/ml) and examined by light transmission aggregometry (LTA). 
The integrin derived inhibitory peptide (Pal-KVGAAKR; Pal-AA) (Raab, 
Parthasarathi, et al. 2010) was included in each assay to indicate the 
antagonistic properties of a palmitoylated peptide that interfered with integrin 
binding proteins. Results in Figure 5.2 illustrate bar graph analyses of LTA 
experiments representing the average percentage of aggregation (with 
standard deviations) from three separate experiments. In each experiment, 
thrombin alone (0.2u/ml) induced platelet aggregation to 71% ± 6.5% whilst 
Pal-AA (25µM) inhibited thrombin induced platelet aggregation to 6 ± 10%. 
The most notable observation from these set of experiments is that Pal-HQ 
(graph A) and Pal-DQ (graph B) were able to inhibit thrombin induced 
aggregation in a dose dependant manner, with peptide concentrations of 
50µM, 25µM and 12.5µM having significant inhibitory effects. However there 
was a considerable difference of inhibition among the donors at the peptide 
concentration of 12.5µM. In contrast to the previous platelet adhesion to 
fibrinogen, the modified Pal-HA had no significant effect on thrombin induced 
platelet aggregation at any concentration (graph C), suggesting that the 
137QQQQ140 is important for peptide function, specifically during the 
interference of platelet activation by the potent platelet agonist; thrombin. In 
accordance with the previous functional experiments in Figure 5.1 and the 
binding experiments in the previous chapter 4, the control peptide (Pal-MD) 
derived from RNF181’s non integrin binding region had no significant effect 
on thrombin induced platelet aggregation at the peptide concentrations; 50µM 
and 25µM.   
 
In conclusion, the palmitoylated peptides derived from RNF181’s integrin 
binding significantly and specifically modulate platelet function. Moreover, the 
modified peptide; Pal-HA displays a differential capacity of interference, 
whereby it has a less potent effect on platelet aggregation in comparison to 
platelet adhesion.  
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Figure 5.2: RNF181 derived peptides inhibit platelet aggregation 
Peptides derived from the RNF181 binding region for integrin αIIb (plus controls) were 
examined for their effects on thrombin induced platelet aggregation by light transmission 
aggregometry. The following palmitoylated peptides; Pal-HRRDKARKQ (Pal-HQ); Pal-
DKARKQQQQ (Pal-DQ); Pal-HRRDKAAAA (Pal-HA); Pal-MASYFDEHD (Pal-MD) or Pal-
KVGAAKR (Pal-AA) were each incubated (at the described concentrations) with washed 
platelets (3x108/ml) for 15 minutes while stirring. Subsequently, thrombin (0.2u/ml) was 
added to each sample and aggregations were recorded for three minutes. Each graph (A, 
B and C) represents the average percentage of platelet aggregation at the 3 minute time 
point from three separate experiments.  Significant differences were confirmed by one 
way-anova and measured by student t-test. P value < 0.05 *; < 0.01 **; < 0.005 ***.  
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Part 2: Interference of RNF181 expression in CHO cells using siRNA 
5.3: Introduction 
The use of double stranded small interfering RNA (siRNA) molecules to 
obstruct protein expression was a breakthrough in the development of 
genetic interference and protein expression (Fire et al. 1998). The generally 
accepted pathway of gene silencing by siRNA molecules consists of mRNA 
degradation by the RNA induced silencing complex (RISC) (Hammond et al. 
2000). RISC is a natural biological enzymatic process that breaks down 
cellular RNA into small RNA fragments of approximately 25 nucleotides in 
length (Hammond et al. 2000). As a result of RNA degradation by RISC, the 
targeted RNA is unable to translate its genetic information to protein 
expression. The siRNA technique takes advantage of this RISC process by 
introducing synthetic short interfering RNA sequences to selectively target 
native mRNA that codes for specific proteins. For this method, small double 
stranded RNA molecules that are 19 – 21 nucleotides in length and that 
contain a complementary strand specific for regions of selected mRNA are 
introduced to the cell. Once inside the cell the double stranded molecules 
separate. The purposely designed unstable sense strand becomes quickly 
degraded while the more stable antisense strand (complementary for a 
specific region of a selected mRNA) guides the RISC to the targeted mRNA 
and causes degradation. As a result of gene silencing, the translation of 
protein is hindered.  
 
The following results demonstrate attempts at silencing the RNF181 gene in 
CHO cells using siRNA molecules from two separate sources. The initial 
investigation (Section 5.4) was carried out using commercially available 
siRNA molecules. For reasons suggested in the relevant section, these 
molecules were ineffective at silencing the RNF181 gene. Therefore, a 
second investigation was carried out (Sections 5.6) using custom siRNA 
molecules personally designed (described in Section 5.5) to target the 
RNF181 gene in CHO cells. In contrast to the above, these molecules 
effectively reduced the capacity of CHO cells to express RNF181.  
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5.4: Attempted silencing of the RNF181 gene in CHO cells using 
commercially available siRNA molecules 
Given that RNF181 is ubiquitously expressed across many species, 
including the Chinese hamster ovarian (CHO) cell line, it was targeted for 
silencing using a pool of siRNA molecules, commercially available from 
Santa Cruz Biotechnology (SCBT). The pool of SCBT constructs were 
specifically directed at three regions of the RNF181 gene sequence from 
mouse (outlined in Table 5.1). However, following RNF181 gene sequence 
cross referencing, one siRNA molecule from the SCBT pool matched a 
region of the RNF181 gene in CHO genome. Therefore,  although two of the 
three molecules from the siRNA pool (siRNA 2 and 3; Table 5.1) were non-
targeting for the RNF181 gene in CHO cells but molecule was targeting 
(siRNA 1; Table 5.1), it was estimated that the SCBT siRNA pool might be 
sufficiently capable of interfering with RNF181 expression system in the 
CHO cell line. To investigate this, CHO cells were cultured under a variety of 
conditions. These conditions included; i) incubating cells with 10nM or 25nM 
of the siRNA pool, for a range of time points (48 – 96 hours following 
transfection); ii) separately incubating the cells with two individual non-gene 
targeting control siRNA molecules (also purchased from SCBT) for 48 – 96 
hours; iii) treating the cells to normal culturing conditions for equal times or 
iv) treating the cells to transfection reagent alone for the indicated times of 
48 – 96 hours.  
 
To briefly describe experimental design, CHO cells were seeded into 6 well 
tissue culture plates for 24 hours in serum free media. Subsequently, the 
siRNA molecules were mixed (at indicated concentrations) with transfection 
reagent and incubated with the CHO cells. After 7 hours, the cells were 
washed and media was replaced with normal cell culture media and 
incubated for a further 48, 72 and 96 hours. After each time point, the cells 
were prepared to lysates and examined for RNF181 protein expression by 
loading in equal volumes into polyacrylamide gels and analyzed by western 
blot for protein expression levels of either α-actinin (as a loading control) or 
RNF181. Western blot analysis for each treatment is illustrated in Figure 5.3. 
The upper blots in each panel represent α-actinin expression while the lower 
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blots represent RNF181 expression. The experiments were performed twice. 
However, no significant protein knockdown effect was observed under any 
siRNA incubation time or concentration.  
It is suggested that one siRNA molecule can dominate the RNA induced 
silencing complex (RISC) over alternative siRNA molecules when 
transfected in combination. Therefore, the inability for the siRNA pool to 
cause protein silencing could be due to a dominant occupation of RISC by 
the two non-targeting siRNA molecules over the targeting siRNA.  
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Table 5.1: Small interfering RNA’s designed to target the RNF181 gene in mouse 
Santa Cruz biotechnology developed a pool of siRNA molecules (A) to specifically 
target three various nucleotide regions of the Mus musculus (mouse) mRNA gene 
encoding for RNF181 (B).The siRNA 1 also matched a region of the mRNA gene 
encoding for RNF181 in Cricetulus griseus (Chinese hamster) (C). This pool of siRNA 
molecules was therefore examined for its knockdown effect on RNF181 protein 
expression in CHO cells, described below in Figure 5.3.     
 
A
siRNA 1 • Sense 5’ CCCUGGCUAAGUAAGACAA tt 3’
•Antisense 5’ UUGUCUUACUUAGCCAGGG tt 3’
siRNA 2 • Sense 5’ CUGUAGGCGCCAUUAUCAA tt 3’
•Antisense 5’ UUGAUAAUGGCGCCUACAG tt 3’
siRNA 3  • Sense 5’ GUACUUAGGACAUCCUUCU tt 3’
CGGCAGCCCAGGAGCCAUGGCGUCUUAUUUUGAUGAGCACGACUGCGAGCCGUUGAACCCUGAGCG
UGAGGCCCGCAACA AUAUGUUGCUGGAACUCGCGAGAAGAGUGCGCGGGGCUUGGAGCUGGGCC 
CCGGGCGGCAGAUCACUCUUUAAUAGGAUGGACUUUGAGGACCUGGGAUUGGUAGAUUGGGAACAC
CACCUUCCCCCACCAGCUGCCAAGGCUGUGGUGGAGAGCCUCCCUAGAACAGUCAUCAGUAGCGCCA
AGGCUGAUCUCAAGUGCCCCGUGUGCCUUUUGGAAUUUGAGGCGGAGGAGACUGUGAUUGAGAUGC
CCUGCCAUCAUCUCUUCCAUUCCAACUGCAUUCUGCCCUGGCUAAGUAAGACAAAUUCCUGCCCUCU
GUGCCGCCAUGAGCUGCCCACUGAUGAUGACAGCUAUGAAGAGCACAAGAAAGACAAGGCUCGCAGG
CAGCAGCAGCAGCACCGCCUGGAGAACCUCCACGGAGCCAUGUACACGUGAGGCAGCUGCCAGGGC
UGAGCGCUCAGCCUCUCUGAUACCUUCCCUCUGCACUCUGAAUCAUUAAAGGUUUCUUUACCCACCC
UGCAGCUGCACGGCUCACCAGCCGAAGCAGGGGCUCCUUCCGAAUCCUCCACCCUGCUGCUAGCCA
GAAAGAUGUCAAAGGUGUCAAAUGUCCGAAGGUGCCAGGCUGCAAUUCCCUCUGCCAGCCUCUAGAC
UCUGGGUGGUGGGGCCCUAGAACAACCAGGGCUUGGGUCUGAGUGUUCUUUUAGAAGUCAAACUGU
GUCAGAGCCUGGCGCUUUGUAGCUGUUUAAAACUGAUAAAUUAACUUGCACCACCCCACUCCGGAAA
UCUCUAGUUAACCUUGGAACCUUUAGUUAACCGUGGAAUCCUGGGGGUGUUCUUUAUUUCCACAUAG
AAAACUUUUAACAUUGUAAAAGUUGCUCUCUGUAUCCCACUCCUGUAGGCGCCAUUAUCAAGGAAUC
AAAGGUCAAGCCAGCCCAAGUAGGGCAAGGCUGUUUAGAGACUCUUCAAAGGGGGACAGUCCUUGUG
GAAGUUUUGAAAGUGGGUUUCAUUCACUAUGUGACCUUGGCUGUCUUGGAACCCACUAUAUAGACCA 
GGCUCGCCUUGUACUUAGGACAUCCUUCUGCUCUGUCUUCCCAGUGUUGGGAUUACUGGUAUGUAC
ACACCCUUACGAUGUAUCUGAAUGGCAUCUGUCACUCUUAGUUUCUGGCAACCUCAAGAAUCUUUCC
UGGGGGA AGGACUUCUGUCCAUCCCUGCCCACUGGAUCGGACCCUCCGUGAUUCUCCAGAACACAC 
UGCAGACGUGCAAAUUAGAA UUCUUUUAAUAGAUAUAAAA AAGUACUAAAAUAAAAAAAA AAAAAAA
B
C
AUGGCGUCUUAUUUUGAUGAGCACGACUGCGAGCCGUUGAACCCUGAGCGCGAGGCCCGCAAC
AACAUGUUGCUGGAGCUCGCGAGGAGAGUGCGCGGGGCUUGGAGCUGGGCCCCGGGCAGCAG
AUCACUCUUUAAUAGGAUGGACUUUGAGGACUUGGGAUUGGUGGAUUGGGAACAUCACCUGCC
UCCACCAGCUGCCAAGGCUGUGGUGGAGAGCCUCCCCAGAACAGUCAUCGGUAGCUCCAAGGC
UGAGCUCAAGUGCCCUGUGUGCCUUUUGGAAUUUGAGGAGGAGGAGACUGUCAUUGAGAUGCC
CUGCCGUCACCUCUUCCAUUCCAGCUGCAUUCUGCCCUGGCUAAGUAAGACAAAUUCCUGCCC
CCUGUGCCGCCAUGAGCUGCCCACUGAUGAUGACAGUUAUGAAGAGCACAAGAAAGACAAGGCU
CGGAGGCAGCAGCAGCAGCACCGUCUGGAGAAUCUCCACGGAGCCAUGUACACGUGA 
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Figure 5.3: A pool of siRNA molecules had no silencing effect on RNF181 
expression 
A pool containing three siRNA molecules specific for mouse RNF181 mRNA were 
purchased from SCBT. Table 5.1 illustrates the three duplexes and also indicates the 
RNF181 mRNA region in mouse and Chinese hamster targeted by ach siRNA. To 
examine optimal conditions for RNF181 gene silencing, CHO cells were seeded into 6 
well tissue culture plates at 3x103 cells per ml and cultured for 24 hours (at 37°C with 5% 
CO2) in cell medium (DMEM) free from fetal calf serum and antibiotics. Cells were 
treated to 1 – normal conditions; 2 – with transfection reagent; 3 – with non-targeting 
(control) siRNA 1; 4 – control siRNA 2; 5 – with the pool of RNF181 gene targeting 
siRNA molecules according to the manufacturer’s instructions. Thereafter, cells lysed 
using 2X SDS sample buffer and loaded in equal volumes into polyacrylamide gels. 
Western blots were carried out for the proteins α-actinin and RNF181. Lanes 1 – 5 in 
each blot represent the cell treatments carried out to examine the effect of the siRNA 
molecules, which are described by the following; lane 1 - no treatment; lane 2 - 
transfection reagent alone; lane 3 – non targeting siRNA 1, lane 4 - non targeting siRNA 
2; lane 5 – a pool of RNF181 mouse gene targeting siRNA molecules. The siRNA 
concentrations and incubation times are presented in each panel as; A - 10nmolar 
siRNA for 48 hours incubation; B - 25nmolar siRNA for 48 hours incubation; C - 
10nmolar siRNA for 72 hours incubation; D - 25nmolar siRNA for 72 hours incubation; E 
- 10nmolar siRNA for 96 hours incubation; F - 25nmolar siRNA for 96 hours incubation. 
Protein detection by western blots for α-actinin (at 100kDa) are represented by the upper 
blots  while RNF181 is represented by lower blots (at 40 kDa) in each panel A – F. 
Experiments were performed two times 
1 = no treatment
2 = Transfection reagent only
3 = Control siRNA (1)
4 = Control siRNA (2)
5 = Mouse siRNA
1 2 3 4 5 1 2 3 4 5A B
C D
E F
A= siRNA concentration of 10nMolar for 48 hours
B= siRNA concentration of 25nMolar for 48 hours
C= siRNA concentration of 10nMolar for 72 hours
D= siRNA concentration of 25nMolar for 72 hours
E= siRNA concentration of 10nMolar for 96 hours
F= siRNA concentration of 25nMolar for 96 hours
α-actinin
α-actinin
α-actinin
RNF181
RNF181
RNF181
1 2 3 4 5 1 2 4 53
31 2 3 4 5 1 2 4 5
Targeting knock down of RNF181 in CHO cells
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5.5: Custom design of siRNA molecules 
Given that the previous, commercially available siRNA molecules were 
ineffective at silencing the RNF181 gene in CHO cells, a new approach was 
taken to design individual siRNA molecules that targeted RNF181 mRNA in 
CHO cells using previously described methods and algorithms (Yuan et al. 
2004). The mRNA nucleotide sequence encoding for RNF181 in Chinese 
Hamster (described in Table 5.2, B) was obtained from the NCBI GenBank 
database (Fernandez-Suarez, Rigden, and Galperin 2014). Using the 
computational methods (Yuan et al. 2004) three double stranded siRNA 
molecules were selectively designed based on a number of fitting criteria. To 
begin with, each siRNA duplex contained a sense and antisense strand, 19 
nucleotides in length with one strand complementary for the target mRNA. 
Two thymine (TT) overhangs were added at the 3 prime end of each strand to 
improve efficiency of mRNA degradation, as previously observed (Elbashir et 
al. 2001). Molecules were designed with particular nucleotides at critical 
positions from the 5’ to the 3’ end; which are as follows; A at position 3, U at 
position 10, A/C/U at position 13 and an A but not a G or C at position 19 
(1,2A4,5,6,7,8,9U11,12,A/C/U/T,14,15,16,17,18,A (not G or C)) (Nucleotides: Adenine 
(A); Cytosine (C) Guanine (G); Thymine (T) for DNA or Uracil (U) for RNA). 
Each molecule was low in thermodynamic stability and were each greater and 
less than 50nt from the start and stop codons respectively. Intron regions and 
nucleotide regions of four or more repeats were avoided. Guanine (G) and 
cytosine (C) content was between 30% - 60%. Nucleotide sequences that 
translated into protein sequences of amino acid complex repeats were 
avoided. These regions were avoided by analyzing the amino acid – codon 
sequence in table 5.3, panel B. A basic local alignment search (BLAST) using 
the nucleotide collection database megablast tool (Altschul et al. 1997) was 
carried out on the selected siRNA sequences to identify any potential off 
target effects. No cross-matching nucleotide sequences were identified in 
Chinese hamster although some hits were identified in alternative species. 
The sequence alignment searches (Tables 5.4, 5.5 and 5.6) illustrate the top 
twelve hits from each BLAST on the custom designed siRNA molecules 
(described in Table 5.2, A).   
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Table 5.2: Small interfering siRNA molecules targeting the RNF181 gene 
in Chinese hamster 
Using computational outputs generated by (Yuan et al. 2004), in addition to 
the selection based criteria described in section 5.5, double stranded siRNA 
molecules were designed to target RNF181 gene in Chinese hamster. Each 
molecule was 19 nucleotides in length with two thymine overhangs added to 
the 3’ end are presented in panel A. The nucleotide regions that each siRNA 
targeted within the RNF181 mRNA gene of the Chinese hamster are 
illustrated in panel B, highlighted in red text.  
 
 
 
 
 
 
 
 
 
 
 
 
 
siRNA (1) Position 117 – 136 
•Sense 5’ GGCAGCAGAUCACUCUUUA dTdT 3’
•Antisense 5’ UAAAGAGUGAUCUGCUGCC dTdT 3’
siRNA (2) Position 415 - 434
•Sense 5’ AUGAAGAGCACAAGAAAGA dTdT 3’
•Antisense 5’ UCUUUCUUGUGCUCUUCAU dTdT 3’
siRNA (3) Position 58 - 77
•Sense 5’ GCAACAACAUGUUGCUGGA dTdT 3’
•Antisense 5’ UCCAGCAACAUGUUGUUGC dTdT 3’
A
siRNA (1) Position 117 – 136 
•Sense 5’ GGCAGCAGAUCACUCUUUA dTdT 3’
•Antisense 5’ UAAAGAGUGAUCUGCUGCC dTdT 3’
siRNA (2) Position 415 - 434
•Sense 5’ AUGAAGAGCACAAGAAAGA dTdT 3’
•Antisense 5’ UCUUUCUUGUGCUCUUCAU dTdT 3’
siRNA (3) Position 58 - 77
•Sense 5’ GCAACAACAUGUUGCUGGA dTdT 3’
•Antisense 5’ UCCAGCAACAUGUUGUUGC dTdT 3’
A
AUGGCGUCUUAUUUUGAUGAGCACGACUGCGAGCCGUUGAACCCUGAGCGCG
AGGCCCGCAACAACAUGUUGCUGGAGCUCGCGAGGAGAGUGCGCGGGGCUU
GGAGCUGGGCCCCGGGCAGCAGAUCACUCUUUAAUAGGAUGGACUUUGAGGA
CUUGGGAUUGGUGGAUUGGGAACAUCACCUGCCUCCACCAGCUGCCAAGGCU
GUGGUGGAGAGCCUCCCCAGAACAGUCAUCGGUAGCUCCAAGGCUGAGCUCA
AGUGCCCUGUGUGCCUUUUGGAAUUUGAGGAGGAGGAGACUGUCAUUGAGAU
GCCCUGCCGUCACCUCUUCCAUUCCAGCUGCAUUCUGCCCUGGCUAAGUAAG
ACAAAUUCCUGCCCCCUGUGCCGCCAUGAGCUGCCCACUGAUGAUGACAGUU
AUGAAGAGCACAAGAAAGACAAGGCUCGGAGGCAGCAGCAGCAGCACCGUCU
GGAGAAUCUCCACGGAGCCAUGUACACGUGA
B
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Table 5.3: Codon to protein sequences for RNF181 
The Chinese hamster DNA sequence encoding for RNF181 and 
complimentary amino acids transcribed to each codon is illustrated. The 
details of all the possible codons that can transcribe each individual amino 
acid are also described. 
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Table 5.4: Basic local alignment search (BLAST) with custom designed, 
sigma siRNA1 
Top hits identified by the megablast search tool (Altschul et al. 1997), 
indicating the genes with significant alignments with sigma siRNA 1 sense 
strand – GGCAGCAGAUCACUCUUUA. Displayed are the identified hits 
accession number, gene description and sequence similarity.   
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Table 5.5: Basic local alignment search (BLAST) with custom designed, 
sigma siRNA2 
Top hits identified by the megablast search tool (Altschul et al. 1997) indicating 
the nucleotide sequences producing significant alignments with custom siRNA 2 
sense strand – AUGAAGAGCACAAGAAAGA. Displayed are the identified hits 
accession number, gene description and sequence similarity.   
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Table 5.6: Basic local alignment search (BLAST) with custom designed, 
sigma siRNA3 
Top hits identified by the megablast search tool (Altschul et al. 1997) 
indicating the nucleotide sequences producing significant alignments with 
siRNA 3 sense strand – GCAACAACAUGUUGCUGGA. Displayed are the 
identified hits accession number, gene description and sequence similarity.   
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5.6: Custom siRNA molecules reduce RNF181 protein expression in 
CHO cells 
To investigate the ability for the newly-designed siRNA molecules (described 
in table 5.2) to silence RNF181 protein expression in CHO cells, constructs 
were ordered from Sigma Aldrich. Firstly, it must be noted that the SCBT-
siRNA-pool that targeted the RNF181 mouse gene, used in section 5.4 above 
acted as the control siRNA for these subsequent experiments, because it was 
ineffective at interfering with CHO cell RNF181 expression (Figure 5.3). Also, 
the transfection reagent (CHO cell transfection reagent) in this section was 
purchased from Altogen Biosystems whereas in the previous section it was 
purchased from Santa Cruz Biotechnology. Briefly; as before, experiments 
were carried out by seeding CHO cells into 6 well tissue culture plates for 24 
hours, incubating for a variety of times with either targeting siRNA’s; a control 
siRNA; or no treatment at all, and analyzing protein expression levels of 
RNF181 and α-actinin by western blot.  
 
To be more specific, CHO cells were seeded at 3x103/ml into 6 well plates in 
DMEM media free from fetal calf serum (FCS) and penicillin/streptomycin 
(PenStrep) antibiotics overnight. The Sigma Aldrich siRNA molecules were 
solubilised in RNase free dilution buffer to a 100µM stock solution and 
subsequently prepared to concentrations of 10nM or 25nM in 1ml of Opti-
mem transfection buffer, which also contained 10µl of transfection reagent. 
The cells were treated to five experimental conditions which were; no 
treatment, treated with the SCBT-siRNA-pool, as a control (Table 5.1, A) or 
treated with the Sigma Aldrich – siRNA-1, siRNA-2 and siRNA-3 (Table 5.2, 
A) at the two separate doses (i.e 10nM and 25nM) for 7 hours. Thereafter, the 
siRNA / transfection mixture was removed and replaced with fresh DMEM 
supplemented with 10% (v/v) FCS and PenStrep antibiotics. The CHO cells 
were then incubated for an additional 72 and 120 hours, post-transfection. 
Subsequently the cells were harvested and analyzed by western blot for 
expression levels of the proteins α-actinin and RNF181, which is illustrated in 
Figure 5.4. The western blots demonstrate RNF181 knock-down in response 
to the targeted RNF181 siRNA constructs. Moreover, the effect of each siRNA 
on silencing the RNF181 gene in CHO cells was determined by densitometry 
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analysis of western blots from 2 experiments (Figure 5.5). The protein α-
actinin was used as a loading control and represented standard protein 
expression levels from the CHO cells lysates. As a result, the true reduction of 
RNF181 was calculated by using α-actinin as a reference for normal protein 
expression levels and ratioing its band densities to the band densities of 
RNF181 in each lane from the corresponding western blots.  
 
From the data it can be concluded that the most effective conditions at 
silencing RNF181 was by transfecting CHO cells with 10nM of siRNA-2 or 
siRNA-3 for 72 hours. The siRNA molecules became less effective as the 
incubation times increased to 120 hours, no doubt due to the doubling time of 
the parent CHO cells and therefore the reduction in concentration of siRNA in 
the daughter cells. Incubating the siRNA molecules with CHO cells at a higher 
concentration of 25nM for 72 hours was also effective at reducing RNF181 
expression but in contrast to the 10nM siRNA conditions, the control siRNA 
also reduced protein expression levels. Given that the control siRNA was a 
pool of three siRNA molecules, with one molecule specific to RNF181 in CHO 
cells, the effectiveness of this siRNA pool (in comparison to the earlier 
knockdown experiments in Figure 5.3) could be as a result of changing the 
transfection reagent to a transfection reagent specific to CHO cells. 
Nevertheless, densitometry analysis illustrates that the 25nM siRNA 
conditions are less effective at silencing RNF181 in comparison to the 10nM 
conditions. Similar to the 10nM siRNA conditions, the effectiveness of the 
25nM siRNA treatments reduced as incubation times increased to 120 hours.  
.  
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Figure 5.4: Small interfering RNA molecules that target the RNF181 gene 
reduce RNF181 protein expression in CHO cells 
To alter the gene expression of RNF181 in CHO cells, 3 siRNA molecules 
were designed to target RNF181 gene. The nucleotide sequences for each 
duplex are given in table 5.2. To examine the direct effect of each siRNA on 
RNF181 protein expression, CHO cells (3x103/ml) were seeded into 6 well 
plates for 24 hours. Thereafter, the cells were treated with a 1ml of Opti-mem 
containing a mixture of transfection reagent / siRNA molecules (at 10nM or 
25nM final concentration) or the controlled conditions (no treatment and 
control siRNA) as indicated for 7 hours. Subsequently, the cells were washed 
and the transfection / siRNA mixture was replaced with fresh DMEM for an 
additional 72 or 120 hours. Following each specific transfection time the cells 
were lysed, mixed with 2X sample buffer, heated at 95°C for 3 minutes and 
loaded into 10% polyacrylamide gels at equal volumes. Detection of α-actinin 
(100kDa) (loading control) and RNF181 (40kDa) from the lysate samples was 
carried out by western blots as previously described. Specifically, panels A 
and B represent CHO cell lysates previously treated with 10nM and 25nM of 
siRNA (or controlled conditions) respectively, for 72 hours while panels C and 
D represent the samples treated for 120 hours. Upper blot in each panel 
illustrates α-actinin detection while the lower panels illustrate RNF181 
detection from each sample. Samples 1 – 5 in each panel describe CHO cell 
treatment during the protein silencing procedure which are specifically; lane 1 
– no treatment; lane 2 – treated with SCBT-siRNA-pool, as a control 
(described in Table 5.1); lane 3 - 5 – treated with the siRNA 1 – 3 
respectively, (described in table 5.2). Results are representative of two 
separate experiments.  
 
 
1 = no treatment
2 = Control siRNA
3 = siRNA1
4 = siRNA2
5 = siRNA3
1 2 3 4 5 1 2 3 4 5
A B
C D
A= siRNA concentration of 10nMolar for 72 hours
B= siRNA concentration of 25nMolar for 72 hours
C= siRNA concentration of 10nMolar for 120 hours
D= siRNA concentration of 25nMolar for 120 hours
1 2 3 4 5 1 2 4 53
α-actinin
100kDa
RNF181
40 kDa
α-actinin
100kDa
RNF181
40 kDa
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Figure 5.5: Densitometry analysis of RNF181 protein expression in CHO 
cells treated with siRNA molecules targeting the RNF181 gene 
Western blot analysis of CHO cells lysates cultured under gene silencing 
conditions displayed a reduction in RNF181 protein expression (presented in 
Figure 5.4). To examine these results in more detail densitometry analysis 
was carried out on the respective protein bands from each western blot to 
quantitatively determine the reduction in RNF181 protein following treatment 
conditions; i) No treatment; ii) treatment with SCBT-siRNA-pool; iii - v) 
treatment with the Sigma Aldrich siRNA molecules 1, 2 and 3 that targeted 
the RNF181 gene. Using Image J, protein bands for α-actinin (used as a 
loading control) and RNF181 were quantified. The reduction in RNF181 was 
calculated by using α-actinin as a reference for the normal protein quantity 
and dividing the density of RNF181 by the density of α-actinin. Graph A 
illustrates RNF181 expression in CHO cells treated with 10nM and 25nM 
siRNA for 72 hours. Graph B illustrates RNF181 expression in CHO cells 
treated with 10nM and 25nM siRNA for 120 hours. Densitometry analysis 
was carried out using data from two separate knockdown experiments. Error 
bars indicate mean ± range.  
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5.7: RNF181 silencing reduces CHO-FF cell spreading on immobilized 
fibrinogen 
Given that the Sigma Aldrich siRNA molecules; siRNA-2 and -3 (described in 
table 5.2) were most effective at causing gene silencing of RNF181 at 10nM, 
72 hours post transfection (Figures 5.4 and 5.5); but because time was of the 
essence and there were a large number of experimental conditions to be 
explored, only one construct (siRNA-2) was chosen for further analysis in 
order to explore if RNF181 protein played a functional role in integrin αIIbβ3 
regulation. The specific purpose of this investigation was to examine the direct 
effect of RNF181 silencing in CHO-FF cells spreading on immobilized 
fibrinogen. Since RNF181 directly interacts with integrin αIIbβ3, it was therefore 
proposed that RNF181 directly regulates its activation state. To test this 
hypothesis, CHO-FF cells were cultured for 72 hours under normal conditions, 
or treated with 10nM of the Sigma Aldrich siRNA 2 (described in Table 5.2) or 
treated with the SCBT-siRNA-pool (from Table 5.1). These conditions were 
selected as they were previously demonstrated as the most optimal to 
selectively modulate RNF181 expression in CHO cells (described in Figure 
5.4 and 5.5). Following siRNA treatment, the cells were harvested and 
assessed for their capacity to spread on immobilized fibrinogen.  To carry this 
out, the CHO cells were harvested with cell dissociation solution following 
treatment, diluted to a concentration of 5 x 106/ml and added to either BSA or 
fibrinogen coated surfaces for 45 minutes. Subsequently the cells were 
prepared and processed for confocal imaging by fluorescent labeling with 
alexa-flour546 conjugated phalloidin, as previously described in Chapter 3; 
Figure 3.7. Representative images acquired from CHO cell adhesion to either 
BSA (3% w/v) or immobilized fibrinogen (25µg/ml) following siRNA treatment 
are illustrated in Figure 5.6. A total of 30 images were acquired from each 
treatment sample. Using ImageJ, the average CHO cell surface coverage (a 
measure of cell spreading) was then estimated. This quantitative analysis of 
cell spreading is illustrated in Figure 5, panel C. Differences between each 
sample set were determined using the statistical significance; two-tailed 
student’s t-test.  
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Ultimately the results demonstrated that the CHO-FF cells treated with the 
RNF181 gene targeting siRNA showed a reduced capacity to undergo cell 
spreading. This conclusion is derived from a number of observations. Firstly, 
normal treated CHO-FF cells which were adhered to fibrinogen showed 
significantly greater dimensions in surface coverage in comparison to normal 
treated CHO-FF cells that adhered to BSA. This event (previously 
demonstrated in Chapter 3) indicated that the CHO-FF cells underwent 
integrin-dependent changes in morphology following adhesion to fibrinogen. 
Secondly, the CHO-FF cells treated with the Sigma Aldrich siRNA-2 showed a 
significant reduction in cell spreading, when adhered to fibrinogen, in 
comparison to the normal treated cells or the cells treated with the control 
SCBT-siRNA-pool that were adhered to fibrinogen. Moreover, no significant 
difference was observed between the siRNA-2 treated CHO-FF cells that 
were adhered to BSA and fibrinogen. Thus, treatment with Sigma siRNA-2 
reduces spreading capacity of the CHO-FF cells to levels comparable to 
normal treated cells adhered to BSA. Finally, although the CHO-FF cells 
treated with the control SCBT-siRNA-pool showed significant differences in 
cell morphology in comparison to normal treated CHO-FF cells; when both 
samples were adhered to fibrinogen the P-value indicating the statistical 
significance between the samples was not as small (0.05 > P-value * > 0.01) 
in comparison to the statistical significance measured between normal treated 
CHO-FF cells and the targeting siRNA treated CHO cells which were both 
adhered to fibrinogen ( P-value *** < 0.005). In summary, these results 
demonstrated that the siRNA-2 molecule which selectively targeted the 
RNF181 gene correspondingly diminished the ability of CHO-FF cells to 
spread on immobilized fibrinogen. However, it must be noted that this 
experiment is an n = 1, and because of this the evidence does not provide a 
strong argument that what was observed is directly due to the effect of the 
RNF181 targeting siRNA. Essentially, more experiments are required to verify 
the findings from this analysis. Therefore the raw data is given in an appendix 
section at the end of this thesis in order to provide additional data to the next 
researcher wishing to follow on with this project.  
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Figure 5.6: CHO-FF cells adhered to immobilized fibrinogen display a 
reduction in spreading following treatment with siRNA molecules 
targeting the RNF181 gene 
The effect of RNF181 on integrin αIIbβ3 function was examined by targeting the 
RNF181 gene in CHO-FF spreading on immobilized fibrinogen. To examine this 
silencing effect in detail, CHO cells were initially cultured under conditions 
which included the following:   no treatment, transfection with the SCBT-siRNA-
pool control, described in Table 5.1 (used as a control) or transfection with 
Sigma Aldrich siRNA-2 (in Table 5.2). The specific transfections were carried 
out for 72 hours using 10nM siRNA (optimal conditions previously determined 
in Figures 5.4 and 5.5, to specifically reduce RNF181 protein expression). 
Following transfection the CHO cells were harvested with cell dissociation  
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Figure 5.6: CHO-FF cells adhered to immobilized fibrinogen display a 
reduction in spreading following treatment with siRNA molecules 
targeting the RNF181 gene 
solution, diluted to a cell concentration of 5x106/ml and adhered to either BSA 
(3% w/v) or fibrinogen (25µg/ml) coated microscope slides for 45 minutes. 
Subsequently the cells were fixed and cellular actin was fluorescently labelled 
using alexa-fluor546 conjugated phalloidin. Thereafter, image acquisition was 
carried out by confocal microscopy. Panels A1 – A3 represent CHO cells 
adhered to BSA under normal conditions, transfected with the control siRNA or 
siRNA 2 respectively. Panels B1 – B3 represent CHO cells adhered to 
fibrinogen under normal conditions, transfected with the control siRNA or siRNA 
2 respectively. Using a collection of 30 images from each sample condition, cell 
surface coverage (µM2) was measured with ImageJ. An average surface area 
was determined for all cells acquired from each condition (graph C) with 
standard deviations indicated with error bars. Two-tailed Student’s t-test 
estimated the statistical significance scores between the indicated samples 
according to the following; P-value < 0.05 *; < 0.01 **; < 0.005 ***. This 
investigation was carried out once.   
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5.8: Discussion 
The aim of this chapter was to determine if RNF181 binding to integrin αIIbβ3 
is functionally important. Given that the previous chapters in this thesis 
examined the physical nature of the interaction between the proteins, the 
experiments carried out for this chapter sought to gain a deeper 
understanding of the biological importance of the interaction firstly through 
peptide mediated modulation of integrin function in platelets and secondly 
through genetic interference of RNF181 expression in CHO-FF cells.  
It has been recognized for some time now that integrins are extremely 
important adhesion molecules critical to many cellular functions. For 
example, the integrin αIIbβ3 is essential for the role that platelets play in 
haemostasis by acting as a mediator of platelet aggregation and adhesion. 
However, integrin αIIbβ3 does not only mediate platelet - platelet interactions 
and adhesion. It is a bidirectional signalling molecule, important for 
intracellular events in both platelet and integrin function. Moreover, because 
of its transmembrane structure the integrin facilitates a network link between 
the intracellular environment and extracellular matrix components. 
Transmembrane proteins with responsibilities such as those possessed by 
integrins would be expected to contain characteristics of intrinsic enzyme 
activity in order to propagate extracellular events or ligand occupancy. 
However, the short cytoplasmic tails of integrin αIIbβ3 possesses no such trait 
and therefore must recruit catalytic proteins to its membrane and 
cytoplasmic domains to illicit integrin mediated responses. One critical 
characteristic of integrin membrane proteins is the strict regulation of their 
conformation whereby selective binding of the different integrin binding 
proteins may permit or limit integrin activation to specific conformational 
states. Furthermore, a recent report demonstrated that the integrin αIIbβ3 is 
more complex than a single on-off switch as observed in classical membrane 
receptors (Zhu, Zhu, and Springer 2013). In resting platelets, the abundant 
integrin spans the membrane in an inactive state. Following platelet 
activation, inside-out signal transduction forces alterations in the structure of 
integrin αIIbβ3 that shift the protein into an active ligand binding state. 
Subsequent ligand binding to the integrin stimulates outside-in signalling 
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pathways that promote the integrin αIIbβ3 molecules to cluster and undertake 
a stably active ligand bound structure to support haemostasis.  
Within these dynamic inside-out and outside-in signalling mechanisms that 
regulate integrin activation, there are a group of proteins known as integrin 
binding proteins. These integrin binding proteins possess a capacity to 
physically interact with membrane and cytoplasmic domains of both the 
integrin α and β subunits and directly regulate integrin activation. Some 
integrin binding proteins have been proposed to maintain integrin in an 
inactive state, such as PP2A (Gushiken et al. 2008) while others have been 
recognized to promote integrin activation, such as CIB1 (Tsuboi 2002) and 
talin (Goult et al. 2010). Literature demonstrates that the most investigated 
integrin α binding protein is CIB1 while the most celebrated β binding protein 
is Talin; with both having a critical role in regulating integrin activation. The 
purpose of this final chapter was to determine if RNF181 had a direct effect 
on the activation state of integrin αIIbβ3 (in a manner similar to CIB 1, talin or 
even PP2A).  
As previously demonstrated; RNF181 directly binds to the conserved motif 
(989KVGFFKR995) of the cytoplasmic tail of integrin αIIb. This amino acid 
region has been demonstrated as the integrin αIIb regulatory domain, critical 
for maintaining the integrin in an inactive conformation by forming a tight 
clasp with the β3 cytoplasmic tail. Disrupting this clasp between αIIb and β3 
cytoplasmic tails causes the integrin to undergo transition to its ligand 
binding state. Since the conserved motif of αIIb has been regarded as a 
critical structure in integrin regulation and since RNF181 has a specific 
affinity for this site (through its own direct linear binding motif; 
129HRRDKARKQQQQ140), RNF181 was therefore postulated to regulate the 
activation state of the integrin αIIbβ3.  
To examine this hypothesis, platelet function studies were carried out in the 
presence of peptides derived from RNF181’s integrin binding motif to 
determine if RNF181 peptides affected platelet or integrin activation. Results 
in section 5.2 clearly demonstrated that the RNF181 peptides which have an 
affinity for the integrin αIIb cytoplasmic tail were able to modulate platelet 
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function. The two overlapping palmitoylated peptides (Pal-HQ and Pal-DQ) 
which were native to RNF181’s direct integrin binding region 
(129HRRDKARKQQQQ140) had a potent inhibitory effect in both platelet 
spreading on immobilized fibrinogen and thrombin induced platelet 
aggregation. Although the exact mechanism of action of the peptides was 
not investigated, based on previous data from peptide interaction studies 
described in chapter 4, it is strongly suggested that the peptides inhibit 
integrin activation by directly competing with endogenous RNF181 for its 
capacity to bind to the cytoplasmic tail of integrin αIIb. Such an interaction 
would obstruct the regulatory actions of RNF181. If these RNF181-derived 
peptides inhibit platelet responses by specifically blocking RNF181 from 
carrying out its role in integrin regulation, this evidence would indicate that 
RNF181 regulates integrin αIIbβ3 activation in a positive manner. However, it 
is unknown whether the RNF181 derived peptides specifically block the 
binding of only RNF181 to the integrin tail, thus suggesting that the peptides 
may interfere with other integrin binding proteins. Therefore, an alternative 
approach was taken to examine the direct relationship between RNF181 and 
integrin αIIbβ3 which involved the down regulation of RNF181 expression in 
CHO-FF cells followed by assessment of integrin-dependent functionality in 
these cells.  
Overall, these investigations were able to confirm that RNF181 directly 
regulates integrin activation in a positive manner. The initial experiments 
determined that the siRNA molecules which specifically targeted the 
RNF181 gene in CHO-FF cells caused a marked, transient reduction in the 
RNF181 protein expression system. This interference with RNF181 
expression corresponded with a reduced capacity for the CHO-FF cells to 
undergo cell spreading on immobilized fibrinogen. The molecular 
mechanisms behind CHO-FF cell spreading are a direct response to the 
interaction between integrin αIIbβ3 and its immobilized ligand; fibrinogen. 
Therefore, the lack of ability for the CHO-FF cells to undergo integrin 
mediated cell spreading following treatment with the siRNA molecule 
targeting the RNF181 gene finally conclude that RNF181 is an important and 
positive regulator of integrin induced cell spreading.  
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A final conclusion can be made by examining the data from the studies in 
section 5.2 which examined the effect of the RNF181 derived peptides on 
platelet function. The combination of evidence from these experiments 
signifies the influence that RNF181 has on integrin αIIbβ3 signalling. The 
effect of the modified RNF181 peptide, generated with a triple alanine 
substitution at the C-terminus (Pal-HRRDKAAAA v’s Pal-HRRDKARKQ) 
demonstrated that this modification caused a differential potency towards 
inhibiting platelet function assessed by the two tests. While this peptide was 
able to inhibit platelet adhesion and spreading on fibrinogen, it was unable to 
inhibit platelet aggregation. Thus it had a selective effect on outside-in 
signalling versus inside-out integrin activation. Earlier experiments (Section 
4.9; Figure 4.12) indicated that the alanine modification effectively reduced 
(but did not abolish) the interaction between the RNF181 derived peptide 
and the integrin αIIbβ3 protein, further supporting a variable effect of this 
peptide segment. With regard to this, the peptide did retain enough 
interaction capabilities to remain as an active modulator of outside-in integrin 
signalling by inhibiting platelet spreading. However, this modification did 
eliminate the peptide’s potency to inhibit thrombin induced platelet 
aggregation. Thus, this evidence points towards a differential role that 
RNF181 may carry out in relation to integrin regulation.  
 
As explained earlier, the differences in how platelets respond to the function 
tests; spreading and aggregation, are that the former (spreading) is initiated 
through outside-in signalling while the latter (aggregation) is initiated through 
inside-out signalling. Given that the modified peptide affects outside-in 
signalling (mediated by platelet adhesion to fibrinogen) suggests that the 
platelet response mediated through outside-in signaling is extremely 
dependent on, and sensitive to RNF181 function because the platelet 
response that is largely dependent on this outside-in signalling can be 
abolished by a weak integrin-binding derivative of the RNF181 structure. In 
contrast, inside-out signalling initiated by thrombin during platelet 
aggregation is also effected by RNF181 peptides in their native form (Pal-HQ 
and Pal-DQ), but not in the modified version (Pal-HA). Thus, this evidence 
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indicates that activation of integrin αIIbβ3 by inside-out signal transduction is 
more dependent on a various other integrin binding proteins because it is not 
susceptible to manipulation by the RNF181 modified peptide; Pal-HA. 
Moreover, this conclusion corroborates with the results observed earlier in 
Chapters 3, 4 and 5 above. Firstly, CO-IP analysis (Chapter 4) was unable to 
capture an RNF181 – integrin interaction following platelet aggregation, thus 
suggesting transient binding (or less integrin dependency on RNF181 during 
aggregation or inside-out signalling). Secondly, the confocal analysis in 
Chapter 3 illustrated a large degree of co-localization between RNF181 and 
αIIbβ3 following cell adhesion and fibrinogen mediated cell spreading initiated 
by outside-in signalling. Finally, siRNA knockdown of RNF181 in CHO-FF 
cells demonstrated the dependency that integrin αIIbβ3 has for RNF181 
during cell spreading regulated by fibrinogen mediated outside-in signalling. 
Collectively these results permit the conclusion that RNF181 has a specific 
and important role in regulating integrin αIIbβ3 outside-in signalling. 
Interestingly, from a therapeutic point of view, molecules that inhibit one 
specific signalling pathway within a complex signalling system such as the 
integrin signalling pathways could provide an interesting avenue in anti-
integrin or anti-platelet drug development.         
In summary, fibrinogen mediated integrin αIIbβ3 activation is dependent on 
RNF181. The amino acid sequence within RNF181 
(129HRRDKARKQQQQ140) that is responsible for mediating the protein’s 
binding to the integrin demonstrated an ability to modulate platelet / integrin 
activation. Moreover, the differential potency of the modified RNF181 peptide 
(Pal-HRRDKAAAA) may develop into more interesting opportunities for 
targeting platelet / integrin related disease.     
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General Discussion 
The concept of protein – protein interactions (PPI) is becoming increasingly 
important in our effort to understand biological processes, disease prognosis 
and drug development. Advances within the field of proteomics have evolved 
to allow the generation of vasts amount of data comprised of potential 
protein interaction networks. Eventhough statistical and computational 
methods that facilitate data analysis are expanding; we remain limited in 
processing and understanding these large quantities of data. The nature of 
PPI’s can be explored from many different angles; from the molecular level 
to the cellular level and right up to the whole organism. While many 
investigating avenues lead to analytical findings that consequently determine 
further studies, others result in dead ends. By and large, identifying and 
understanding true PPI’s is a complex process and even though 
methodologies have been developed that can explore or verify PPIs, the 
scientific consensus is that such interactions need to be confirmed by 
multiple experimental techniques.  
 
The foundation of this thesis originated from attempts to unravel the 
molecular structures surrounding the regulation of the platelet integrin αIIbβ3 
(Larkin et al. 2004) whereby a Hypothetical protein MGC bound to the 
integrin αIIb motif - 
989KVGFFKR995. Due to its zinc type ring finger domain, 
the protein was renamed RNF181 (Brophy et al. 2008). In addition it was 
verified that  RNF181  protein directly bound to the integrin αIIb motif (Brophy 
et al. 2008) and that it had more preference of being a potential regulator of 
integrin function in comparison to other identified integrin binding proteins 
(Raab, Daxecker, et al. 2010). Due to the preliminary nature of the 
experimental techniques (array technology, protein interaction database 
predictions and affinity purification in conjunction with mass spectrometry) 
used throughout the studies (Larkin et al. 2004) (Brophy et al. 2008) (Raab, 
Daxecker, et al. 2010), the interaction between RNF181 and integrin αIIbβ3 
required further examination by a variety of in vivo and in vitro 
methodologies. The opening hypothesis in chapter 1 proposed that the 
protein RNF181 directly interacts with the platelet integrin αIIbβ3 in order to 
 178 
regulate its activation state. The work presented in this thesis has 
demonstrated my scientific research which sought to gain a deeper 
understanding of the physical and functional relationship that exists between 
RNF181 and the platelet integrin αIIbβ3. Initially, I examined how the 
activation state of the integrin might favour the interaction. Subsequently, 
specific structural motifs that were critical in mediating the interaction were 
explored. Finally, the consequences of RNF181 binding to the platelet 
integrin αIIbβ3 was investigated.      
 
The initial investigations (Chapter 3) explored the relationship between 
RNF181 and integrin αIIbβ3 by examining co-localization in platelets adhered 
to immobilized fibrinogen. These in depth studies aimed to determine if the 
platelet integrin co-localized with RNF181 in an integrin activation dependant 
manner. Conclusive results determined that co-localization between RNF181 
and integrin αIIbβ3 was directly related to the spreading profile of platelets; 
whereby co-localization was significantly prominent during early times of 
platelet spreading but which reduced considerably following longer adhesion 
and spreading times (Figure 3.8 and Figure 3.12) thus demonstrating that 
there was a time-dependent interaction of integrin with RNF181 during 
platelet spreading. Even though platelets are the most ideal cellular system 
for examining platelet protein interactions, washed platelet preparations can 
pose limitations when defining and examining specific activation states of the 
platelet integrin αIIbβ3. This is in consideration of the numerous conformation 
states that the integrin αIIbβ3 can undertake (Zhu, Zhu, and Springer 2013). 
Because of this structural inconsistency, confocal microscopy becomes 
limited in defining an exact conformational state of integrin αIIbβ3 during 
platelet spreading. Therefore, CHO cells stably transfected with a native 
(CHO-FF) or constitutively active integrin gene (CHO-AA) (Aylward et al. 
2006) were examined for protein co-localization. In accordance with the 
platelet adhesion studies, the RNF181 protein had a strong co-localization 
profile in CHO-FF cells during early adhesion times to fibrinogen but which 
reduced following longer adhesion times (Figure 3.13). Interestingly, CHO-
FF cells adhered to BSA (and that represent a resting integrin conformation 
(Aylward et al. 2006) displayed weak co-localization while in contrast, the 
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CHO-AA cells displayed prominent co-localization under the same adhesive 
conditions, but which reduced when spreading on fibrinogen. Thus, this 
cumulative evidence indicates that RNF181 co-localizes with the integrin, not 
in a resting and not in an prolonged active state; but in a transitional stage of 
activation. Moreover, the contrasting capacity for the two integrin binding 
proteins; HIC-5 and RNF181 to co-localize either with integrin or together 
confirm that there was an integrin activation state favoured by RNF181 
relative to cell spreading. Overall these confocal studies demonstrated that 
the RNF181 co-localized with the integrin during a specific and early stage of 
activation mediated by fibrinogen.  
 
But due to the inability for the confocal microscopy studies pinpoint a defined 
integrin conformation during which it co-localized with RNF181, subsequent 
studies (Chapter 4) were carried out by performing co-immunoprecipitation 
(CO-IP) experiments of integrin αIIbβ3 from cell lysates generated from 
washed platelets and CHO-FF / CHO-AA cells. The CO-IP’s were carried out 
under various conditions in order to capture any critical stages of platelet 
activation that orientated the interaction between RNF181 and integrin αIIbβ3. 
However, it was extremely difficult to determine any specific state of platelet / 
integrin activation that was favoured by RNF181 for molecular binding, 
because the interactions appeared to be highly transient in nature. This type 
of transient binding relationship is appropriate, given the dynamic stages that 
integrin undergoes during its transition from an inactive to active state (Zhu, 
Zhu, and Springer 2013). Yet, the inability for the CO-IP experiments to 
reliably demonstrate an activation dependent interaction between RNF181 
and the platelet integrin in a reproducible manner, did cast some doubts over 
the basis of the study. Thus it became critical to confirm a direct interaction 
between the two proteins. The more traditional methods of confocal 
microscopy and CO-IP’s provide only a single snap-shot representation of a 
specific condition, whereas in reality, integrins are  dynamic transmembrane 
proteins (Zhu, Zhu, and Springer 2013) that react and respond 
simultaneously to both their extracellular and intracellular environments 
(Chen et al. 2012) (Pouwels et al. 2012). In hindsight, the molecular biology 
approach of CO-IP’s appeared to be unable to deal with the complexity of 
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integrin activation for measuring integrin binding proteins. Therefore, due to 
these limitations, but also to confirm that the original results which identified 
RNF181 as a potential regulator of integrin activation (Larkin et al. 2004) 
(Brophy et al. 2008) (Raab, Daxecker, et al. 2010) were accurate, purified 
integrin αIIbβ3 and recombinant RNF181 were assessed for their binding 
potential using microscale thermophoresis (MST) and isothermal titration 
calorimetry (ITC). The molecular binding analyses by both MST and ITC 
(Sections 4.5 and 4.6) measured biologically relevant binding affinities within 
the same order of magnitude (Kd - 2.5µM – 10µM), and thus provided 
confident assurance to carry out further investigations into the physical 
relationship between RNF181 and the platelet integrin. Moreover, this 
moderate binding affinity has also been observed between the integrin αIIb 
cytoplasmic tail and its binding protein; CIB1 (Freeman et al. 2013), thus 
supporting the evidence observed in this thesis. Moreover, an interaction 
with the molecular strengths demonstrated in the binding studies by MST 
and ITC, are often observed in transient interactions (Nooren and Thornton 
2003) (Perkins et al. 2010) and therefore substantiates the conclusion that 
the interaction between RNF181 and integrin is of a transient nature. After 
clarifying that a secure protein: protein interaction occurs between the 
proteins of interest, the following studies were designed to determine the 
critical points of contact between RNF181 and the integrin αIIb cytoplasmic 
tail domain. To examine these binding parameters and establish the protein: 
protein interaction interface between RNF181 and the integrin αIIb 
cytoplasmic tail, a computer generated binding prediction approach was 
taken (Section 4.6). Truncated, overlapping peptides derived from the entire 
protein sequence of RNF181 were individually docked onto a number of 
experimentally generated virtual models of the integrin αIIb cytoplasmic tail. In 
a parallel study, membrane array experiments carrying RNF181 derived 
peptides identical to those described in Section 4.6 were incubated with a 
peptide derived from the integrin αIIb cytoplasmic motif and examined for 
binding. The analyses carried out by the computational binding predictions 
and wet lab conditions (Sections 4.6 and 4.7) complemented each other 
significantly and identified a unique SLiM region within RNF181 
(128EHRRDKARKQQQQHRL143) that had a specific affinity for the integrin αIIb 
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cytoplasmic motif. In addition, peptide - pull down experiments (Section 4.8) 
were in agreement with the above observations and demonstrated strong 
supporting evidence that the platelet integrin specifically interacts with 
RNF181 through this specific peptide motif. Moreover, because short linear 
motifs generally mediate transient protein interactions (Perkins et al. 2010) 
the observations confirmed that the interaction between RNF181 and the 
platelet integrin was of a transient nature.  
 
The final supporting evidence that confirmed a critical SLiM region within 
RNF181 mediated integrin binding was demonstrated by the ITC analyses in 
Section 4.9. Briefly, these experiments measured (i) RNF181 derived peptide 
(129HRRDKARKQ137 and 132DKARKQQQQ140) binding to the integrin αIIb 
motif and (ii) an integrin αIIb derived peptide interaction with recombinant, full 
length RNF181. Thermodynamic profiles of each interaction demonstrated 
binding affinities within the same order of magnitude previously observed 
between full length protein interactions (Section 4.5); with Kd values ranging 
between 10µM and 78µM. At this point, it would have been interesting to 
carry out competitive binding assays to measure if a RNF181 derived 
integrin binding peptide could inhibit or interfere with the protein: protein 
interaction between recombinant, full length RNF181 and purified integrin 
αIIbβ3. But with limited resources, I was unable to investigate this.  
 
Targeting the interface of protein: protein interactions for therapeutic 
intervention has attained much interest in recent years (Cardinale et al. 
2011) (Wells and McClendon 2007) (Whitty and Kumaravel 2006) (Guo, 
Wisniewski, and Ji 2014) with many small molecule PPI inhibitors advancing 
into clinical trials (Arkin, Tang, and Wells 2014); for example in treating 
cancer (Zhao et al. 2015). Targeting PPI has partially risen from the fact that 
30% of patented drugs target G-protein coupled receptors (GPCR), even 
though the GPCR gene superfamily comprise of just over 3.5% of the human 
genome (Strosberg and Nahmias 2007). In contrast to receptor antagonists 
that simply block single, specific cellular responses by inhibiting receptor 
occupation from their natural agonists; such as the use of β-blockers in 
antagonizing the G protein coupled β-adrenoceptors (Gille et al. 1985) or the 
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P2Y12 antagonists in anti-platelet therapy (Mills et al. 1992), the path of 
identifying and inhibiting protein: protein interactions, by small molecules, in 
the treatment of diseases can be extremely complex due to the multifaceted 
system of intracellular protein interactions. Therefore, a detailed 
understanding of the molecular mechanisms leading to and following protein 
interaction targets would be demanded to develop novel PPI inhibitor 
therapeutics. Moreover, with a decline in novel drug targets (Scannell et al. 
2012) for the increasingly demanding clinical conditions; for example, 
Visceral leishmaniasis, (den Boer et al. 2009), a parasitic disease that kills 
up to 400,000 people a year (Desjeux 2001); Lupus, an incurable 
autoimmune disease (Rosario et al. 2013) associated with up regulation 
(Takeuchi et al. 1993) and genetic variation of integrin receptors (Fagerholm 
et al. 2013); or even the recent Ebola outbreak (Yazdanpanah, Arribas, and 
Malvy 2015) an incurable disease that involves viral infection through integrin 
binding (Schornberg et al. 2009); PPI inhibitors may become an even more 
attractable approach for therapeutic intervention.  
 
While the platelet integrin was an ideal target for treating cardiovascular 
disease patients, the integrin antagonists were clinically limited in terms of 
efficacy and safety  (Serebruany et al. 2004). Since these antagonists were 
directed to the extracellular domain of integrin αIIbβ3, targeting the 
intracellular cytoplasmic tail domain gained interest for (i) understanding the 
molecular mechanisms of integrin signalling in response to receptor 
antagonism and for (ii) developing therapies for thrombotic intervention 
(Shen et al. 2013). With the perception that small molecule or peptide 
mimetic inhibitors of PPI’s could contrive the way for future pharmacological 
intervention in the treatment of integrin related disorders; Chapter 5 (Part 1) 
demonstrated the capacity for the integrin binding - RNF181 derived 
peptides to modulate platelet / integrin function. The native RNF181 derived 
peptides which were delivered to platelets and that targeted the integrin αIIb 
regulatory motif significantly inhibit platelet responses to the thrombotic 
simulations; platelet aggregation (by thrombin) and platelet adhesion (to 
fibrinogen). These inhibition studies highlighted the specific capacity for 
RNF181 to modulate integrin function. Interestingly, the modified peptide 
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(Pal-HA) abolished outside-in signalling (as measured by the inhibition of 
platelet spreading on immobilized fibrinogen) without affecting inside-out 
mediated platelet aggregation (as indicated by thrombin induced platelet 
aggregation). However, without determining the effects of the peptide 
inhibitors on these downstream signalling events following integrin αIIbβ3 
activation, the integrity of this conclusion is limited. Nevertheless, the 
capacity for the RNF181 derived peptides to inhibit platelet spreading and 
aggregation renders them as novel inhibitors of platelet function.  
 
Up to that point of the PhD program the actual role of RNF181 on integrin 
function was unknown. Therefore, genetic interference of RNF181 (by siRNA 
molecules) in CHO-FF cells was carried out. Following adhesion analysis, 
RNF181’s regulatory role over integrin activation was demonstrated (Chapter 
5, Part 2). As a consequence to the reduction of RNF181 expression, there 
was marked reduction in the capacity for the CHO-FF cells to undergo 
integrin mediated spreading on fibrinogen, thus conforming RNF181 as a 
critical component of integrin activation, with a specific role towards driving 
activation.  While the adhesion experiments with siRNA knockdown of 
RNF181 were limited in number, they were efficiently controlled and the 
knockdown resulted from a sequence of optimization experiments that 
identified crucial transfection times and conditions that enabled an effect to 
be observed. Thus, although only a single adhesion experiment was 
performed following RNF181 knockdown at the optimized experimental 
conditions, I am confident that this result is valid. Moreover, knockdown 
experiments supported the observations from the peptide inhibition studies 
on platelet function. Firstly, the RNF181 derived peptides acted with an 
inhibitory mechanism of action. Secondly, RNF181 regulates integrin 
activation in a positive manner. Therefore, blocking native RNF181 protein 
from binding to the integrin αIIb tails through RNF181 derived peptide 
mimetics would no doubt block RNF181 integrin binding and therefore inhibit 
integrin activation, as was observed. A more detailed account of this event 
would have been complemented by RNF181 derived peptide interference of 
RNF181 co-immunoprecipitation with integrin αIIbβ3. But given the difficulty of 
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the CO-IP’s to capture the protein interaction, this aspect of investigation 
was unattainable.  
 
Finally, and as mentioned in the discussion section of Chapter 5; by 
accumulating a number of experimental observations it can be concluded 
that RNF181 has a specific and important role in regulating integrin αIIbβ3 
outside-in signalling in contrast to inside-out signalling. This is derived from a 
number of factors including; i) the confocal imaging studies demonstrated 
strong co-localization between RNF181 and the platelet integrin following 
adhesion to immobilized fibrinogen (an outside-in signalling driven 
response); ii) the siRNA studies that showed the significant dependency that 
integrin αIIbβ3 has for RNF181 during fibrinogen mediated cell spreading 
(again an outside-in signalling driven response); iii) the inability to repeatedly 
capture a protein interaction by CO-IP following platelet aggregation (an 
inside-out signalling driven response) and finally iv) the capacity for a weak 
integrin binding peptide (Pal-HA) to inhibit cell spreading on fibrinogen (an 
outside-in signalling driven response) but not aggregation (an inside-out 
signalling driven response).    
 
 
Throughout the PhD, there was a great deal of experimental complications 
that limited my time to expand the research further. As a consequence, many 
questions remain unanswered; including the significance of RNF181 acting 
as an E3 ligase and the implications this function could have on integrin 
signalling. Moreover, direct targets of RNF181 ubiquitination were not 
uncovered. However, during the course of the project another research 
group did observe proteins that were affected by RNF181 expression levels 
in hepatocellular carcinoma (Wang, Huang, et al. 2011) (many of which were 
in the platelet proteome and two which were classed as integrin binding 
proteins). Measuring the expression levels of these proteins in CHO cells 
treated with siRNA molecules targeting the RNF181 gene would also have 
been a significant step towards understanding the molecular mechanisms of 
RNF181 function, but again resources limited my ability to carry this out. 
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Nonetheless, this thesis has contributed towards understanding the complex 
mechanisms of integrin regulation.  
 
In summary, a role for RNF181 in the regulation of integrin αIIbβ3 function 
was demonstrated. Using a variety of experimental approaches I have 
revealed strong evidence for a functional co-association of integrin αIIbβ3 and 
RNF181. In addition, I have explored the precise molecular mechanism 
underlying the capacity of RNF181 to interact with the integrin αIIb 
cytoplasmic tail and identified the short linear sequences on both proteins 
that mediate their capacity to interact. This interaction has a moderate affinity 
and is transient. Yet it appears to have the capacity to profoundly affect 
integrin function. Moreover, given that the RNF181 derived peptides can 
potently and specifically modulate integrin function in platelets, then perhaps 
their effect can be translated into other integrin dependent systems.  
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This appendix section provides the raw data obtained from the final analysis in 
chapter 5, figure 5.6. As previously described in section 5.x, the experimental 
analysis for figure 5.6 was carried out to determine if the knockdown of RNF181 
from CHO-FF cells interfered with CHO-FF cells spreading, a process that is 
mediated through the integrin αIIbβ3 – fibrinogen interaction.  To investigate this, 
CHO-FF cells were cultured under 3 conditions which were 1 - normal culturing 
conditions; 2- cultured following transfection with a control siRNA; 3 – cultured 
following transfection with an effective RNF181 targeting siRNA. Following 
siRNA transfection, the cells were harvested from culture and adhered to either 
a non-thrombotic surface (BSA) or thrombotic surface (Fibrinogen). Cells were 
adhered to the surfaces for 45 minutes and then processed for confocal 
microscopy analysis through fluorescent immunostaining of actin. Microscopy 
was carried out to determine if the RNF181 targeting siRNA had an effect on 
cell spreading. This analysis involved acquiring multiple images of the CHO 
cells from each treatment. After image acquisition, ImageJ was used to assess 
the extent of cell spreading in each treatment in order to determine if CHO-FF 
cells underwent differential spreading following siRNA treatment in comparison 
to the normally cultured controls. Cell spreading / cell surface coverage was 
assessed for each individual cell from each condition with ImageJ. This was 
done by first maximizing the flourescent threshold of the cells and then 
quantifying the particles within each cell. This method provided an accurate 
area of the CHO cells per µm2. Thereafter the mean cell area for each treatment 
was calculated and plotted as a bar graph. This bar graph is displayed in figure 
5.6. In the appendix tables 1 – 6 below, the raw data following the measurement 
of the area of the CHO cells is provided. Table 1 and table 4 represent the 
surface area data of CHO-FF cells cultured under normal conditions and 
adhered to BSA (table 1) and fibrinogen (table 4). Table 2 and table 5 
represents the surface area data of CHO-FF cells cultured with the transfected 
control siRNA and adhered to BSA (table 2) and fibrinogen (table 5). Table 3 
and table 6 represents the surface area data of CHO-FF cells cultured with the 
transfected the RNF181 targeting siRNA and adhered to BSA (table 3) and 
fibrinogen (table 6). Each data entry in each column represents a CHO-FF cell 
measured with ImageJ while the final two data entries in each table represent 
the mean data of the table and the standard deviation of the mean.   
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Appendix table 1: CHO-FF cell spreading measurement. Surface area data (µm2) of 
CHO cells cultured under normal conditions and adhered to the non-thrombotic substrate 
BSA.  
455.6550 370.1760 291.5910 241.2690 184.0540 132.3540 94.4400 
454.2760 368.7980 291.5910 238.5120 181.9860 132.3540 91.6820 
453.5870 368.1080 291.5910 237.1330 180.6070 130.9750  
452.8970 367.4190 290.9020 235.5890 179.9180 130.2860  
451.5190 365.3510 290.9020 234.3760 177.8500 129.5960 247.1445 
448.0720 364.6620 289.7470 232.3080 176.4710 127.5280 103.8356 
446.6930 357.7680 288.8340 231.6190 174.4030 127.5280 
446.0040 345.3600 288.1450 229.5510 173.0250 126.8390 
443.7290 344.6710 286.0770 226.7930 173.0250 125.4600 
443.2460 343.2920 285.3870 225.4150 172.7705 125.4600 
443.2460 341.9130 284.6980 224.7250 172.7705 124.9270 
441.8680 339.1560 284.6980 224.7250 172.3350 124.7710 
440.4890 338.4670 284.2045 223.3470 171.8135 124.1244 
436.3530 338.4670 284.2045 222.6570 171.8135 122.0130 
435.6640 337.0880 284.0090 222.6570 170.9570 120.6350 
435.6640 335.7090 284.0090 220.5890 168.8890 118.7210 
435.6640 335.0200 283.2940 216.4530 166.8210 117.8770 
432.9060 332.9520 280.5620 215.7640 166.1310 116.4990 
432.9060 332.2630 278.4940 215.0740 164.7530 116.4990 
428.7700 330.1950 277.1150 212.4930 164.0630 115.1200 
426.0130 329.5050 275.7370 209.5600 163.3740 114.4310 
423.9450 328.8160 275.0470 209.5600 160.6170 113.7410 
420.4980 328.1260 272.6100 207.4920 160.6170 113.7410 
418.4300 326.7480 268.8430 207.4920 160.6170 112.3630 
417.7410 319.8540 268.8430 206.8120 157.1700 112.3630 
414.2940 319.8540 268.8430 206.8120 157.1700 108.9160 
410.8470 319.8540 267.4640 206.1130 154.4120 108.9160 
402.5750 318.4760 266.7750 205.4240 153.7230 108.7170 
397.0610 315.7180 264.7070 204.7740 153.1170 107.6670 
397.0610 314.3400 263.3280 204.7340 149.5050 106.8480 
392.9250 313.6500 262.6390 203.8170 148.8980 106.8480 
391.5460 310.2040 259.8820 203.3560 148.2080 104.7800 
388.7890 309.5140 259.8820 201.9770 147.4670 104.0910 
381.8950 308.8250 258.5030 198.5300 146.1400 102.0230 
381.8950 305.3780 255.8440 198.5300 145.7469 102.0230 
380.5160 304.0000 255.7460 197.8410 143.9160 101.3330 
378.4480 302.6210 254.3670 196.4620 142.0040 99.9540 
377.0700 301.2420 252.9880 194.3940 140.5510 99.2650 
376.3800 299.8630 250.2310 191.7440 139.8710 99.2650 
375.0020 299.1740 248.1630 191.6370 139.2540 99.2650 
375.0020 296.4170 245.4060 190.9480 138.5580 99.2650 
373.6230 295.7270 245.4060 189.5690 137.8680 97.8860 
372.2440 295.7270 244.7160 188.8800 135.1110 97.8860 
372.2440 295.7270 243.3370 186.8120 135.1010 97.1970 
371.5550 294.3490 243.3370 186.8120 135.1010 95.1290 
371.5550 292.2810 243.3370 185.8780 134.4220 94.4400 
370.1760 292.2810 242.6480 185.1670 133.0430 94.4400 
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Appendix table 2: CHO-FF cell spreading measurement. Surface area data (µm2) of 
CHO-FF cells cultured with a transfected control siRNA and adhered to the non-thrombotic 
substrate BSA.  
684.516000 487.364000 388.099000 328.126000 274.358000 232.997000 193.705000 157.859000 122.013000 
682.448000 486.675000 386.031000 326.748000 273.669000 232.308000 193.016000 157.170000 121.324000 
681.069000 485.986000 384.652000 326.058000 272.979000 231.619000 192.326000 156.480000 120.635000 
676.933000 485.296000 383.274000 325.369000 272.290000 230.929000 191.637000 155.791000 119.945000 
653.496000 483.918000 382.584000 324.680000 271.600000 230.240000 190.948000 155.102000 119.256000 
650.049000 483.228000 381.895000 321.922000 270.911000 229.551000 190.258000 154.412000 118.567000 
645.223000 482.539000 380.516000 321.233000 270.222000 228.172000 189.569000 153.723000 117.877000 
643.845000 481.160000 379.827000 320.544000 269.532000 227.483000 188.880000 153.034000 117.188000 
639.709000 474.267000 377.070000 319.854000 267.464000 226.793000 188.190000 152.344000 116.499000 
636.951000 470.820000 375.691000 319.165000 266.775000 226.104000 187.501000 151.655000 115.809000 
635.573000 468.063000 372.934000 317.786000 266.086000 225.415000 186.812000 150.966000 115.120000 
632.815000 464.616000 372.244000 316.408000 265.396000 224.725000 186.122000 150.276000 114.431000 
624.543000 463.237000 371.555000 315.718000 264.707000 224.036000 185.433000 149.587000 113.741000 
619.029000 461.169000 368.108000 315.029000 264.018000 223.347000 184.743000 148.898000 113.052000 
613.514000 460.480000 367.419000 309.514000 262.639000 222.657000 184.054000 148.208000 112.363000 
612.135000 459.791000 366.730000 308.825000 261.950000 221.968000 183.365000 147.519000 111.673000 
608.688000 458.412000 366.040000 308.136000 261.260000 221.279000 182.675000 146.830000 110.984000 
596.280000 457.033000 365.351000 307.446000 260.571000 220.589000 181.986000 146.140000 110.295000 
594.212000 454.965000 364.662000 306.757000 259.882000 219.900000 181.297000 145.451000 109.605000 
593.523000 450.829000 363.972000 305.378000 259.192000 219.211000 180.607000 144.762000 108.916000 
585.940000 447.383000 361.904000 304.689000 258.503000 218.521000 179.918000 144.072000 108.227000 
583.872000 442.557000 361.215000 303.310000 257.814000 217.143000 179.229000 143.383000 107.537000 
583.183000 440.489000 359.836000 302.621000 257.124000 216.453000 178.539000 142.694000 106.848000 
580.425000 439.800000 359.147000 300.553000 256.435000 215.764000 177.850000 142.004000 106.159000 
576.289000 437.732000 358.457000 299.863000 255.746000 215.074000 177.161000 141.315000 105.469000 
572.843000 436.353000 357.768000 299.174000 255.056000 213.696000 176.471000 140.626000 104.780000 
570.775000 434.285000 354.321000 298.485000 254.367000 213.006000 175.782000 139.936000 103.401000 
570.085000 432.217000 352.253000 297.795000 253.678000 212.317000 175.093000 139.247000 102.712000 
563.192000 429.460000 351.564000 297.106000 252.988000 211.628000 174.403000 138.558000 102.023000 
548.716000 426.702000 350.185000 296.417000 252.299000 210.249000 173.714000 137.868000 101.333000 
543.890000 424.634000 349.496000 295.727000 250.920000 209.560000 173.025000 137.179000 100.644000 
543.201000 423.945000 348.807000 295.038000 250.231000 208.870000 172.335000 136.490000 99.954000 
536.308000 423.256000 348.117000 294.349000 249.542000 208.181000 171.646000 135.800000 99.265000 
532.172000 422.566000 347.428000 293.659000 248.852000 207.492000 170.957000 135.111000 98.576000 
530.103000 416.362000 346.739000 292.970000 248.163000 206.802000 170.267000 134.422000 97.886000 
529.414000 412.915000 345.360000 291.591000 247.474000 206.113000 169.578000 133.732000 97.197000 
528.725000 412.226000 344.671000 290.902000 246.095000 205.424000 168.889000 133.043000 96.508000 
521.142000 407.401000 343.981000 289.523000 245.406000 204.734000 168.199000 132.354000 95.818000 
519.074000 406.022000 343.292000 288.834000 244.716000 204.045000 167.510000 131.664000 94.440000 
516.317000 405.333000 341.913000 287.455000 243.337000 202.666000 166.821000 130.975000 93.750000 
514.249000 404.643000 341.224000 286.766000 242.648000 201.977000 166.131000 130.286000 93.061000 
513.559000 403.265000 340.535000 286.077000 241.269000 201.288000 165.442000 129.596000 92.372000 
510.113000 401.886000 336.399000 282.630000 239.891000 200.598000 164.753000 128.907000 91.682000 
504.598000 401.197000 335.709000 281.941000 239.201000 199.909000 164.063000 128.217000 90.993000 
501.840000 400.507000 335.020000 281.251000 238.512000 199.220000 163.374000 127.528000 90.304000 
500.462000 396.371000 332.952000 280.562000 237.823000 198.530000 162.685000 126.839000   
496.326000 395.682000 332.263000 279.873000 237.133000 197.841000 161.995000 126.149000 287.152600 
494.258000 393.614000 331.573000 279.183000 236.444000 197.152000 161.306000 125.460000 143.624000 
492.190000 392.925000 330.884000 277.805000 235.755000 196.462000 160.617000 124.771000 
490.811000 392.235000 330.195000 276.426000 235.065000 195.773000 159.927000 124.081000 
488.743000 389.478000 329.505000 275.737000 234.376000 195.084000 159.238000 123.392000 
488.054000 388.789000 328.816000 275.047000 233.687000 194.394000 158.549000 122.703000 
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Appendix table 3: CHO-FF cell spreading measurement. Surface area data (µm2) of 
CHO-FF cells cultured with a transfected RNF181 gene targeting siRNA and adhered to 
the non-thrombotic substrate BSA.  
920.960000 259.882000 164.753000 160.617000 238.580500 
899.590000 257.814000 162.685000 159.927000 142.209400 
792.053000 254.367000 160.617000 159.927000 
641.777000 250.231000 159.927000 155.791000 
477.024000 247.474000 159.927000 155.791000 
465.305000 235.065000 155.791000 155.102000 
463.927000 232.997000 155.791000 154.412000 
448.761000 231.619000 155.102000 153.723000 
435.664000 231.619000 154.412000 149.587000 
421.188000 228.861000 153.723000 148.208000 
392.235000 224.725000 149.587000 147.519000 
390.167000 222.657000 148.208000 143.383000 
387.410000 217.832000 147.519000 143.383000 
386.031000 213.696000 143.383000 140.626000 
359.147000 211.628000 143.383000 137.179000 
358.457000 210.938000 140.626000 137.179000 
337.088000 208.870000 137.179000 133.732000 
335.020000 206.113000 137.179000 133.732000 
326.748000 204.734000 133.732000 133.043000 
312.961000 204.734000 133.732000 132.354000 
306.757000 199.220000 133.043000 128.907000 
306.068000 197.152000 132.354000 125.460000 
306.068000 196.462000 128.907000 124.771000 
305.378000 196.462000 125.460000 118.567000 
304.000000 194.394000 124.771000 117.188000 
302.621000 194.394000 118.567000 117.188000 
295.038000 186.812000 117.188000 116.499000 
292.970000 186.812000 117.188000 115.809000 
292.281000 183.365000 116.499000 113.052000 
288.145000 181.986000 115.809000 112.363000 
288.145000 179.229000 113.052000 110.984000 
288.145000 178.539000 112.363000 109.605000 
283.319000 174.403000 110.984000 106.848000 
278.494000 174.403000 109.605000 104.780000 
277.115000 172.335000 106.848000 95.129000 
276.426000 170.267000 104.780000 95.129000 
275.047000 168.199000 95.129000 93.061000 
270.222000 168.199000 95.129000 91.682000 
269.532000 167.510000 164.753000 90.993000 
268.154000 166.131000 162.685000 
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Appendix table 4: : CHO-FF cell spreading measurement Surface area data (µm2) of 
CHO cells cultured under normal conditions and adhered to the thrombotic substrate 
fibrinogen.  
1955.661000 865.123000 577.668000 444.625000 357.079000 261.950000 192.326000 
1857.775000 849.269000 575.600000 442.557000 356.389000 261.950000 182.675000 
1792.977000 849.269000 569.396000 441.868000 355.700000 261.260000 182.675000 
1730.936000 845.822000 568.707000 441.178000 347.428000 260.571000 144.762000 
1691.988000 840.996000 565.949000 440.489000 346.739000 260.571000 143.383000 
1686.129000 833.414000 558.366000 439.800000 346.049000 259.882000 126.149000 
1636.496000 826.520000 557.677000 438.421000 344.671000 259.192000 125.460000 
1608.233000 808.597000 553.541000 437.042000 343.292000 258.503000 121.324000 
1556.874000 792.053000 550.094000 429.460000 337.088000 256.435000 118.567000 
1566.873000 790.675000 547.337000 428.770000 336.399000 255.746000 118.567000 
1553.775000 779.645000 547.337000 427.392000 334.331000 255.056000 117.188000 
1537.231000 737.595000 536.308000 426.013000 333.641000 250.920000 114.431000 
1524.134000 735.527000 535.618000 421.188000 332.952000 249.542000 113.741000 
1524.134000 725.187000 533.550000 420.498000 328.816000 249.542000 108.227000 
1484.841000 725.187000 532.861000 417.741000 323.990000 240.580000 108.227000 
1451.753000 710.711000 528.725000 417.052000 323.301000 239.891000 104.780000 
1444.859000 706.575000 528.035000 414.983000 321.922000 239.891000 104.780000 
1434.519000 705.196000 526.657000 399.818000 320.544000 235.755000 102.023000 
1383.922000 702.439000 525.967000 398.439000 317.786000 235.065000 102.023000 
1380.751000 698.303000 525.278000 397.061000 314.340000 235.065000 95.129000 
1297.395000 690.720000 513.559000 397.061000 312.961000 234.376000 93.750000 
1341.734000 672.108000 510.802000 396.371000 304.689000 232.308000 92.372000 
1308.370000 667.972000 510.113000 394.303000 304.000000 230.240000   
1302.855000 663.836000 505.977000 393.614000 303.310000 229.551000 505.183600 
1283.554000 660.389000 503.219000 393.614000 299.863000 228.172000 247.330200 
1249.914000 654.874000 492.190000 392.235000 295.727000 227.483000 
1213.930000 650.049000 485.986000 392.235000 295.727000 225.415000 
1209.794000 639.709000 485.296000 383.963000 293.659000 225.415000 
1206.072000 637.641000 483.228000 381.895000 292.970000 224.725000 
1186.356000 632.126000 476.335000 381.206000 289.523000 222.657000 
1153.268000 625.922000 472.888000 378.448000 288.834000 222.657000 
1104.325000 625.233000 466.684000 378.448000 288.834000 221.968000 
1081.163000 621.786000 466.684000 378.448000 288.145000 221.968000 
1118.112000 620.407000 461.169000 378.448000 285.387000 220.589000 
1112.597000 615.582000 460.480000 377.070000 284.698000 218.521000 
1109.150000 613.514000 458.412000 376.380000 275.737000 217.832000 
1019.123000 613.514000 458.412000 373.623000 274.358000 216.453000 
1041.595000 612.824000 455.655000 373.623000 271.600000 215.764000 
1038.148000 610.756000 454.965000 372.934000 270.911000 215.764000 
1016.089000 610.067000 454.276000 372.244000 270.222000 215.074000 
1005.060000 608.688000 452.897000 366.730000 270.222000 204.734000 
958.184000 602.484000 452.208000 366.040000 270.222000 204.045000 
947.844000 599.038000 450.140000 365.351000 270.222000 204.045000 
920.271000 598.348000 450.140000 363.972000 268.843000 202.666000 
900.969000 595.591000 448.761000 363.283000 265.396000 201.288000 
893.386000 590.076000 444.625000 363.283000 264.018000 199.220000 
877.532000 581.115000 444.625000 357.768000 263.328000 193.016000 
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Appendix table 5: CHO-FF cell spreading measurement. Surface area data (µm2) of 
CHO-FF cells cultured with a transfected control siRNA and adhered to the thrombotic 
substrate fibrinogen.  
1351.109 883.046 614.892 521.142 428.081 355.700 306.068 264.018 220.589 
1348.352 876.842 610.756 519.763 427.392 355.011 305.378 262.639 219.900 
1321.468 874.085 608.688 519.074 426.702 354.321 304.689 261.950 219.200 
1292.171 866.502 607.310 515.627 423.945 353.632 304.000 261.260 218.521 
1156.715 858.919 605.931 513.559 421.877 352.943 303.310 255.056 217.830 
1152.349 856.162 605.242 512.870 420.498 352.253 302.621 254.367 217.143 
1147.064 854.094 603.174 509.423 419.809 350.875 301.242 252.988 216.453 
1144.996 835.482 599.038 508.734 419.120 347.428 299.863 252.299 215.764 
1137.758 829.278 598.348 508.045 417.741 346.049 295.727 251.610 215.074 
1125.005 828.588 597.659 507.355 416.360 345.360 295.038 250.920 214.385 
1103.119 827.899 596.280 506.666 415.673 344.671 294.349 250.231 213.696 
1099.500 741.042 594.902 503.909 414.294 343.981 293.659 249.542 213.006 
1097.431 739.663 590.076 501.840 412.915 343.292 292.970 248.852 212.317 
1060.207 736.217 588.698 500.462 409.469 338.467 292.281 248.163 211.628 
1052.624 734.838 581.804 499.083 408.779 337.777 291.591 247.474 210.938 
1047.799 729.323 579.047 497.015 408.090 337.088 290.902 246.784 210.249 
1044.697 725.876 573.532 496.326 407.401 335.709 290.213 245.406 209.560 
1044.352 722.430 572.843 494.947 406.022 335.020 289.523 244.716 208.870 
1042.974 716.915 571.464 494.258 405.333 333.641 288.834 244.027 208.181 
1038.837 710.711 568.707 493.568 404.643 332.260 288.145 243.337 207.492 
1036.769 709.332 566.639 491.500 403.265 331.573 287.455 242.648 206.802 
1034.356 707.954 563.881 488.054 402.575 330.195 286.766 241.959 206.113 
1026.429 705.886 561.124 486.675 399.129 328.816 286.077 241.269 205.424 
1025.740 703.128 559.745 485.986 398.439 328.126 285.387 240.580 204.734 
1021.604 701.060 558.366 483.918 397.061 327.437 284.698 239.201 204.045 
1014.021 699.681 557.677 482.539 396.371 326.748 284.009 238.512 203.356 
1012.642 697.613 554.920 481.160 394.303 326.058 280.562 237.823 202.666 
969.903 695.545 553.541 477.714 393.614 324.680 279.183 237.133 201.977 
960.252 656.942 552.162 477.024 392.920 323.990 277.805 236.444 201.288 
953.359 656.253 549.405 475.646 390.857 323.301 277.115 235.755 200.598 
951.980 651.428 548.026 459.101 375.691 322.612 276.426 235.065 199.909 
950.602 648.670 547.337 458.412 374.310 321.922 275.737 234.376 199.220 
946.466 647.981 545.269 456.344 373.623 321.233 275.047 233.687 198.530 
943.708 646.602 542.512 455.655 372.244 320.544 274.358 232.997 197.841 
936.126 643.155 541.822 451.519 371.555 319.165 273.669 232.308 197.152 
933.368 641.777 539.065 450.829 370.866 317.786 272.979 231.619 196.462 
929.232 639.019 536.308 450.140 370.176 317.097 272.290 230.929 195.773 
 920.960 635.573 531.482 449.451 368.798 316.408 271.600 230.240 195.084 
919.581 634.883 529.414 448.072 368.108 315.718 270.911 229.551 194.394 
918.892 634.194 528.035 441.868 366.730 315.029 270.222 226.104 192.326 
914.067 632.815 527.346 441.178 363.972 314.340 269.532 225.415 191.637 
911.999 625.922 525.967 437.732 363.283 313.650 268.843 224.725 190.948 
906.484 623.854 525.278 435.664 362.594 312.961 268.154 224.036 190.258 
904.416 621.786 524.589 434.974 361.215 312.272 267.464 223.347 189.569 
900.969 619.718 523.899 432.217 359.836 311.582 266.086 222.657 188.880 
890.629 617.650 523.210 429.460 358.457 310.893 265.396 221.968 188.190 
883.736 616.271 521.831 428.770 356.389 307.446 264.707 221.279 187.501 
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 186.122000 
 
 
 
146.83000 
 
 
 
91.68200 
185.433000 146.14000 90.99300 
184.743000 145.45100 90.30400 
184.054000 143.38300   
183.365000 140.62600   
182.675000 139.93600 406.127700 
181.297000 139.24700 265.396400 
180.607000 138.55800 
179.918000 137.86800 
179.229000 137.17900 
178.539000 136.49000 
177.850000 135.80000 
177.161000 135.11100 
176.471000 134.42200 
175.782000 133.73200 
175.093000 133.04300 
174.403000 132.35400 
173.714000 131.66400 
173.025000 130.97500 
172.335000 130.28600 
171.646000 123.39200 
170.957000 122.70300 
170.267000 122.01300 
169.578000 121.32400 
168.889000 120.63500 
166.131000 119.94500 
164.753000 117.18800 
164.063000 116.49900 
163.374000 115.80900 
162.685000 115.12000 
161.995000 114.43100 
161.306000 113.74100 
160.617000 113.05200 
159.927000 112.36300 
159.238000 111.67300 
158.549000 107.53700 
157.170000 106.84800 
156.480000 106.15900 
155.791000 105.46900 
155.102000 104.78000 
154.412000 104.09100 
153.723000 103.40100 
153.034000 101.33300 
152.344000 100.64400 
151.655000 96.50800 
150.966000 95.81800 
150.276000 95.12900 
149.587000 94.44000 
148.898000 93.75000 
148.208000 93.06100 
147.519000 92.37200 
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Appendix table 6: CHO-FF cell spreading measurement. Surface area data (µm2) of 
CHO-FF cells cultured with a transfected RNF181 gene targeting siRNA and adhered to 
the thrombotic substrate fibrinogen.  
820.960000 406.022000 320.544000 272.290000 226.104000 186.122000 133.043000 96.508000 
691.409000 403.954000 320.544000 271.600000 226.104000 185.433000 132.354000 95.129000 
661.078000 402.575000 319.165000 269.532000 224.725000 185.433000 132.354000 94.440000 
643.845000 399.818000 318.476000 269.532000 224.036000 185.433000 131.664000 94.440000 
699.727000 398.439000 318.476000 268.154000 223.347000 184.743000 130.975000 93.061000 
685.940000 397.750000 317.786000 267.464000 223.347000 184.743000 130.286000 90.993000 
683.183000 395.682000 314.340000 266.775000 221.968000 184.054000 130.286000 90.993000 
673.532000 392.235000 313.650000 266.775000 221.279000 184.054000 129.596000 90.993000 
670.085000 391.546000 312.961000 266.086000 220.589000 181.297000 129.596000 90.304000 
561.813000 390.857000 311.582000 265.396000 217.143000 177.850000 129.596000   
556.298000 388.789000 311.582000 264.018000 215.074000 175.093000 126.839000   
541.133000 386.720000 310.893000 264.018000 212.317000 175.093000 125.460000   
538.376000 379.138000 308.825000 261.950000 212.317000 168.889000 124.771000   
529.414000 379.138000 308.825000 261.260000 211.628000 166.131000 124.081000   
523.899000 377.070000 307.446000 257.124000 211.628000 164.063000 124.081000 267.028600 
519.074000 371.555000 306.757000 257.124000 211.628000 163.374000 124.081000 133.231700 
517.006000 369.487000 306.757000 255.056000 210.249000 160.617000 123.392000 
514.249000 368.798000 305.378000 254.367000 209.560000 160.617000 122.703000 
507.355000 368.108000 304.689000 252.299000 208.870000 160.617000 122.013000 
503.909000 367.419000 304.000000 250.920000 208.181000 159.238000 120.635000 
501.840000 363.972000 300.553000 250.231000 207.492000 157.859000 117.877000 
491.500000 361.215000 297.795000 248.852000 207.492000 155.102000 115.809000 
485.296000 359.836000 296.417000 246.784000 206.802000 154.412000 114.431000 
483.228000 357.079000 295.727000 246.784000 206.113000 153.723000 112.363000 
475.646000 355.700000 294.349000 246.095000 204.734000 153.034000 111.673000 
475.646000 355.011000 293.659000 246.095000 204.045000 153.034000 110.295000 
472.888000 353.632000 291.591000 245.406000 203.356000 151.655000 109.605000 
469.441000 351.564000 290.213000 244.027000 201.977000 148.898000 108.227000 
463.237000 350.185000 290.213000 242.648000 201.977000 148.208000 108.227000 
460.480000 347.428000 289.523000 241.269000 200.598000 147.519000 108.227000 
457.723000 346.049000 289.523000 241.269000 199.909000 147.519000 106.848000 
457.723000 344.671000 289.523000 240.580000 199.909000 146.830000 106.848000 
455.655000 343.981000 288.145000 240.580000 197.152000 146.830000 106.848000 
454.965000 343.981000 288.145000 238.512000 194.394000 146.830000 106.159000 
452.897000 341.224000 286.766000 237.823000 193.705000 144.072000 105.469000 
448.072000 340.535000 286.077000 237.823000 193.705000 144.072000 105.469000 
439.800000 339.156000 285.387000 237.823000 193.016000 143.383000 104.780000 
437.732000 337.088000 285.387000 237.133000 193.016000 142.694000 104.780000 
430.149000 337.088000 284.009000 236.444000 193.016000 140.626000 104.091000 
429.460000 334.331000 284.009000 235.065000 190.948000 137.868000 102.023000 
426.702000 333.641000 284.009000 232.997000 190.258000 137.868000 102.023000 
426.013000 332.263000 284.009000 232.997000 190.258000 137.179000 102.023000 
420.498000 330.195000 282.630000 231.619000 189.569000 135.800000 102.023000 
417.741000 329.505000 281.941000 229.551000 188.880000 135.800000 101.333000 
415.673000 326.748000 281.251000 229.551000 188.190000 133.732000 99.265000 
410.847000 326.058000 273.669000 228.172000 187.501000 133.732000 98.576000 
410.158000 322.612000 272.290000 228.172000 186.812000 133.732000 97.197000 
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